IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 1PROTOCOL
TITLE: Phase 3 Study of Ibrutinib in Combination with Venetoclax in 
Subjects with Mantle Cell Lymphoma
PROTOCOL NUMBER: PCYC -1143- CA
STUDY DRUG: Ibrutinib 
IND NUMBER: 102,688
EudraCT NUMBER: 2017-
000129-12
SPONSOR MEDICAL 
MONITOR: MD, PhD
Pharmacyclics LLC
Phone:
Email:
SPONSOR: Pharmacyclics LLC , an AbbVie company
1000 Gateway Boulevard
South San Francisco, CA 94080
United States of America
DATE FINAL: 16 December 2016
Amendment 0.1 16 May 2017 (UK only)
Amendment 1 17 November 2017
Amendment 2 7 November 2019
Amendment 2.1 27 April 2020 (France only)
Amendment 3 25 March 2021
Amendment 4: 16 September 2022
Confidentiality Statement
This document contains confidential information of Pharmacyclics LLC that must not be disclosed to 
anyone other than the recipient study staff and members of the institutional review board/ethics 
committee. This information cannot be used for any other purpose other than the evaluation or 
conduct of the clinical study without the prior written consent of Pharmacyclics LLC.
[STUDY_ID_REMOVED]

IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 3TABLE OF CONTENTS
PROTOCOL APPROVAL PA GE...........................................................................................2
TABLE OF CONTENTS ..........................................................................................................3
LIST OF APPENDICES ...........................................................................................................8
LIST OF IN -TEXT TABLES AND FIG URES ........................................................................9
SYNOPSIS ............................................................................................................................... 10
ABBREVIATIONS ................................................................................................................. 22
1 BACKGROUND .................................................................................................... 25
1.1 Mantle Cell Lympho ma........................................................................................... 25
1.1.1 Disease Background ................................................................................................ 25
1.1.2 Current Treatment Options ....................................................................................... 25
1.2 Ibrutinib Overview ................................................................................................... 26
1.2.1 Summary  of Nonclinical Data .................................................................................. 27
1.2.1.1 Pharmaco logy.......................................................................................................... 27
1.2.1.2 Safety Pharmaco logy and Toxi cology...................................................................... 27
1.2.2 Summary  of Clinical Data ........................................................................................ 28
1.2.2.1 Pharmacokinet ics and Product Metabolism .............................................................. 28
1.2.3 Summary  of Clinical Safet y..................................................................................... 28
1.2.3.1 Monotherapy  Studies ............................................................................................... 28
1.2.3.2 Combinat ion Studi es................................................................................................ 29
1.2.4 Risks ........................................................................................................................ 30
1.2.4.1 Bleeding- related Events ........................................................................................... 30
1.2.4.2 Leukostasi s.............................................................................................................. 30
1.2.4.3 Infections ................................................................................................................. 30
1.2.4.4 Cytopeni as............................................................................................................... 30
1.2.4.5 Intersti tial Lung Disease (ILD) ................................................................................ 31
1.2.4.6 Cardi ac Arrhy thmias and Cardiac Failure .................................................................31
1.2.4.7 Tumor Lysis Syndrom e............................................................................................ 31
1.2.4.8 Non-melanoma Skin Cancer .................................................................................... 31
1.2.4.9 Lymphocy tosis........................................................................................................ 31
1.2.4.10 Cerebrovascular Accidents ....................................................................................... 32
1.2.4.11 Diarrhea ................................................................................................................... 32
1.2.4.12 Rash ........................................................................................................................ 32
1.2.4.13 Hypertensio n........................................................................................................... 32
1.3 Venetoclax Overview ............................................................................................... 33
1.3.1 Summary  of Nonclinical Data .................................................................................. 33
1.3.2 Summary  of Venetoclax Clinical Data ..................................................................... 34
1.3.2.1 Clinical Pharmacokinet ics........................................................................................ 34
1.3.2.2 Summary  of Clinical Safet y..................................................................................... 34
1.3.3 Risks ........................................................................................................................ 35
1.3.3.1 Tumor Ly sis Syndro me............................................................................................ 35
1.3.3.2 Neutropenia ............................................................................................................. 36
1.3.3.3 Serious Infect ions.................................................................................................... 36
1.4 Study  Rati onale ....................................................................................................... 36
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 41.4.1 Rationale for the Ibruti nib and Venetoclax Co mbination .......................................... 36
1.4.2 Dose Rati onale ......................................................................................................... 37
1.4.3 Rationale for the Safet y Run-in Period ..................................................................... 38
1.4.4 Rationale for the Desi gn of  the Treatm ent Arm s...................................................... 39
1.4.5 Rationale for the PFS Assumpt ion of 23 Months in the Ibrutinib and Venetoclax 
Relapsed/Refractory  Treatm ent Arm ........................................................................ 39
1.4.6 Rationale for MRD Testing ...................................................................................... 39
1.4.7 Rationale for Treatm ent-naive Open -label Arm, Inclusion o f Patients wi th a 
TP53 Mutation and Exclusio n of Blastoi d Vari ant................................................... 40
1.4.8 Sample Si ze Considerat ions for Treatm ent-naive Open -label Arm Including 
Patients wi th a TP53 Mutati on................................................................................. 41
2 STUDY OBJECTIVES .......................................................................................... 42
2.1 Safety Run-in Period ................................................................................................ 42
2.1.1 Primary Object ive.................................................................................................... 42
2.1.2 Secondary  Object ives............................................................................................... 42
2.2 Randomization Phase ............................................................................................... 42
2.2.1 Primary Object ive.................................................................................................... 42
2.2.2 Secondary  Object ives............................................................................................... 42
2.2.3 Exploratory  Objectives ............................................................................................ 43
2.3 Treatment -naive Open -label Arm ............................................................................. 43
2.3.1 Primary Object ive.................................................................................................... 43
2.3.2 Secondary  Object ives............................................................................................... 43
2.3.3 Exploratory  Objectives ............................................................................................ 44
3 STUDY DESIGN ................................................................................................... 44
3.1 Overview of Study  Design ....................................................................................... 44
3.1.1 Safety Run-in Period ................................................................................................ 44
3.1.2 Randomization Phase ............................................................................................... 48
3.1.3 Treatment -naive Open -label Arm ............................................................................. 50
4 SUBJECT SELECTION ....................................................................................... 51
4.1 Eligibilit y Criteria for SRI and Randomizat ion Phase ............................................... 51
4.1.1 Inclusio n Cri teria..................................................................................................... 51
4.1.2 Exclusio n Cri teria.................................................................................................... 53
4.2 Eligibilit y Criteria for the Treatm ent-naive Open -label Arm .................................... 55
4.2.1 Inclusio n Cri teria for the Treatm ent-naive Open -label Arm...................................... 55
4.2.2 Exclusio n Cri teria for the Treatment -naive Open -label Arm ..................................... 56
5 TREATMENT OF SUBJECT S............................................................................. 58
5.1 Treatment Allocat ion and Blinding .......................................................................... 58
5.1.1 Safety Run-in Period ................................................................................................ 58
5.1.2 Randomization Phase ............................................................................................... 58
5.1.2.1 Randomization ......................................................................................................... 58
5.1.2.2 Blinding ................................................................................................................... 59
5.1.3 Replac ement of Subjects .......................................................................................... 59
5.1.4 Treatment -naive Open -label Arm ............................................................................. 59
5.2 Study  Treatm ent...................................................................................................... 60
5.2.1 SRI and Randomized Phase ..................................................................................... 60
5.2.2 Treatment -naive Open -label Cohort ......................................................................... 61
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 55.3 Study  Medicat ion..................................................................................................... 61
5.3.1 Ibrutinib ................................................................................................................... 61
5.3.1.1 Form ulation/Packaging/Storage ............................................................................... 61
5.3.1.2 Dose and Administration ......................................................................................... 61
5.3.1.3 Overdose ................................................................................................................. 62
5.3.1.4 Dose Modificat ion for Adverse Reactions ................................................................ 62
5.3.1.5 Leukocy tosis/Leukostasis ........................................................................................ 64
5.3.1.6 Dose Modificat ion for Hepati c Impaired Subjects .................................................... 64
5.3.2 Venetoclax ............................................................................................................... 65
5.3.2.1 Form ulation/Packaging/Storage ............................................................................... 65
5.3.2.2 Venetoclax Toxicit y Management ............................................................................ 66
5.3.2.3 Dose and Administration ......................................................................................... 67
5.3.2.4 Overdose ................................................................................................................. 67
5.3.2.5 Dose Modificat ion for Adverse Reactions ................................................................ 68
5.3.2.6 Dose Modificat ion for Hepati c Impaired Subjects .................................................... 69
5.4 Criteria for Perm anent Discont inuat ion of Study  Drug ............................................. 69
6 CONCOMITANT MEDICATI ONS/PROCEDURES .......................................... 69
6.1 Permi tted Concomitant Medications ........................................................................ 69
6.2 Medicat ions to be Used with Caut ion....................................................................... 70
6.2.1 CYP3A Inhibitors/Inducers ...................................................................................... 70
6.2.1.1 Concomitant Use with Ibrutinib ............................................................................... 70
6.2.1.2 Concomitant Use with Venetoclax/placebo .............................................................. 70
6.2.2 Drugs that May  have Their Plasma Concentration Altered by Ibrutinib .................... 71
6.2.3 Drugs That May  Have Thei r Plasma Concentrati ons Al tered by Venetocl ax............ 72
6.2.4 Antiplatelet Agents and Ant icoagulants ................................................................... 72
6.2.4.1 Concomitant Use with Ibrutinib ............................................................................... 72
6.2.4.2 Concomitant Use with Venetoclax ........................................................................... 72
6.2.5 Prohibited Conco mitant Medi cations and Products for Ibrutinib and/or 
Venetoclax/placebo .................................................................................................. 72
6.3 Guidelines for Ibrutinib Management with Surgeries or Procedures ......................... 73
6.3.1 Minor Surgical Procedures ....................................................................................... 73
6.3.2 Major Surgi cal Procedures ....................................................................................... 73
7 STUDY EVALUATIONS ...................................................................................... 74
7.1 Descript ion of Procedures ........................................................................................ 74
7.1.1 Assessments ............................................................................................................ 74
7.1.1.1 ICF.......................................................................................................................... 74
7.1.1.2 Confirm Eligibilit y................................................................................................... 74
7.1.1.3 Medical History  and Dem ographics ................................
......................................... 74
7.1.1.4 Prior and Concomi tant Medicat ions......................................................................... 74
7.1.1.5 Adverse Events ........................................................................................................ 74
7.1.1.6 Physical Examinat ion............................................................................................... 75
7.1.1.7 Eye
-related Symptom  Assessment ........................................................................... 75
7.1.1.8 ECOG ...................................................................................................................... 75
7.1.1.9 Vital Signs............................................................................................................... 75
7.1.1.10 Tumor Lysis Syndrom e (TLS) Risk Assessment ...................................................... 75
7.1.1.11 B-Symptom s............................................................................................................ 76
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 67.1.2 Laboratory ............................................................................................................... 76
7.1.2.1 Hem atology............................................................................................................. 76
7.1.2.2 Chemistry  (Serum )................................................................................................... 76
7.1.2.3 Coagulation Studies .................................................................................................76
7.1.2.4 Hepati tis Serol ogies .................................................................................................76
7.1.2.5 Serum  β2-microglobulin .......................................................................................... 77
7.1.2.6 Urinalysis ................................................................................................................ 77
7.1.2.7 Pregnancy Test ........................................................................................................ 77
7.1.3 Diagnostics/Procedures ............................................................................................ 77
7.1.3.1 ECG ........................................................................................................................ 77
7.1.3.2 CT/MRI and PET ..................................................................................................... 77
7.1.3.3 Endoscopy ............................................................................................................... 79
7.1.3.4 Tumor Ti ssue........................................................................................................... 79
7.1.3.5 Bone Marrow Biopsies for Evaluat ion of Bone Marrow Involvement ...................... 79
7.1.3.6 Bone Marrow Aspirate and Peripheral Blood for Minimal Residual Disease (MRD) 
Assessment .............................................................................................................. 80
7.1.3.7 Bone Marrow Aspirate and Peripheral Blood for Bio marker Assessment ................. 80
7.1.4 Pharmacokinet ics/Bio markers .................................................................................. 81
7.1.4.1 Pharmacokinet ics for Safety  Run -in and Randomization Phase ................................ 81
7.1.4.2 Pharmacokinet ics Treatment -naive Open -label Arm ................................................ 82
7.1.4.3 Exploratory  Biomarkers ........................................................................................... 83
7.1.5 Patient-Reported Outcomes ...................................................................................... 83
7.1.5.1 FACT -Lym for Saf ety Run-in and Rando mizat ion Phase ......................................... 83
7.1.5.2 EQ-5D- 5L for SRI, Randomizat ion Phase and Treatment -naive Open -label Arm.....84
7.1.6 Medical Resource Utilizat ion (MRU) ....................................................................... 84
7.2 Efficacy Evaluations ................................................................................................ 84
7.2.1 Overall Response Assessments ................................................................................ 84
7.2.2 Survival ................................................................................................................... 85
7.3 Sample Collect ion and Handling .............................................................................. 85
8 STUDY PROCEDURES ........................................................................................ 85
8.1 Screening Phase ....................................................................................................... 85
8.1.1 Screening/Consent ing Visit ...................................................................................... 85
8.2 Treatment Phase ...................................................................................................... 86
8.2.1 Treatment Visit s for Standard Ram p-up Schedule for SRI, Randomization 
Phase, and Treatment -naive (TN) Open -label Arm ................................................... 87
8.2.1.1 Week 1 Day  1 and Week 2 Day  1
............................................................................ 87
8.2.1.2 Week 1 Day  2 and Week 2 Day  2 ............................................................................ 88
8.2.1.3 Week 1 Day  3 and Week 2 Day  3 (Hospi talized Subjects Only) ............................... 88
8.2.1.4 Weeks 3, 4, and 5 Day  1 for Standard Ramp- up Schedule ........................................ 89
8.2.1.5 Week 6 Day  1 .......................................................................................................... 90
8.2.1.6 Week 8 Day  1 (± 1 Day ) and Week 10 Day  1 (± 1 Day )........................................... 91
8.2.1.7 Week 13 and beyo nd (±7 Days) ............................................................................... 91
8.2.2 Response Evaluat ion................................................................................................ 92
8.2.3 End-of-Treatm ent Visi t............................................................................................ 93
8.3 Follow-up Phase ...................................................................................................... 93
8.3.1 Response Fo llow-up ................................................................................................ 93
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 78.3.2 Long -term Follow-up ............................................................................................... 93
9 SUBJECT COMPLETION A ND WITHDRAWAL ............................................. 94
9.1 Com pletion.............................................................................................................. 94
9.2 Withdrawal fro m Study  Treatm ent........................................................................... 94
9.3 Withdrawal fro m Study ............................................................................................ 94
10 STATISTICAL METHODS AND ANALYSIS .................................................... 95
10.1 Analysis Populat ion.................................................................................................95
10.1.1 Saf ety Run-in Period Evaluable Populat ion.............................................................. 95
10.1.2 Safety Popul ation..................................................................................................... 96
10.1.3 Intent -to-Treat Popul ation in Randomizat ion Phase .................................................. 96
10.1.4 All-Treated Population for Treatment -naive Open -label Arm ................................... 96
10.1.5 Addit ional Analysis Population ................................................................................ 96
10.2 Endpoints ................................................................................................................. 96
10.2.1 Safety Run-in Period ................................................................................................ 96
10.2.2 Randomization Phase Primary Endpo int.................................................................. 96
10.2.3 Randomization Phase Secondary  Endpo ints............................................................. 97
10.2.4 Randomization Phase Exploratory  Endpo ints........................................................... 98
10.2.5 Treatment -naive Open -label Arm Primary  Endpoint ................................................ 98
10.2.6 Treatment -Naive Open -Label  Arm Secondary  Endpoints ......................................... 98
10.2.7 Treatment -naive Open -label Arm Exploratory  Endpoints ......................................... 98
10.3 Sample Si ze Determinat ion (Rand omization Phase) ................................................. 98
10.4 Sample Si ze Determinat ion (Treatment -naive Open -label Arm) ............................... 99
10.5 Efficacy Analysis ................................................................................................... 100
10.5.1 Randomization Phase ............................................................................................. 100
10.5.1.1 Analysis for Primary  Efficacy Endpoint .................................................................100
10.5.1.2 Analysis for Secondary  Efficacy Endpoints ............................................................ 100
10.5.2 Treatment -naive Open -label Arm ........................................................................... 101
10.5.2.1 Analysis for the Primary Efficacy  Endpoint ........................................................... 101
10.5.2.2 Analysis for Secondary  Efficacy Endpoints ............................................................ 102
10.6 Safety Analysis ...................................................................................................... 102
10.7 Pharmacokinet ic Analysis ...................................................................................... 103
10.7.1 Ibrutinib ................................................................................................................. 103
10.7.2 Venetoclax ............................................................................................................. 103
10.8 Biomarker Analyses ............................................................................................... 104
11 ADVERSE EVENT REPORT ING ..................................................................... 104
11.1 Definit ions............................................................................................................. 104
11.1.1 Adverse Events ...................................................................................................... 104
11.1.2 Serious Adverse Events ......................................................................................... 105
11.1.3 Severit y Criteria (Grade 1 -5).................................................................................. 106
11.1.4 Causalit y (Attribution)........................................................................................... 107
11.2 Unexpected Adverse Events ................................................................................... 107
11.3 Speci al Reporting Si tuations.................................................................................. 107
11.4 Docum enting and Reporting of Adverse Events and Serious Adverse Events by 
Invest igators .......................................................................................................... 108
11.4.1 Assessment of Adver se Events ............................................................................... 108
11.4.2 Adverse Event Reporting Period ............................................................................ 108
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 811.4.3 Expedit ing Reporting Requirements for Serious Adverse Events ........................... 109
11.4.4 Pregnancy .............................................................................................................. 109
11.4.5 Other Malignancies ................................................................................................ 110
11.4.6 Eye-Related Adverse Events .................................................................................. 110
11.4.7 Adverse Events of Special Interest (AESI) ............................................................. 110
11.4.7.1 Major Hem orrhage .................................................................................................110
12 STUDY ADMINISTRATION AND INVESTIGATOR OB LIGATIONS ......... 111
12.1 Regulatory  and Ethi cal Com pliance ....................................................................... 111
12.2 Institutional Review Board (IRB), Research Ethics Board (REB) and 
Independent Ethics Committee (IEC) Approval ..................................................... 111
12.3 Inform ed Consent .................................................................................................. 111
12.4 Quality Control  and Qualit y Assurance .................................................................. 112
12.5 Protected Subject Health Information Authorization .............................................. 112
12.6 Study  Files and Record Retention .......................................................................... 112
12.7 Case Report Forms and Record Maintenance ......................................................... 113
12.8 Invest igational Study  Drug Accountabilit y............................................................. 114
12.9 Study  Moni toring/Audi t Requi rements ................................................................... 114
12.10 Invest igator Responsibilit ies.................................................................................. 115
12.11 Sponsor Responsibilit ies........................................................................................ 115
12.12 Financial Disclo sure .............................................................................................. 115
12.13 Liabilit y and Clinical Trial Insurance ..................................................................... 116
12.14 Protocol  Amendments ............................................................................................ 116
12.15 Publicat ion of Study  Resul ts.................................................................................. 116
12.16 Study  Discont inuat ion............................................................................................ 117
12.17 Study  Com pletion.................................................................................................. 117
13 REFERENCES .................................................................................................... 118
14 APPENDICES ...................................................................................................... 123
LIST OF APPENDICES
Appendix A. Schedule of Assessments –Standard Ramp -up Schedul e............................... 124
Appendix B. Schedule of Assessments –Treatment -naive Open -label Arm ....................... 127
Appendix C. ECOG Status Scores ..................................................................................... 130
Appendix D. Sample List of Cautionary  Medicat ions......................................................... 131
Appendix E. Revised Criteria for Response Assessment for Malignant Lympho ma........... 133
Appendix F. Child -Pugh Score for Subjects with Liver Impairment ................................... 136
Appendix G. Howard Cri teria for Laboratory  and Clinical TLS* (Howard etal,NEJM 2011)
................................
..................................................................................... 137
Appendix H. Reco mmendat ions for Initial Management of El ectroly te Abnorm alities and 
Prevent ion of Tum or Lysis Syndro me (TL S)................................................. 138
Appendix I. FACT -Lym questi onnai re (versi on 4)............................................................ 142
Appendix J. EQ-5D-5L ..................................................................................................... 146
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 9LIST OF IN -TEXT TABL ES AND FIGURES
TABLES
Table 1. Ibrutinib Dose Modificat ions........................................................................ 63
Table 2. Ibrutinib Dose Modificat ions for Cardi ac Failure or Cardiac 
Arrhyt hmias .................................................................................................64
Table 3. Ibrutinib Dose Reduction Levels .................................................................. 64
Table 4. Ident ity of Venetocl ax/Placebo Drug Product ............................................... 65
Table 5. Reco mmended Dose Modificat ions for Venetocl ax/pl acebo -related 
Toxicit ies..................................................................................................... 68
Table 6. Dose Modifi cation for Toxi city During Venetocl ax/pl acebo Treatm ent........ 69
Table 7. Management of Potential Ibrut inib and Venetoclax/placebo Interactions 
with CYP3A Inhibitors ................................................................................. 71
Table 8. Ibrutinib and Venetoclax PK Samples Schedule at the Target Dose .............. 81
Table 9. Pharmacokinet ic Sample Schedule for Ibrutinib and Venetoclax or 
placebo on the PK Days ............................................................................... 81
Table 10. Pharmacokinet ic Sample Schedule for Treatment -naive Open -label Arm .....82
FIGURES
Figure 1. Study  Schemat ic–Safety Run-in Period ...................................................... 11
Figure 2. Standard Ramp- up Schedule ......................................................................... 13
Figure 3. Randomization Phase Schemat ic.................................................................. 14
Figure 4. Venetoclax Ramp -up Schedule for Treatment -naive Open -label Arm ........... 15
Figure 5. Study  Schema for Treatment -naive Open -label Arm ..................................... 16
Figure 6. Study  Schemat ic –Safety Run-in Period ...................................................... 45
Figure 7. Standard Ramp- up Schedule ......................................................................... 46
Figure 8. Randomization Phase Schemat ic.................................................................. 49
Figure 9. Study  Design: Treatm ent-naive Open -label Arm .......................................... 50
Figure 10. Venetoclax Standard Ramp -up Schedule ...................................................... 50
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 10SYNOPSIS
Study Title: Phase 3 study of ibrutinib in combination with venetoclax in subjects with 
mantle cell lymphoma (MCL) 
Protocol Number: PCYC -1143- CA 
Study Phase: 3
Study Duration: Estimated to be 5 years
Investigational 
Product and 
Reference Therapy:Ibrutinib will be supplied as 140 mg hard gelatin capsules or 560 mg tablets for 
oral (PO) administration.
Venetoclax will be supplied as 10 mg, 50 mg, and 100 mg tablets for oral (PO) 
administration.
Objectives:
(Safety Run -in [SRI] 
Period and 
Randomization Phase)Safety Run -in Period
Primary Objective:
To evaluate the occurrence of tumor lysis syndrome (TLS) and dose -limiting 
toxicities (DLTs) with the concurrent administration of ibrutinib and venetoclax.
Secondary Objectives:
To evaluate response (partial and complete response), progression -free survival 
(PFS), duration of response (DOR), and overall survival (OS).
Randomization Phase 
Primary Objective:
To evaluate whether the combination of ibrutinib and venetoclax will result in 
prolongation of PFS compared to ibrutinib and placebo in subjects with relapsed 
or refractory MCL.
Secondary Objectives:
To evaluate whether the combination of ibrutinib and veneto clax will 
increase the complete response (CR) rate, the overall response rate 
(ORR), the minimal residual disease ( MRD) negative remission rate in 
subjects who were MRD positive at screening and achieve CR, OS, 
DOR, and time -to-next treatment (TTNT) compar ed to ibrutinib and 
placebo.
To evaluate the frequency, severity, and relatedness of adverse events 
(AEs); frequency, severity and management of TLS; AEs requiring dose 
reductions and/or discontinuation of study drug, or leading to death. 
To determine the pharm acokinetics (PK) of ibrutinib and venetoclax.
To evaluate whether the combination of ibrutinib and venetoclax will 
improve quality of life using a Health -related quality of life 
questionnaire (FACT -Lym, etc.), compared to ibrutinib and placebo.
Objectives:
(Treatment -naive 
Open -label Arm)Primary Objective:
To evaluate the complete response (CR) rate with the combination of ibrutinib 
and venetoclax in subjects with treatment -naive MCL
Secondary Objectives:
To evaluate the overall response rate (O RR), the duration of response 
(DOR) and duration of CR 
To evaluate the minima l residual disease ( MRD) -negative remission 
rate in subjects who achieve CR who were MRD positive at screening
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 11To evaluate progression- free survival (PFS), overall survival (OS), and 
time-to-next treatment (TTNT) with the combination of ibrutinib and 
venetoclax
To evaluate the frequency, severity, and relatedness of adverse events 
(AEs); frequency, severity and management of TLS; AEs requiring dose 
reductions and/or discontinuatio n of study drug, or leading to death
To determine the pharmacokinetics (PK) of ibrutinib and venetoclax
Exploratory Objectives:
To evaluate biomarkers in relationship to efficacy outcomes
To evaluate whether the combination of ibrutinib and venetoclax will
improve quality of life using a health -related quality of life 
questionnaire (EQ -5D-5L, etc.)
Study Design:
1. Safety Run -in 
Period
2. Randomization 
Phase
3. Treatment -naive 
Open -label ArmThis Phase 3 multinational, randomized, double -blind study is des igned to 
compare the efficacy and safety of the combination of ibrutinib and venetoclax 
vs. ibrutinib and placebo in subjects with MCL. 
Approximately 287 subjects will be enrolled. In the treatment -naive open -label 
arm, approximately 75 subjects will be e nrolled.
1. Safety Run -in Period
The study will start with an open -label Safety Run -in Period to evaluate the 
occurrence of tumor lysis syndrome (TLS) and DLTs with the concurrent 
administration of ibrutinib and venetoclax. TLS and DLT occurrence will be 
assessed during the venetoclax Ramp -up Period for a minimum of 5 weeks.
Up to 27 subjects may be enrolled during the Safety Run -in Period ( Figure 1):
Figure 1. Study Schematic – Safety Run -in Period
PD = progressive disease; WC = withdrawal of consent
Tumor Lysis Syndrome (TLS) Categories
Two TLS risk categories will be evaluated separately and in parallel:
Increased risk for TLS –Subjects with high tumor burden (at least one 
lesion > 10 cm; or at least one lesion > 5 cm and circulating 
lymphocytes > 25,000 cells/mm3) and/or with baseline creatinine 
clearance (CrCl) < 60mL/min. During the Safety Run- in Peri od, 
subjects at increased risk for TLS will be hospitalized for a minimum of 
24 hours (and up to 48 hours at the discretion of the investigator) at the 
start of the 20 mg ramp -up dose and again at the start o f the 50 mg 
ramp-up dose of venetoclax for monit oring and prophylaxis of TLS.
Low risk for TLS –Subjects not meeting the criteria described above 
       
        
   
 
   
  
          
          
       
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 12TLS events are defined as follows: 
Clinical TLS –any event that meets Howard criteria ( Appendix G) with 
the following exceptions: 
oFor the purpose of TLS assessment during the Safety Run -in Period, 
only those increases in serum creatinine > 1.0 mg/dL from 
pre-treatment baseline will be co nsidered clinical TLS.
oIn subjects with renal dysfunction at baseline (CrCl < 60 mL/min), 
clinical TLS is defined as the presence of laboratory TLS plus either 
seizures, cardiac dysrhythmia, or death.
Laboratory TLS –any event that meets Howard criteria ( Appendix G) 
for laboratory TLS, that does not resolve within 72 hours despite 
protocol required management
Dose -Limiting Toxicities (DLT) 
A DLT is defined as any Grade 3 or higher non -TLS AE at least possibly related 
to study drug (ibrutinib and/or venetoclax) and occurring during the DLT 
assessment period with the following clarifications:
Non-Hematologic DLTs:
Grade ≥3 nausea, vomiting or diarrhea uncontrolled despite maximum 
medical supportive care and persisting > 5 days
Grade 3 fatigue persisting > 7 days
Grade 3 infection is not a DLT, however an infection with life -
threatening consequences or requiring urgent intervention (Grade 4) 
will be con sidered a DLT
Treatment delay of any study drug > 7 days for toxicity 
Hematologic DLTs:
Grade 3 neutropenia is not a DLT; however, Grade 4 neutropenia
(ANC <500/mm3) lasting for > 7 days is a DLT 
Grade 3 or 4 neutropenia complicated by fever ≥38.5°C or infection 
Grade 4 thrombocytopenia (< 25,000/mm3) that persists for > 7 days 
Grade 3 or 4 thrombocytopenia associated with Grade 2 or greater 
bleeding
Grade 3 anemia is not a DLT; however, Grade 4 anemia is a DLT
Treatment delay of any study dr ug > 7 days for hematologic toxicity
Initially, 6 subjects at low risk for TLS and 12 subjects at increased risk for TLS 
will receive ibrutinib at 560 mg once daily and venetoclax starting at 20 mg, and 
gradually ramped up to a target dose of 400 mg once d aily over a 5 -week period 
(see Figure 2below). TLS events and DLTs will be assessed during the 
venetoclax Ramp- up Period for a minimum of 5 weeks. 
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 13Figure 2. Standard Ramp -up Schedule
Subjects at Low Risk for TLS
Evaluation of TLS
Three additional subjects will be dosed, if 1 out of 6 subjects at low risk for TLS 
experiences a laboratory TLS event and no subjects experience a clinical TLS 
event. If 0 out of 6 or ≤1 out of 9 subjects experience a laboratory TLS event 
and no subjects experience a clinical TLS event, the Randomization Phase will 
start using the standard ramp -up schedule for subjects at low risk for T LS. 
If ≥2 out of 6 -9 subjects at low risk for TLS experience a laboratory TLS event 
or any subject experiences a clinical TLS event, the Randomization Phase will 
start with a 4- week ibrutinib lead -in followed by the standard Ramp -up 
Schedule ( Figure 2) for subjects in both TLS risk categories.
Evaluation of DLTs
With respect to DLTs, if < 2 out of 6 or < 3 out of 9 subjects experience DLT(s) 
during the DLT assessment period, the Randomization Phase will commence 
using the standard Ramp -up Schedule for subjects at low risk for TLS 
(Figur e
2). However, i f ≥3 out of 9 subjects experience DLT(s), the 
Randomization Phase will commence with a 4 -week ibrutinib lead -in followed 
by the standard Ramp -up Schedule for subjects in both TLS risk categories 
(Figur e 2).
The Safety Review Committee (SRC) will evaluate TLS and DLT data during 
the Safety Run -in Period prior to initiation of the Randomization Phase .
Subjects at Increased Risk for TLS
Evaluation of TLS 
If <3 out of the 12 subjects at increased risk for TLS experience a laboratory 
TLS event and no subjects experience a clinical TLS event, enrollment of 
increased -risk TLS subjects to the Randomization Phase will commence using 
the standard Ramp -up Schedule for subjects at increased risk for TLS 
(Figur e 2).
However, if ≥3 out of the 12 increased risk subjects experience a laboratory 
TLS event or any of these subjects experience a clinical TLS event, at least 
6subjects at increased risk for TLS should be treated with the 4- week ibrutinib 
lead-in and assessed for safety either in an external study or within this study. If 
≤2 out of these 6 subjec ts experience a laboratory TLS event and no subjects 
experience a clinical TLS event, the Randomization Phase will commence with 
a 4-week ibrutinib lead -in followed by the standard Ramp -up Schedule for 
subjects at increased risk of TLS ( Figure 2).
    
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 14Evaluation of DLTs
If <4 out of the 12 subjects at increased risk for TLS experience DLT(s) during 
the DLT assessment period, the Randomization Phase will commence using the 
standard Ramp -up Schedule. However, if ≥4 out of the 12 subjects experience 
DLT(s), the Randomization Phase will commence with a 4 -week ibrutinib 
lead-in followed by the standard Ramp -up Schedule for subjects at increased 
risk of TLS.
The SRC will evaluate TLS and DLT data during the Safety Run -in Period prior 
to the Randomization Phase.
Subjects in either TLS risk category who experience a laboratory or clinical 
TLS event will be managed according to standard institutional practice. 
For subjects who experience laboratory TLS, dosing of venetoclax will be 
withheld per protocol and may be resumed when all laboratory abnormalities 
have returned to baseline. Dose reduction of venetoclax is not allowed for 
subjects enrolled in the Safety Run -in Period. Once venetoclax dosing is 
resumed, the applicable ramp -up week will re -start at the same dose level.
Those subjects incurring clinical TLS (regardless of TLS risk category) must be 
documented and discussed with the study medical monitor to dete rmine whether 
the risk -benefit ratio justifies the subject remaining on study.
Subjects will be treated with ibrutinib and venetoclax for approximately 
104weeks followed by ibrutinib monotherapy until disease progression (PD), 
unacceptable toxicity or wit hdrawal of consent. Venetoclax will be discontinued 
after 104 weeks of treatment regardless of response assessment. Subjects who 
discontinue study treatment for any reason will be followed for progression (if 
not progressed before treatment discontinuation ), subsequent anti -cancer 
therapy and survival status until study closure.
2. Randomization Phase 
The Randomization Phase portion of the study will follow a randomized, 
double -blind design ( Figure 3). Ibrutinib and venetoclax/placebo will be 
administered using the Standard Ramp -up Schedule. 
Subject eligibility will be determined up to 28 days prior to randomization. 
Approximately 260 eligible subjects w ill be randomized at a 1:1 ratio to 
ibrutinib andvenetoclax or ibrutinib and placebo. Randomization will be 
stratified by number of prior lines of therapy, ECOG performance status (PS), 
and by TLS risk category.
Figure 3. Random ization Phase Schematic
 
 
 
      
     
 
            
    
   
 
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 15Initially, subjects at increased risk of TLS will be hospitalized for a minimum of 
24hours (and up to 48 hours at the discretion of the investigator) at the start of 
the 20 mg ramp -up dose and again at the start of the 50 mg ramp-up dose of 
venetoclax for monitoring and prophylaxis of TLS. The data monitoring 
committee (DMC) will review unblinded safety data during the course of the 
study to determine whether continued hospitalization of these subjects during 
ramp-up remains w arranted.
Subjects will be treated with either ibrutinib and venetoclax or ibrutinib and 
placebo for approximately 104 weeks, followed by ibrutinib monotherapy until 
PD, unacceptable toxicity or withdrawal of consent. Venetoclax/placebo will be 
discontinue d after 104 weeks of treatment, regardless of response assessment.
Subjects who discontinue study treatment for any reason will be followed for 
progr ession (if not progressed before treatment discontinuation), subsequent 
anticancer therapy, and survival st atus until study closure.
3. Treatment -naive Open -label Arm
A separate open -label arm is designed to explore the efficacy and safety of the 
combination of ibrutinib and venetoclax in subjects with treatment -naive MCL 
(Figur e 5).
In the treatment -naive open -label arm, approximately 75 subjects will be 
enrolled and treated with ibrutinib 560mg and venetoclax 400 mg. Amo ng 
them, approximately 50 subjects ≥65 years and approximately 25 subjects with 
a TP53 mutation will be enrolled.
Ibrutinib and venetoclax will be administered using the 5 -week ramp -up 
schedule shown in Figur e 4. Treatment -naive MCL patients will use the same 
dose and schedule as established in the Safety Run -in for the Randomization 
Phase of the study. Therefore, there will be no Safety Run -in for the treatment -
naive cohort.
Note: Sponsor may hold enrollment for patients in the treatment -naive open -
label arm to ensure that at least 25 patients with a TP53 mutation are enrolled.
Figure 4. Venetoclax Ramp -up Schedule for Treatmen t -naive 
Open -label Arm
    
 
 
 
   
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 16Figure 5. Study Schema for Treatment -naive Open -label Arm
PD = progressive disease; WC = withdrawal of consent
Subject eligibility will be determined up to 28 days prior to the first dose of 
study drug.
Subjects in the protocol -defined increased risk for tumor lysis syndrome (TLS) 
group will be hospitalized for a minimum of 24 hours (and up to 48 hours at the 
discretion of the investigator) at the start of the 20 mg and 50 mg ramp -up dose 
of venetoc lax for monitoring and prophylaxis of TLS; subjects in the low -risk 
for TLS group may be hospitalized at the discretion of the investigator.
Subjects will be treated with ibrutinib and venetoclax for approximately 
104weeks (2 years), followed by ibrutinib monotherapy until PD, unacceptable 
toxicity or withdrawal of consent or study closure. Venetoclax will be 
discontinued after 104 weeks (2 years) of treatment, regardless of response 
assessment.
CT and PET or PET/CT: A CT scan (with contrast unless contrai ndicated) of the 
neck, chest, abdomen, and pelvis and any other disease sites (eg, extremity) and 
a PET scan are required for the pretreatment tumor assessment within 28 days of 
the 1stdose. Thereafter, CT scans will be done for tumor assessments on 
Week 13 Day 1 (±7 days); every 12 weeks for the remainder of the 1styear; 
every 16 weeks during the 2ndand 3rdyears; and every 24 weeks thereafter until 
PD. PET or PET/CT is mandatory for all subjects at the Week 13 visit 
(+/- 7days), the Week 25 visit (+/ - 7days) for subjects in SD or PR who did not 
achieve CR at Week 13, and at the 1 -year visit (Week 49 +/ -7 days) for all 
subjects, as well as at any other time point to confirm a CR. Other PET or 
PET/CT scans that are NOT mandatory can be performed within a 30-day 
window of the visit. 
Subjects who discontinue study treatment for any reason other than progressive 
disease will be followed for disease progression from the first dose of study 
drug every 12 weeks for the remaining of the 1styear; every 16 wee ks during the 
2ndand 3rdyears; and every 24 weeks thereafter until subsequent anticancer 
therapy, and survival status until study closure.
Population: SRI and Randomization Phase: Subjects with relapsed/refractory mantle cell 
lymphoma 
Treat ment -naive Open -label Arm: Subjects with treatment -naive mantle cell 
lymphoma
Centers: Multiple, US and ex -US 
 
         
  
              
  
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 17Inclusion Criteria:
SRI and 
Randomization Phase)
Refer to Section 4.1
for the complete and 
detailed list of 
inclusion/exclusion 
criteria.Disease -Related (see Section 4.1.1 for details)
Pathologically confirmed MCL (in tumor tissue), with documentation of 
either overexpression of cyclin D1 in association with other relevant 
markers (eg, CD19, CD20, PAX5, CD5) or evidence of t(11;14) as 
assessed by cytogeneti cs, fluorescent in situ hybridization (FISH), or 
polymerase chain reaction (PCR)
At least 1 measurable site of disease that is ≥2.0cm in the longest 
diameter and measurable in 2 perpendicular dimensions per CT
At least 1, but no more than 5, prior treatm ent regimens for MCL 
including at least 1 prior rituximab/anti -CD20 containing regimen
Failure to achieve at least partial response (PR) with, or documented 
disease progression after, the most recent treatment regimen
Subjects must have adequate fresh or p araffin embedded tissue
Laboratory (see Section 4.1.1 for details)
Adequate hematologic function
Adequate hepatic and renal function
Demographic 
Men and women ≥18 years of age
Eastern Cooperative Oncology Group (ECOG) performance status (PS) 
of≤ 2
Exclusion Criteria:
(SRI and 
Randomization Phase)Disease -Related (see Section 4.1.2 for details)
History or current evidence of central nervous system lymphoma
Concurrent Conditions (see Section 4.1.2 for details)
Concurrent enrollment in another therapeutic investigational study or 
prior therapy with ibrutinib or other BTK inhibitors
Prior treatment with venetoclax or other BCL2 inhibitors
Anticancer therapy including chemotherapy, radiotherapy, small 
molecule and investigational agents ≤21 days prior to receiving the first 
dose of study drug
Treatment with any of the following within 7 days prior to the first 
dose of study drug:
omoderate or strong cytochrome P450 3A (CYP3A) inhibitors
omoderate or strong CYP3A inducers
Inclusion Criteria: 
(Treatment -naive 
Open -label Arm)1. Pathologically confirmed treatment -naive MCL (tumor tissue), with 
documentation of either overexpression of cyclin D1 in association with other 
relevant markers (eg, CD19, CD20, PAX5, CD5) or evidence of t(11;14), as 
assessed by cytogenetics, fluorescent in situ hybridization (FISH), or 
polymerase chain reaction (PCR).
A report from the local laboratory is acceptable if available; however, it 
must be reviewed and approved by the central pathology laboratory to 
verify the above criteria prior to enrollment.
If the report from the local laboratory is not available, a tumor block or 
slides must be sent to the central patholog y laboratory for confirmation 
of the MCL diagnosis prior to enrollment
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 182. Men and women ≥18 years of age with a TP53 mutation1
3. At least 1 measurable site of disease that is ≥2.0 cm in the longest diameter 
and measurable in 2 perpendicular dimensions per CT
4. Subjects must have adequate fresh or paraffin -embedded tissue
5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of ≤
2
6. Adequate hematologic function independent of transfusion and growth factor 
support for at least 7 days pri or to first dose, with the exception of pegylated 
G-CSF (pegfilgrastim) and darbepoeitin which require at least 14 days prior 
to the first dose defined as: 
Absolute neutrophil count (ANC) > 1000 cells/mm3(1.0x 109/L)
Platelet count > 50,000 cells/mm3(50 x 109/L)
Hemoglobin > 8.0 g/dL
7. Adequate hepatic and renal function defined as:
Serum aspartate transaminase (AST) or alanine transaminase (ALT) 
≤3.0xupper limit of normal (ULN)
Estimated Creatinine Clearance (CrCl) ≥30 mL/min (Cockcroft -Gault)
Bilirubin ≤1.5 x ULN (unless bilirubin rise is due to Gilbert’s 
syndrome or of non -hepatic origin)
8. Prothrombin time (PT) or International normal ratio (INR) < 1.5 x upper limit 
of normal (ULN) and PTT (activated partial thromboplastin time [aPTT]) 
<1.5 x ULN (unless abnormalities are unrelated to coagulopathy or bleeding 
disor der). When treated with warfarin or other vitamin K antagonists, then 
INR ≤3.0
9. Male and female subjects of reproductive potential who agree to use 
both a hi ghly effect ive method of  birth control  (eg, implants, 
injectables, combined oral contraceptives, so me intrauteri ne devices 
[IUDs], com plete abst inence2, or sterilized partner) and a barrier 
method (eg, condoms, cervical ring, sponge, etc) during the period of 
therapy  and f or 90 day s after the l ast dose of study  drug
Exclusion Criteria: 
(Treatment -naive 
Open -label Arm)1. Blastoid variant of MCL
2. History or current evidence of central nervous system lymphoma
3. Concurrent enrollment in another therapeutic investigational study or prior 
therapy, including ibrutinib or other BTK inhibitors
4. Prior treatment with venetocl ax or other BCL2 inhibitors
                                               
1TP53 test by local or central lab
2Complete abstinence is a highly effective method only if defined as refraining from heterosexual intercourse during the entir e 
period of risk associated with the study treatments. The reliability of sexual abstinence ne eds to be evaluated in relation to the 
duration of the clinical trial and the preferred and usual lifestyle of the subject. 
http://www hma.eu/fileadmin/dateien/Human_Medicines/01 
About_HMA/Working_Groups/CTFG/2014_09_HMA_CTFG_Contraception.pdf
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 195. History of other malignancies, except:
Malignancy treated with curative intent and with no known active 
disease present for ≥ 3years before the first dose of study drug and felt 
to be at low risk for recurrence by treating physician
Adequately treated non -mela noma skin cancer or lentigo maligna 
without evidence of disease
Adequately treated carcinoma in situ without evidence of disease
6. Vaccinated with live, attenuated vaccines within 4 weeks of the first dose of 
study drug
7. Clinically significant infection requiring IV systemic treatment that was 
completed ≤14 days before the first dose of study drug
8. Any uncontrolled ac tive systemic infection
9. Known bleeding disorders (eg, von Willebrand’s disease or hemophilia)
10. History of stroke or intracranial hemorrhage within 6 months prior to 
enrollment
11. Known history of human immunodeficiency virus (HIV) or active with 
hepatitis C virus (HCV) or hepatitis B virus (HBV). Subjects who are 
positive for hepatitis B core antibody, or hepatitis C antibody must have a 
negative polymerase chain reaction (PCR) result before enrollment. Those 
who are hepatitis B surface antigen (HBsA g) or PCR positive will be 
excluded.
12. Major surgery within 4 weeks of the first dose of study drug.
13. Any life -threatening illness, medical condition, or organ system dysfunction 
that, in the investigator’s opinion, could compromise the subject’s safe ty or 
put the study outcomes at undue risk
14. Currently active, clinically significant cardiovascular disease, such as 
uncontrolled arrhythmia or Class 3 or 4 congestive heart failure as defined 
by the New York Heart Association Functional Classification; or a history 
of myocardial infarction, unstable angina, or acute coronary syndrome 
within 6 mont hs prior to randomization
15. Unable to swallow capsules or tablets, or malabsorption syndrome, disease 
significantly affecting gastrointestinal function, or r esection of the stomach 
or small bowel, symptomatic inflammatory bowel disease or ulcerative 
colitis, or partial or complete bowel obstruction
16. Treatment with any of the following within 7 days prior to the first dose of 
study drug:
Moderate or strong cytochrome P450 3A (CYP3A) inhibitors 
(Appendix D)
Moderate or strong CYP3A inducers ( Appendix D)
17. Administration or consumption of any of the following within 3 days prior 
to the first dose of study drug:
grapefruit or grapefruit products
Seville oranges (including marmalade containing Seville oranges)
star fruit
18. Known allergy to xanthine oxidase inhibitors and/or rasburicase for subjects 
with known risk factors (as defined by high tumor burden and/or diminished 
renal function, as detailed in “Study Design” section above) for TLS
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 2019. Subjects with chronic liver dis ease with hepatic impairment Child -Pugh 
class B or C
20. Female subject who is pregnant, breastfeeding or is considering becoming 
pregnant during the study or for approximately 90 days after the last dose of 
study drug
21. Male subject who is considering f athering a child or donating sperm during 
the study or for approximately 90 days after the last dose of study drug
22. Unwilling or unable to participate in all required study evaluations and 
procedures
23. Unable to understand the purpose and risks of the study and to provide a 
signed and dated informed consent form (ICF) and authorization to use 
protected health information (in accordance with national and local subject 
privacy regulations)
24. Known hypersensitivity to the active ingredient or other comp onents of one 
or more study drugs
Study Treatment: 
(Safety Run -in and 
Randomization Phase)Ibrutinib: 
560 mg of ibrutinib dosed orally once daily. Ibrutinib may be supplied either as 
560mg tablet (maximum of 1 tablet dosed once daily) or as 140 mg capsules 
(maxim um of 4 capsules dosed once daily)
Venetoclax: 
Orally once daily venetoclax started either concurrently with ibrutinib using the 
standard Ramp -up Schedule
Placebo:
Oral matching placebo for venetoclax started concurrently with ibrutinib us ing 
the standard Ramp -up Schedule
Study Treatment: 
(Treatment -naive
Open -label Arm)Ibrutinib: 
560 mg of ibrutinib dosed orally once daily. Ibrutinib may be supplied either as 
a 560 mg tablet (maximum 1 tablet dosed once daily) or as 140 mg capsules 
(maximum of 4 capsules dosed once daily)
Important: If using tablets, please ensure that patients do not take more than 
one 560 mg tablet per day.
Venetoclax: 
Orally once daily venetoclax started concurrently with ibrutinib using the 
Venetoclax Standard Ramp -up Schedule ( Figure 4).
Concomitant 
Therapy:Caution is advised when administering moderate or strong CYP3A inhibitors or 
inducers or P -gp inhibitors. Refer to Section 6for information on concomitant 
therapy.
Sample Size 
Determination: 
(SRI and 
Randomization Phase)Safety Run -in Period
Sample size determination for the Safety Run -in Period follows the standard 
dose escalation convention as described in the DLT and TLS assessment 
section. Up to 27 subjects may be enrolled in the Safety Run -in Period for 
evaluation.
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 21Randomization Phase 
The primary efficacy endpoint of PFS will be determined by investigator 
assessment. Approximately 260 subjects will be enrolled and randomized at a 
1:1ratio. With a targeted HR of 0.61 (corresponding to an improvement in 
media n PFS from 14 months to 23 months), 134 PFS events will provide at least 
80% power at a 1 -sided ov erall significance level of 0.025 . Overall survival will 
be analyzed at the time of the primary analysis of PFS when the superiority 
boundary for PFS is crossed. Details are presented in Section 10of the protocol.
Sample Size 
Determination: 
(Treatment -naive
Open -label Arm)A sample size of 75 treatment -naive subjects is needed to exclude a 35% CR 
rate at a 1 -sided significance level of 0.025 with app roximately 80% power, 
assuming a target CR rate of 51%. 
For the subpopulation with a TP53 mutation, a sample size of 48 subjects is 
needed to exclude a 25% CR rate with approximately 80% power, assuming a 
target CR rate of 45%. The TP53 population could b e a mix of treatment -naive 
MCL subjects and/or R/R MCL subjects with a TP53 mutation.
Statistical 
Methods/Data 
Analy sis:
(SRI and 
Randomization 
Phase)Endpoints for the Safety Run -in Period will be summarized descriptively and 
separately from the Randomization Phase data. 
The primary endpoint in the Randomization Phase, PFS, will be compared 
between treatment arms using the stratified log -rank test. The hazard ratio will 
be estimated using a stratified Cox proportional hazard model. Details are 
presented in Section 10of the protocol.
Statistical 
Methods/Data 
Analy sis:
(Treatment -naive 
Open -label Arm)The CR rate is the primary endpoint for the open -label arm and will be 
estimated based on exact binomial d istribution. The confidence interval will be 
provided. Details are presented in Section 10of the protocol.
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 22ABBREVIATIONS
AE adverse event 
AESI Adverse Events of Special Interest (AESI)
ALT alanine aminotransferase 
AML acute myeloid leukemia
ANC absolute neutrophil count 
ASCO American Society of Clinical Oncology
AST aspartate am inotransferase 
AUC area under the concentration -time curve
BCL -2 B-cell lymphom a 2
BCR B-cell receptor 
BCRP Breast Cancer Resistance Protein
BTK Bruton’s tyrosine kinase 
BUN blood urea nitrogen
CI confidence interval
CLL chronic lymphocytic leukemia 
Cmax maximum observed plasm a concentration
CR complete response rate
CrCl creatinine clearance
CFR Code of Federal Regulations
CRF case report form (paper or electronic as appropriate for this study)
cGVHD chronic graft vs. host disease
CMH Cochran -Mantel -Haenszel
CT Computed Tomography
CTCAE Common Terminology Criteria for Adverse Events 
CYP cytochrome P450
DLT Dose -limiting toxicity
DMC Data Monitoring Committee
DOR duration of response
ECOG Eastern Cooperative Oncology Group
ECG Electrocardiogram
eCRF Electronic case report form
EDC electronic data capture
EMR electronic medical records
EOT End of treatment
EQ5-D European Quality of Life -5 Dim ensions
EU European Union
FDA Food and Drug Administration
FFPE formalin-fixed paraffin -embedded tumor tissue
FL follicular lymphom a
GCP Good Clinical Practice
G-CSF granulocyte colony -stimulating factor
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 23HBsAg hepatitis B surface antigen
HBV hepatitis B virus
HCV hepatitis C virus
HDPE high density polyethylene
HIV human immunodeficiency virus
HIPAA Health Insurance Portability and Accountability Act
IB Investigator's Brochure
IV Intravenous
IC50 concentration that inhibits a process by 50%
ICF informed consent form
ICH International Conference on Harmonisation
IEC Independent Ethics Committee
ILD Interstitial Lung Disease
INR International norm alized ratio
IRB Institutional Review Board
IRT Interactive Response Technology
LDH lactate dehydrogenase
MCL mantle cell lymphom a
MedDRA Medical Dictionary for Regulatory Activities
MDS myelodysplastic syndrome
MRD minimal residual disease
MRI Magnetic Resonance Imaging
MRU Medical Resource Utilization
MTD maximum tolerated dose
NCI-ODWG National Cancer Institute Organ Dysfunction Working Group
NHL Non-Hodgkin’s Lymphom a
ORR overall response rate
OS overall survival
PCR polymerase chain reaction
PD progressive disease
PET Positron Emission Tomography
PFS Progression free survival
P-gp P-glycoprotein
PK Pharm acokinetics
PML progressive multifocal leukoencephalopathy
PR partial response 
PRO patient -reported outcome(s)
PS perform ance status
aPTT activated partial thromboplastin time
PT prothrombin time 
QTc QT interval corrected for heart rate 
REB Research Ethics Board
RP3D Recommended Phase 3 Dose 
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 24SAE serious adverse event
SAP Statistical Analysis Plan
SCARs severe cutaneous adverse reactions 
SJS Stevens -Johnson syndrome 
SLL small lymphocytic lymphom a 
SmPC Summary of product characteristics
SRI Safety Run -in
t1/2 half-life
Tmax time to m aximum plasm a concentration 
TEAE treatm ent-emergent adverse event
TLS tumor lysis syndrome
TN treatm ent-naive
TTN T time-to-next treatment
ULN upper limit of norm al
USPI United States Prescribing Inform ation
WC withdrawal of consent
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 251BACKGROUND
1.1 Mantle Cell Lymphoma
1.1.1 Disease Background
Mantle cell lymphoma (MCL) is a dist inct clinical -pathol ogic enti ty within the non- Hodgkin’s 
lympho mas (NHL). Init ially term ed “centrocy tic lymphom a” in the Kiel Classificat ion system 
(Lennert 1981 ), MCL has subseq uently been shown to harbor the translocat ion t(11,14)(q13;q32), 
which results in constitutive overexpression o f cyclin D1 (Zucca 1994 ). These features are now 
considered requisite for the diagnosis of the disease.
Mantle cell lymphoma accounts for about 6 -9% of all NHL cases in the Western world. The annual 
incidence of MCL has increased during recent decades to 1 -2/100,000. MCL occurs more 
frequently in o lder adults (Zhou 2008 ). Mo st patients with MCL are men (median age: 65 years) 
who present with advanced stage disease (ie, Stage III or IV) and most cases fo llow an aggressive 
clinical course ( Dreyling 2014 ). The typical presentation is with generalized lymphadenopathy , 
and extranodal invo lvement frequent ly occurs in the gastrointestinal tract, spleen, bone marrow, 
and liver; less commo n extranodal  sites are skin, l ungs, and breast or soft tissues. Though the 
clinical course of MCL may  be somewhat indo lent at di agnosis, the course invariably beco mes 
aggressive over time. Unlike other NHLs, MCL is considered incurable with standard therapies 
and is associated with a poor prognosis and a relatively short median overall survival (OS) 
(Lenz 2004). There i s no curative therapy  for MCL. A few pati ents m ay achieve lo ng-term, 
disease -free survival after allogeneic stem cell transplantation ( Goy 2011), but in general, the 
disease is characterized by  a ser ies of relapses wit h a m edian OS of 4 to 5 y ears. A number of 
MCL prognostic variables have been ident ified, including the presence or absence of extranodal 
disease, age, l
actate dehy drogenase (LDH) levels, performance status, and Ki -67 proliferat ive 
index (Hoster 2008).
1.1.2 Current Treatment Options
Current init ial therapy for the treatment of MCL includes cyclophosphamide, doxorubicin, 
vincrist ine, and prednisone (CHOP) or hyperfract ionated cy clophosphamide, vincristine, 
doxorub icin, and dexamethasone alternat ing with methotrexate and cytarabine (Hyper -CVAD), 
often in co mbinat ion with rituximab (R -
CHOP or R- Hyper CVAD). In recent years, treatment 
with bendamust ine and rituximab has gained increasing use fo llowing studi es showing that thi s 
combinat ion significantly prolongs PFS, while maintaining a favorable safet y profile amo ng 
patients wi th previ ously untreated MCL ( Robinson 2008, Rummel 2005 ). 
For patients who rel apse after ini tial therapy , chemoi mmunotherapy  treatm ent opti ons involve 
the use of rituximab in co mbinat ion with one or more of the following: bendamustine, cladribine, 
fludarabine, cy clophosphamide, mitoxantrone, etoposide and procarbazine. ( Dreyling 2013, 
NCCN 2016). In cases of early relapses or in pat ients with refractory  disease, newer targeted 
approaches should be strongly  considered. Three non -cytotoxic drugs, ibrut inib, bortezomib and 
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 26lenalido mide, are FDA approved for previously treated patients with MCL in the US. In the 
European Unio n, approved treatment in the relapsed and refractory  MCL setting was limited to 
temsirolimus until the approval of ibrut inib in 2014. Based on registration trials, the ORR for 
these drugs are 68% (21% CR) with ibrut inib, 33% (8% CR) with bortezomib, 28% (8% CR) 
with lenalido mide, and 22% (2% CR) with temsirolimus, with a median PFS of 13.9, 6.5, 4 and 
4.8 m onths, respect ively ( Campo 2015 ). These drugs are being combined wit h rituximab and 
incorporated into standard therapeutic and maintenance regimens showing some improved 
efficacy  (Ghielmini  2009 ). Despi te the fact that resul ts from ibrutinib showed marked 
improvement over temsiro limus ( Dreyling 2016 ), the median PFS of approximately 14 months 
underscores the need to improve further on the dismal outcome for relapsed MCL pat ients. 
However, new strategies are needed that may substant ially improve outcom es for R/R MCL 
patients and ma y in long-term obviate intensive chemotherapy  and/or transplantation in y ounger 
MCL pat ients and chemotherapy  in older pati ents wi th MCL ( Campo
2015 ).Based on the 
preliminary data showing a CR rate of 70% with an acceptable safety profile observed in an 
ongoing study  of ibrutinib and venetoclax in pat ients wi th relapsed or refractory  MCL 
(Tam 2016) coupl ed wi th the durabilit y of responses observed with ibrut inib monotherapy  and 
venetoclax monoth erapy  in pat ients with relapsed or refractory  MCL who achieved CR observed 
with each ( Rule 2016, Gerecitano 2015), the combinat ion of ibrut inib and venetoclax is expected 
to induce deep and durable responses in patients wit h relapsed/refractory  MCL.
1.2 Ibrutinib Overview
Ibrutinib (I MBRUVICA®) is a fi rst-in-class, potent, orally  administered, coval ently binding 
inhibitor of Bruton’s ty rosine kinase (BTK) co -developed by Pharmacyclics LLC and Janssen 
Research & Development LLC for the treatm ent of B -cell malignancies.
Ibrutinib has been approved in many regio ns, including the United States (US) and European 
Unio n (EU), for indicat ions including the treatment of patients with MCL who have received at 
least 1 prior therapy, patients with chroni c lymphocy tic leukemia (CLL)/small lymphocy tic 
lympho ma (SLL) including CLL/SLL with a delet ion of the short arm of chro mosome 
17(del17p), patients with Waldenström’s macroglobulinemia (WM), patients with marginal zone 
lympho ma (MZL) who requir e systemic therapy  and have received at l east one pri or 
anti
-CD20 -based therapy , and cGVHD after failure of one or more lines of systemic therapy .
For the most up -to-date and comprehensive nonclinical and clinical informat ion regarding 
ibrutinib background , safet y, efficacy , in vi tro and in vivo preclinical activit y, and toxi cology of 
ibrutinib, always refer to the latest version o f the ibrutinib Invest igator's Brochure (IB) and/or the 
applicable regio nal labeling informat ion.
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 271.2.1 Summary of Nonclinical Data
1.2.1.1 Pharmacology
Ibrutinib was designed as a selective and covalent inhibitor of BTK ( Pan 2007 ). In vi tro, 
ibrutinib is a potent inhibitor of BTK act ivity (IC 50= 0.39 nM). The irreversible binding o f 
ibrutinib to Cys -481 in the ac tive site of BTK results in sustained inhibit ion of BTK cataly tic 
activit y and enhanced select ivity over other kinases that do not contain a cysteine at this position. 
When added directly to human who le blood, ibrut inib inhibits signal transduct ion from the BCR 
and blocks primary B -cell activation (IC 50= 80 nM) as assayed by ant i-IgM st imulation fo llowed 
by CD69 expressio n (Herm an 2011 ).
Ibrutinib arrested cell growth and induced apoptosis in human B -cell lympho ma cell lines in 
vitro and inhibited tumor growth in vivo in xenograft models ( Herm an 2011 ). Ibrutinib also 
inhibited adhesio n and migration o f MCL cells in co -culture and reduced tumor burden in lymph 
node and bone marrow in a murine mode l of MCL disseminat ion and progression ( Chang 2013a, 
Chang 2013b )
For m ore detailed and comprehensive informat ion regarding nonclinical pharmaco logy, please 
refer to the current ibrutinib IB.
1.2.1.2 Safety Pharmacology and Toxicolog y
No treatment -related effects were observed in the central nervous system or respiratory  system  in 
rats at any  dose tested. Further, no treatment- related corrected QT interval (QTc) prolongation 
effect was observed at any  tested dose in a cardiovascular s tudy using tel emetry -monitored dogs. 
Based on data from rat and dog including general toxicit y studi es up to 13 weeks duration, the 
greatest potential for human toxicit y with ibrutinib is predicted to be in lympho id tissues 
(lympho id deplet ion) and the gas trointest inal tract (soft feces/diarrhea wit h or without 
inflammat ion). Addit ional toxicit y findings seen in only one species with no observed human 
correl ate in clinical studies to date include pancreatic acinar cell atrophy  (rat), minimally 
decreased tra becular and cortical bone (rat) and corneal dystrophy (dog). In studies in pregnant 
rats and rabbits, ibrut inib administration was associated with malformat ions (teratogenicit y) at 
ibrutinib doses that result in approximately 14 and 2 times the exposure (a rea under the 
concentration -time curve [AUC]) in pat ients administered the dose of 560 mg daily, respect ively. 
Fetal  loss and reduced fetal body  weights were al so seen in treated pregnant animals. 
Carcinogenicit y studi es have not been conducted with ibrut inib. In vitro and in vivo genet ic 
toxicity studies showed that ibrut inib is not genotoxic. No effects on fertilit y or reproductive 
capacit ies were observed in a study  in male and female rats.
For the most up -to-date and comprehensive information regarding nonclinical safety  
pharmaco logy and toxi cology, please refer to the current ibrutinib IB.
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 281.2.2 Summary of Clinical Data
1.2.2.1 Pharmacokinetics and Product Metabolism
Following oral  administrati on of  ibrutinib at doses ranging from 420 to 840 mg/day, exposure to 
ibrut inib increased proportionally with substant ial inter-subject variabilit y. The m ean terminal 
plasma eliminat ion half -life (t 1/2) of ibrut inib ranged fro m 4 to 13 hours, with a median time to 
maximum plasma concentration (T max) of 2 hours. Despite the doubli ng in m ean systemic 
exposure when dosed with food, the favorable safety  profile o f ibrut inib allows dosing wit h or 
without food. Ibrutinib is extensively  metabo lized primarily by cytochro me P450 (CYP) 3A4. 
The on -target effects of the main metabo lite PCI -45227 are not considered clinically relevant. 
Steady -state exposure of ibrutinib and PCI -45227 was less than 2
-fold of first dose exposure 
implying non -clinically  relevant accum ulation. Less than 1% of ibrutinib is excreted in the urine. 
Ibrutinib exposure is not altered in patients with creatinine clearance (CrCl) > 30mL/min. 
Patients wi th severe renal impairment or patients on dialysis have not been studied. Fo llowing 
single- dose administrati on, the AUC of ibrut inib increased 2.7- , 8.2-and 9.8- fold in subjects 
with mild (Child -Pugh class A), m oderate (Child -Pugh class B), and severe (Child -Pugh class C) 
hepat ic impairment compared to subjects with normal liver funct ion. A higher proportion of 
Grade 3 or higher adverse react ions were reported in patients w ith B-cell malignancies 
(CLL, MCL and WM) with mild hepat ic impairment based on NCI organ dysfunct ion working 
group (NCI -ODWG) criteria for hepatic dysfunct ion compared to patients with normal hepat ic 
funct ion.
For the most recent and the most comprehensiv e information regarding pharmacokinet ics (PK) 
and product metabo lism, please refer to the current ibrut inib IB.
1.2.3 Summary of Clinical Safety
A brief summary  of safet y data from  monotherapy  and combinat ion therapy  studi es is provi ded 
below. For the most up to date and most comprehensive safety  informat ion regarding ibrut inib, 
please refer to the current ibrut inib IB. Addit ional safet y informat ion may be available for 
approved indications in regional prescribing labels where the study  is conducted (eg, USPI, 
SmPC).
1.2.3.1 Monotherapy Studies 
Pooled safet y data from  a total  of 1578 subjects treated wi th ibrutinib mo notherapy  in 20 studies 
in B-cell malignancies that have completed primary  analysis or final analysis as of 
12November 2018 are summarized below.
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 29The m ost frequently reported treatment -emergent adverse events (TEAEs) in subjects receiving 
ibrutinib as mo notherapy  (N=1578) included:
Most frequently reported 
TEAEs ³15%Most frequently reported Grade 
3 or 4 TEAEs ³3%Most frequently reported Serious 
TEAEs ³2%
Diarrhea Neutropenia Pneumo nia
Fatigue Pneumo nia Atrial fibrillation
Nausea Thrombocytopenia Pyrexia
Cough Anemia Febrile neutropenia
Anemia Hypertension
Pyrexia Diarrhea
Upper respiratory tract infection Atrial fibrillation
Neutropenia
Oedema peripheral
Thrombocytopenia
1.2.3.2 Combination Studies
Pooled safet y data from  a total  of 1449 subjects treated wi th various therapies in combinat ion 
with ibrutinib from 13 studies conducted in subjects with B -cell malignancies are briefly 
summarized below. Therapies used in co mbinat ion with ibrutinib in these studies included BR 
(bendamust ine and rituximab), FCR (fludarabine, cy clophosphamide, and ri tuximab), 
ofatum umab, and R -CHOP (ri tuximab, cycl ophosphamide, doxorubi cin, vincrist ine, and 
prednisone ).
The m ost frequently reported TEAEs in subjects receiving ibrut inib in co mbinat ion therapy  
(N=1449) included:
Most frequently reported 
TEAEs ³20%Most frequently reported Grade 
3 or 4 TEAEs ³3%Most frequently reported Serious 
TEAEs ³2%
Diarrhea Neutrop enia Febrile neutropenia
Neutropenia Anemia Pneumo nia
Nausea Febrile neutropenia Atrial fibrillation
Fatigue Thrombocytopenia Pyrexia
Neutrophil count decreased Anemia
Neutropenia
Anemia
ThrombocytopeniaPneumo nia
White cell count decreased
Leukopenia
Pyrexia Platelet count decreased
Diarrhea
Hypertension
Atrial fibrillation
Hyponatraemia
Diarrhea
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 301.2.4 Risks
1.2.4.1 Bleeding- related Events
There have been reports of hemorrhagic events in subjects treated with ibrut inib, both with and 
without thrombocy topeni a. These include minor hemorrhagic events such as contusion, epistaxis, 
and petechiae; and major hemorrhagic events, some fatal, includin g gastrointestinal bleeding, 
subdural intracranial hemorrhage, and hematuria. Subjects with congenital bleeding diathesis 
have not been studied. 
In an in vitro platelet function study , inhibi tory effects of ibrut inib on co llagen ‑induced pl atelet 
aggregati on were observed, refer to Section 6.2.4 . Use of either ant icoagulant or anti platel et 
agents concomitant ly wit h ibrutinib increases the risk of major bleeding. A higher risk for major 
bleeding was observed wit h ant icoagulant than with antiplatelet agents. Consider the risks and 
benefits of ant icoagul ant or anti platel et therapy  when co -administered with ibrut inib. Monitor for 
signs or symptom s of bleeding. See Secti on 6.2.4 for guidance on c oncomitant use of 
anticoagulants, ant iplatelet therapy  and/or suppl ements.
Suppl ements such as fish oil and vitamin E preparations should be avoided. Ibrutinib should be 
held at least 3 to 7 day s pre -and post -surgery , depending upon the ty pe of surgery  and the ri sk of 
bleeding. See Secti on 6.3for guidance on ibrut inib management with surgeries or procedures. 
Subjects with congenital bleeding diathesis have not been studied. 
1.2.4.2 Leukostasis
There were i solated cases of leukostasis reported in subjects treated with ibrutinib. A high 
number of circulat ing white blood cells (> 400,000/µL) may confer increased risk. For subject 
and ibrut inib management guidan ce, refer to Section 5.3.1.5 .
1.2.4.3 Infections 
Infections (including sepsis, bacterial, viral, or fungal infect ions) were observed in subjects 
treated wi th ibrutinib therapy. Some of these reported infect ions have been associated with 
hospi talizati on and death. Consider prophylaxis according to standard of care in pat ients who are 
at increased risk for opportunist ic infect ions (see Secti on 6.1). Although causalit y has not been 
established, cases of progressive mult ifocal leukoencephalopathy  (PML) have occurred in 
subjects treated with ibrut inib. Subject s should be mo nitored for symptoms (fever, chills, 
weakness, confusio n), and appropriate therapy  shoul d be inst ituted as indicated.
1.2.4.4 Cytopenias 
Treatment -emergent Grade 3 or 4 cytopenias (neutropenia, thrombocytopenia, and anemia) were 
reported in subjects treated with ibrut inib. Monitor complete blood counts monthly.
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 311.2.4.5 Interstitial Lung Disease (ILD)
Cases of interstit ial lung disease (ILD) have been reported in subjects treated with ibrut inib. 
Moni tor subjects for pulmonary  symptom s indicat ive of ILD. If sy mptom s develop, interrupt 
ibrutinib and manage ILD appropriately . If symptoms persist, consider the risks and benefit s of 
ibrutinib treatment and fo llow the protocol  dose modificat ion gui delines as needed (see 
Secti on5.3.1.4 ).
1.2.4.6 Cardiac Arrhythmias and Cardiac Failure 
Atrial fibrillat ion, atri al flutter, and cases of ventricular tachyarrhy thmia and cardiac failure 
including so me fatal even ts, have been reported in subjects treated with ibrut inib, particularly in 
subjects wi th cardi ac risk factors, hy pertensi on, acute i nfect ions, and a previous history  of 
cardi ac arrhy thmia. At baseline and then periodically , moni tor subj ects clinically for cardiac 
arrhy thmia and cardiac failure. Subjects who develop arrhy thmic symptom s (eg, palpitat ions, 
lightheadedness, syncope, chest disco mfort or new onset of dy spnea) shoul d be eval uated 
clinically and, if indicated, have an ECG performed. For cardiac arr hythmias or cardiac failure 
which persist, consider the risks and benefits o f ibrutinib treatment and fo llow the protocol dose 
modificati on guidelines (see Section5.3.1.4 ).
1.2.4.7 Tumor Lysis Syndrome
Tumor lysis syndrom e has been reported with ibrutinib therapy. Subjects at risk of tumor lysis 
syndro me are those with high tumor burden prior to treatment. Monitor subjects closely and take 
appropriate precauti ons. 
1.2.4.8 Non-melanoma Skin Cancer
Non-melanoma skin cancers have occurred in subjects treated with ibrutinib. Monitor subjects 
for the appearance of non -melanoma skin cancer.
1.2.4.9 Lymphocytosis
Upon init iation of single agent treatment with ibrutinib, a reversible increase in lymphocy te 
counts (i e, ≥50% increase from baseline and an absolute count > 5,000/µL), often associated 
with reducti on of  lymphadenopathy , has been observed in most subjects (66%) with CLL/small 
lymphocy tic lympho ma (SLL). This effect has also been observed in so me subjects (35%) with 
MCL treated with ibrut inib. This observed lymphocytosis is a pharmacodynamic effect and 
should not be consi dered progressive disease in the absence of other clinical findings. In both 
disease t ypes, lymphocytosis typically occurs during the first month of ibrut inib therapy and 
typically  resolves wi thin a median of 8 weeks in subjects with MCL and 14 weeks in subjects 
with CLL/SLL (range 0.1 to 104 weeks). When ibrutinib was administered in combination wit h 
BR or wi th obinutuzum ab in subjects with CLL/SLL, lymphocy tosis was infrequent (7% with 
ibrutinib + BR versus 6% with placebo + BR and 7% with ibrut inib + obinutuzumab versus 1% 
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 32with chlorambucil + obinutuzumab). Lymphocy tosis was not observed with WM treated with
ibrutinib. 
For subject and ibrutinib management guidance, refer to Section 5.3.1.5 .
1.2.4.10 Cerebrovascular Accidents
Although causalit y has not been esta blished, cases of cerebrovascular accident, transient 
ischemic attack, and ischemic stroke including fatalit ies have been reported with the use of 
ibrutinib in the post -marketing setting, with and without conco mitant atri al fibrillat ion and/or 
hypertensio n. Regular m onitoring and appropri ate treatm ent of condit ions that can contribute to 
the occurrence of these events is reco mmended.
1.2.4.11 Diarrhea
Diarrhea is the m ost frequent ly reported non -hematol ogic AE wi th ibrutinib monotherapy and 
combinat ion therapy . Othe r frequent ly reported gastrointestinal events include nausea, vo miting, 
and const ipation. These events are rarely severe and are generally managed with supportive 
therapi es including ant idiarrheals and antiemet ics. Subjects should be monitored carefully fo r 
gastrointestinal AEs and cautioned to maintain fluid intake to avoid dehydrat ion. Medical 
evaluat ion shoul d be m ade to rul e out other eti ologies such as Clostridium difficile or other 
infect ious agents. Should symptoms be severe or prolonged fo llow the p rotocol  dose 
modificati on guidelines (see Section 5.3.1.4 ).
1.2.4.12 Rash
Rash has been co mmo nly reported in subjects treated with either single agent ibrutini b or in 
combinat ion with chem otherapy . Rash occurred at a higher rate in the ibrut inib arm than in the 
ofatum umab arm  in Study  1112. Most rashes were mild to moderate in severit y. Isolated cases of 
severe cutaneous adverse react ions (SCARs) including Steve ns-Johnson syndro me (SJS) have 
been reported in subjects treated with ibrut inib. Subjects should be closely mo nitored for si gns 
and symptoms suggest ive of SCAR including SJS. Subjects receiving ibrut inib should be 
observed closely  for rashes and treated sy mptom atically, including interruption of the suspected 
agent as appropriate. In addit ion, hypersensit ivity-related events including ery thema, urti caria, 
and angioedema have been reported .
1.2.4.13 Hypertension
Hypertensio n has been co mmo nly reported in subjects treated wi th ibrutinib. Monitor subjects 
for new onset of hypertensio n or hy pertensio n that is not adequately  controlled after starti ng 
ibrutinib. Adjust existing ant i-hypertensive medications and/or init iate anti -hypertensive 
treatm ent as appropri ate.
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 331.3 Venetoclax Overview
Venetoclax (VENCLEXTA®) is a potent, orally administered inhibitor of B -cell lymphom a 2 
(BCL -2) co -developed by AbbVie Inc and Genentech Inc for the treatment of B -cell 
malignancies.
Venetoclax has been granted accelerated approval in the US based on overall response rate in the 
US for the treatment of patients with CLL with 17p delet ion, as detected by  an FDA approved 
test, who have received at least one prior therapy . In the EU, venetoclax in co mbinat ion with 
rituximab is indicated for th e treatm ent of adult patients with CLL who have received at least 
1prior therapy . Monotherapy  is indicated for the treatment of CLL in the presence of 17p del or 
TP53 m utation in adult patients who are unsuitable for or have failed a B -cell receptor pathw ay 
inhibitor, or in the absence o f 17p del  or TP53 m utation in adult patients who have failed both 
chemo immunotherapy  and a B -cell receptor pathway  inhibitor. Similarly, the Australian 
Therapeut ic Goods Administration approved venetoclax for the treatment of patients wi th 
relapsed/refractory  CLL wi th 17p del etion, and for patients without 17p delet ion who have no 
other sui table treatm ent opti ons.
The Bcl -2 family proteins are important regulators of the intrinsic apoptosis pathway . The Bcl -2 
oncogene was fi rst identified in fo llicular lymphoma (FL) where the t(14;18) chromoso mal 
transl ocati on resul ts in si gnificant over -expressio n of the protein in B -cells. The Bcl -2 family of 
genes encodes a family of closely related proteins that possess either pro -apoptot ic or 
anti-apoptoti c activit y and share up to four Bcl -2 Hom ology (BH) dom ains ( Willis 2003, 
Cory 2002, Borner 2003, Cory  2003 ). Bcl -2 overexpressio n is a major contributor to the 
pathogenesis of so me types o f lympho id malignancies.
Venetoclax (also known as ABT -199) is a novel, orally  available, small mo lecule Bcl -2 family 
protein inhibitor that binds with high affinit y (Ki < 0.010 nM) to Bcl -2 and wit h lower affinit y to 
other Bcl -2 family proteins Bcl -xL and Bcl -w (> 4,000 -fold and > 2,000 -to >20,000 -fold lower 
affinit y than to Bcl -2, respectively) ( Souers 2013 ).Selective inhibit ion by venetoclax disrupts 
Bcl-2 signaling and rapidly  induces m ultiple hallmarks of apoptotic cell death in 
Bcl-2-dependent human tumor cell lines (venetoclax Invest igator’s Brochure [IB]). Importantly, 
venetoclax inhibit ion of Bcl-2 is independent of p53 activit y.
1.3.1 Summary of Nonclinical Data
In vitro, venetoclax demo nstrated broad cell killing activit y against a pan el of lympho ma and 
leukemia cells including B -cell fo llicular lympho mas (FLs), mant le cell lympho mas (MCLs), 
diffuse large B -cell lymphom as (DLBCLs), and acute myelo id leukemias (AMLs). Venetoclax 
was especially potent against cell lines expressing high le vels of Bcl -2. Leukemia and lympho ma 
cell lines bearing the t(14;18) translocation were significant ly more sensit ive to venetoclax than 
nonmutated lines. A detailed discussio n of the non
-clinical toxico logy, m etabo lism, and 
pharmaco logy can be found in the venetoclax IB.
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 341.3.2 Summary of Venetoclax Clinical Data
1.3.2.1 Clinical Pharmacokinetics
Following m ultiple oral  administrati ons under fed condi tions, m aximum plasma concentration of 
venetoclax was reached 5 -8 hours after dose. Venetoclax steady  state AUC increased 
proporti onally over the dose range of 150- 800 m g. Food can increase venetoclax exposure 
(3.4-fold wit h a low-fat meal and 5.1 -to 5.3 -fold with a high -fat meal). Venetocl ax shoul d be 
administered with a meal. The populat ion est imate for the terminal elimina tion half -life of 
venetoclax was approximately 26 hours. In vitro studies demonstrated that venetoclax is 
predominant ly metabo lized by CYP3A4/5. Less than 0.1% of venetoclax is excreted renally. 
Venetoclax exposures in subjects with mild or moderate renal impairment are similar to those 
with norm al renal functi on. The PK of venetocl ax has not been studied in subjects with severe 
renal impairment (CrCl < 30 m L/min) or subjects on dialysis. Venetoclax exposures are similar 
in subjects wi th mild and m oderate h epati c impairment and normal hepatic funct ion based on the 
NCI Organ Dysfunct ion Working Group criteria. Mild hepat ic impairment was defined as 
norm al total  bilirubin and aspartate transaminase (AST) > upper limit of normal (ULN) or total 
bilirubin > 1.0 to 1.5 times ULN, moderate hepatic impairment as total bilirubin > 1.5to
3.0times ULN, and severe hepat ic impairment as total bilirubin > 3.0 times ULN. The PK of 
venetoclax has not been studied in subjects with severe hepat ic impairment.
For the most com prehensive information regarding PK and product metabo lism, please refer to 
the current venetoclax IB.
1.3.2.2 Summary of Clinical Safety
Doses administered in venetoclax clinical studies have ranged fro m 20 m g to 1200 mg.
As of 28 November 2018, on the basis of o pen-label  and unblinded data available in the clinical 
databases for company -sponsored studies in the venetoclax onco logy devel opment program , a 
total of 2543 adul t subjects (1313 CLL/SLL, 361 AML, 218 MM, 570 NHL, and 59 MDS, 
20ALL, 1 rhabdo myosarcom a, and 1 Evans tumor in the pooled analysis dataset across all 
monotherapy  and co mbinat ion therapy  oncol ogy studi es in the venetoclax development program 
have been exposed to at least 1 dose of venetoclax. An addit ional 20 pediatric subjects 
(<18years of age ; 5 ALL, 10 AML, 3 neuroblastoma, other solid tumors) have been exposed to 
at least 1 dose of venetoclax. 
As of 28 November 2018, a total of 576 NHL subjects treated with venetoclax in the oncology 
clinical program had open -label or unblinded safety  data available, including 136 subjects who 
received venetoclax mo notherapy , and 440 subjects who received venetoclax in co mbinat ion 
with other agents including rituximab, BR, R -CHOP, or G -CHOP. Fift y additional subjects 
received BR in Study  BO29337. Of the 576 NHL subjects treated with venetoclax, 570 subjects 
are included in the pooled analyses across all studies, and data from the remaining 6 subjects 
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 35who crossed over to venetoclax treatment in Study BO29337 are excluded fro m the pool ed 
analyses.
Overall for NHL, when treated with venetoclax as a single agent or in co mbinat ion with other 
therapi es, the m ost comm on adverse events were nausea, neutropenia, and diarrhea. 
Approximately  three -fourths of subjects experienced ≥ Grade 3 adverse events, and the most 
commo n events were neutropenia, thrombocy topenia, and anaemia. The most commo n SAEs 
were febrile neutropenia, neutropenia, and pneumo nia. Of the fatal events in the NHL program, 
the majorit y were adverse events of malignant neoplasm progression. Findings fro m the analysis 
based on the exposure -adjusted incidence rates were consistent with the findings from the 
analysis based on the subject incidence rates. Many o f the adverse events reported in the current 
NHL studies are consistent with underlying disease or concomitant medical condit ions, as well 
as other com binat ion agents used to treat NHL patients. Safet y in combinat ion agents appears to 
be consistent with that observed in mo notherapy  trials and combinat ion backbone regimen.
The incidence of TLS in NHL st udies is l ow wi th reports of 2 cases (1.9%) of laboratory  TLS in 
monotherapy  Study  M12- 175, 4 cases of laboratory  TLS (2.5%) in combinat ion Study  BO29337 
(1 subject venetoclax + R, 3 subjects venetoclax + BR), and 4 cases of laboratory  TLS (1.5%) in 
combin ation Study  GO27878 (venetoclax + R -CHOP or G -CHOP). All cases of TLS resolved, 
and none led to discont inuat ion of study  drug. No cases o f clinical TLS were reported. 
Neutropenia has a similar frequency  in the NHL clinical program as in CLL wit h higher 
frequency  in NHL combinat ion studi es. Seri ous adverse events of neutropenia and febrile 
neutropeni a, albeit in small numbers, occurred in higher frequency in combinat ion studi es. 
Infections, including serious, were observed in the NHL clinical program, with s imilar incidence 
in monotherapy  and combinat ion studi es.
For the most comprehensive venetoclax safet y and efficacy data, please refer to the most current 
venetoclax IB.
1.3.3 Risks
1.3.3.1 Tumor Lysis Syndrome 
Tumor lysis syndrom e (TLS) i s an important identified risk for venetocl ax in onco logy studi es, 
especially  in CLL and MCL. As a result of on -target effects, the potential for TLS was ident ified 
early  in the program .
TLS in CLL and MCL
The ri sk is during the first 5 weeks of ramp -up period. A low starting dose fo llowed by  gradual 
dose ram p-up allows for the tumor size to be gradually reduced and has been effective in 
reducing the risk of TLS. Venetoclax should be initiated with the 20 mg dose and gradually 
ramp-up/titrate up to 400 m g target dose over 5 weeks. In gen eral, before ini tiating venetoclax, a 
subject's risk for developing TLS should be assessed based on extent of disease, renal funct ion, 
and known propensit y and ri sk factors for TLS in that tumor ty pe. Prophylaxis wit h hydrat ion 
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 36and uric -acid reducing agent s is recommended as appropriate. Clinical chemistries should be 
corrected. Choice of init ial dose and ramp up to reach the final dose is based on the risk 
assessment in the indicat ions. Monitor clinical chemistries and manage electrolyte abnormalit ies 
prom ptly, as clinically indicated.
1.3.3.2 Neutropenia
Neutropenia is an important ident ified risk for venetoclax. Clinical data from the oncology 
studi es suggest that the neutropenia adverse events are observed amo ng subjects who receive 
venetoclax as a single agent or in combinat ion with other therapeuti c agents, wi th slightly higher 
frequency  observed in som e combinat ion studies. Serious adverse events of neutropenia or 
neutropeni a events that l ead to discont inuat ions are few across the ent ire venetocl ax oncol ogy 
program. For the oncology  studi es, neutropenia management guidelines are provided in the 
protocol . Granul ocyte col ony st imulat ing factors can be used for supportive measures, however 
the guidance for their use in non -CLL indicat ions, especially in AML, is p er routine local 
oncol ogy practice, as well as protocol -specific.
1.3.3.3 Serious Infections
Serious infect ion is an important ident ified risk for venetoclax. Infections have been reported in 
the oncol ogy clinical studies; however, these events are confounded by  the underlying disease, 
comorbidi ties, and other immunosuppressive medications. To date, no clear relat ionship has been 
noted between serious infectious events and neutropenia. The ty pes of  infecti ous events observed 
generally have been consistent with thos e anticipated in the elderly populat ion of heavily  
pretreated subjects with hematologic malignancies and are similar across all indications. 
Infections are closely  monitored in venetocl ax program  across all indicat ions. Patients should be 
advised to report fever and shoul d be assessed for further management as per standard medical 
practi ce. In the oncology  studi es, recommendat ions are included in the protocol regarding the 
need for ant i-infect ive prophylaxis per standard of care (eg, National Comprehensive Cancer 
Network guidelines [NCCN] for oncology  subjects).
1.4 Study Rationale 
1.4.1 Rationale for the Ibrutinib and Venetoclax Combination
Several in vitro studies have shown ibrutinib and venetoclax to be an act ive co mbinat ion. In one 
study , MCL cell lines and leuk emic pat ient cells were exposed to ibrut inib, venetoclax and the 
combinat ion for 72 hours. The combinat ion substant ially increased induction of apoptosis 
compared to each agent alone (combo: 23%, ibrut inib: 3.8%, venetoclax: 3.0%) ( Portell 2014). 
Aseparate study  using MCL cell lines confirmed the synergist ic effect of ibrutinib and 
venetoclax on proliferation inhibit ion and apoptosis through perturbation of the BTK, AKT and 
BCL2 pathways ( Zhao 2015) provi ding further mechanist ic rati onale for co -targeting of these 
two oncogenic pathways. 
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 37Supportive in vivo data is derived fro m a CCMCL1/NSG mouse model where the ibrutinib and 
venetoclax combinat ion was tested. The combination produced apoptosis o f MCL tum or cells, 
which was associated with a down -regulation of SOX11 and PAX5. Simultaneous down -
regul ation of MCL1 via ibrut inib and targeting of BCL2 was hypothesized to contribute to the in 
vitro synergism and in vivo act ivity observed in this report (Zhao 2013).
With respect to venetoclax mo notherapy  activit y, in clinical trial M12 -175, venetocl ax was tested 
in 28 subjects with relapsed/refractory  MCL at target doses of 200 to 1200 mg. The ORR was 
found to be 75% with a CR rate of 21% ( Gerecitano 2015). Based on these data and prior 
ibrutinib studies, the ongoing AIM Trial (ABT -199 and ibrutinib in MCL) is evaluat ing the 
combinat ion of ibrut inib at 560 mg and venetoclax at a target dose of 400mg in subjects with 
relapsed and refractory  MCL. Thi s study  is using a 4 -week venetoclax ramp
-up after 4 weeks of 
ibrutinib mo notherapy . Twent y-one subjects have completed response assessments at the 
primary  endpoint l andmark of 16 weeks; 10 subjects a chieved confirmed CR (including MRD 
clearance), 4 subj ects achieved unconfirmed CR, and 4 subjects achieved PR ( Tam 2017). These 
resul ts display a hi gh ini tial response rate for the ibrutinib and venetoclax combination.
Two other studi es evaluat ing the combinat ion of ibrutinib and venetoclax (one of which will also 
explore the addit ion of anti -CD20 therapy  to the doubl et) in subjects with relapsed/refractory  
MCL have started enrollment, though no toxicit y or safet y data have yet been reported 
(Portell 2016, LeGouill 2016). 
1.4.2 Dose Rationale
As of 28 November 2015, safet y data are available fro m 346 NHL subjects treated with 
venetoclax (128 from monotherapy  studies and 218 fro m combinat ion studi es). The venetocl ax 
Phase 1 dose escalat ion study  M12
-175 incl uded 106 subjects with relapsed/refractory  NHL 
treated in 8 dose cohorts with escalated doses fro m 100 mg to 1200 mg. The primary object ives 
of this study  were to assess the safet y profile, charact erize the PK, and determine the maximum 
tolerated dose (MTD) of venetoclax monotherapy . Two dose -limit ing toxicit ies (DLTs) (Grade 3 
febrile neutropenia and Grade 4 neutropenia) were observed, both at the 600 mg dose level, and 
the MTD was not reached. Themost frequent all -grade AEs were: nausea (46.1%), diarrhea 
(42.2%), fat igue (35.2%), and vo miting (20.3%), and the most frequent Grade ≥3 AEs were 
anemia (14.1%) and neutropenia (12.5%).
In the PCYC-1143- CA study , ibrutinib will be administered at 560 mg /day (approved dose for 
MCL) in co mbinat ion with venetocl ax at a target dose of 400 mg. This dose combinat ion has 
previously been administered in an ongoing dose
-escalat ion study  in subjects with relapsed or 
refractory  MCL ( Portell 2016) wi th low/interm ediate risk for TLS. In the AIM study  using a 
4-week venetoclax ramp -up (50, 100, 200 and 400 mg) after 4 weeks of ibrutinib mo notherapy  at 
560 m g, 16 subjects wi th relapsed or refractory  MCL ( Tam 2017) were dosed and have 
completed the ram p-up wi th TLS events reported in two subjects with high tumor burden, 
leading to revisio n of the protocol venetoclax starting dose fro m 50 m g to 20 mg per day . 
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 38Subsequently, 8 addit ional subjects have been treated using the revised schedule with no cases of 
TLS encountered. Commo n AEs ( ≥25%) were di arrhea, fati gue, nausea and/or vomit ing, upper 
respi ratory  tract infect ion, gastroesophageal reflux, neutropenia, cough, and dyspnea. The most 
frequent Grade 3-4 AE was neutropenia, and no Grade 5 AEs have been reported. The ORR was 
71%, and the CR rate was 63%. All CR subjects were confirmed by PET, endoscopy  (if baseline 
gut invo lvement was present) and bone marrow aspirate, including MRD clearance (assessed by 
flow cy tometry with minimum sensit ivity of10-4). 
These preliminary data suggest that the combinat ion had an acceptable safet y profile wit hout 
unexpected toxicit ies and resulted in high rates of deep remissio n.
1.4.3 Rationale for the Safety Run -in Period
Amo ng the 10 6 subjects with relapsed/refractory  NHL enro lled in the M12 -175 study , 2cases 
(1.9%) of laboratory  TLS were observed during the Ramp -up Peri od at the 200 mg and 300 m g 
dose l evels in subjects with bulky disease (tumor > 10 cm) with MCL (n=28) and DLBCL 
(n=41), respectively . To mi tigate the risk of TLS observed in Cohort 1 in study  M12- 175, a 
Ramp-up Schedule of 3- 4 weeks was used for subsequent cohorts.
The concurrent administration of ibrut inib and venetoclax in subjects at increased risk of TLS 
has not been invest igated. In an ongoing dose -escalat ion study  in subjects with relapsed/ 
refractory  MCL ( Portell 2016 ), the concurrent administration of 420 mg of ibrut inib and 400 mg 
of venetoclax to subjects with low/intermediate risk for TLS observed no cases of TLS, despite 
the fact that the ramp -up started at 100 mg of venetoclax and was only o f 3 weeks duration 
(100, 200 and 400 mg). In the AIM MCL study, 560 mg o f ibrutinib was administered 4 weeks 
prior to the administration of venetoclax. This was based on the rationale that the ibrutinib 
lead-in will reduce the risk of TLS. However, some subjects with high tumor burden did not 
respond to the ibrutinib lead -in and init iated venetoclax wit h increased, rather than reduced, 
tumor burden ( Tam 2016). Therefore, given that the frequency  of TLS in the setting of MCL has 
been reported to be low and to prevent early progressio n with single -
agent ibrutinib, the 
concomitant administration o f ibrutinib and v enetocl ax is warranted to init ially evaluate the 
safet y profile for the combinat ion. 
During the Safety  Run -in Period, 12 subjects at increased risk for TLS (ie, subjects with high 
tumor burden and/or baseline creat inine clearance [CrCl] <60 mL/min) and 6-9 subjects at low 
risk for TLS (not meet ing these criteria) will receive ibrut inib at 560 m g plus venetocl ax starting 
at 20 mg and ramped -up to a target dose of 400 mg over a 5
-week period.
Depending on the number of TLS events and DLTs in each of the TL S risk categori es, the 
Randomization Phase will start with either the concurrent administration of ibrut inib and 
venetoclax using the 5 -week standard Ramp-up Schedule (see Section 3) or with a 4- week 
ibrutinib lead
-in followed by the init iation of venetoclax using the 5 -week standard Ramp-up 
Schedule .
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 39During the Safety  Run -in Period, subjects at increased risk for TLS will be hospitalized for a 
minim um of 24 hours (and up to 48 hours at the discretion of the invest igator) at the start of the 
20 m g ramp -up dose and again at the start of the 50 mg ramp -up dose of venetoclax for 
monitoring and prophylaxis o f TLS. During the Rando mizat ion Phase, an indepe ndent Data 
Moni toring Committee (DMC) will review unblinded safet y data to determine whether cont inued 
hospi talizati on of  these subjects during ramp- up remains warranted.
1.4.4 Rationale for the Design of the Treatment Arms 
The comparison between the ibrut inib and venetoclax combination wit h ibrut inib and placebo 
will evaluate the abilit y of the combined treatment to increase the complete response rate and 
progression -free survival (PFS) compared to ibrutinib mo notherapy . Ibrutinib has shown a higher 
ORR and CR rate as m onotherapy  among treatm ents approved for relapsed or refractory  MCL, 
(Campo 2015 ) and therefore serves as an appropriate control arm for this study . 
1.4.5 Rationale for the PFS Assumption of 23 Months in the Ibrutinib and Venetoclax 
Relapsed/Refractory Treatment Arm
The primary  endpoint in this study  is PFS, with a null hypothesis of hazard ratio (HR) ≥1 for the 
ibrutinib and venetoclax group relat ive to ibrut inib and placebo group and an alternative 
hypothesis of HR of 0 .61 corresponding to an improvement in median PFS from 14 months to 
23months. The PFS of 14 months for the ibrut inib + placebo group is based on results from 
previous studies with ibrut inib monotherapy  in subjects with relapsed/refractory  MCL 
(PCYC -1104-C A, MCL2001 and MCL3001), and the assumption of a PFS of 23 months for the 
ibrutinib and venetoclax group is based on the 24- month PFS rate estimated fro m subjects who 
achieved a CR in these studies. 
In the pool ed analysis of ibrutinib studies PCYC -
1104- CA, MCL2001 and MCL3001, the ORR 
and CR rate were 65.7% and 20.0%, respectively. Importantly, the estimated 24 -month PFS was 
70% in the subjects who achieved a CR, compared to 19% in subjects who failed to achieve a 
CR ( Rule 2016). In the venetoclax phase I trial, the CR rate in subjects with MCL was 21% 
(Gereci tano 2015), and no subjects with CR had experienced relapse. Therefore, based on these 
studi es, subjects wi th a CR are likely to have bette r PFS. In addit ion, based on the preliminary 
efficacy  resul ts of the AIM study  (Tam 2016, Tam 2017 ) for ibrut inib and venetoclax treatm ent, 
if the CR rate in the 1143 trial exceeds 55%, then under the exponent ial distribut ionassumpti on 
for PFS, the m edian PFS with the combinat ion is predi cted to be ≥23 m onths.
1.4.6 Rationale for MRD Testing
The prognostic impact of MRD was analyzed in 259 patients with MCL treated within 
2randomized trials of the European MCL Network (MCL Younge r and MCL Elderly trial). 
After ri tuximab -based induct ion treatment, 106 of 190 evaluable patients (56%) achieved MRD 
negat ivity (by allele specific RT -PCR wi th sensit ivity of at least 10-
4) based on blood and/or 
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 40bone marrow (BM) analysis. MRD negat ivity resulted i n a significant ly improved duration of 
response (DOR 87% vs 61% patients in remissio n at 2 y ears, P =0.004) ( Pott2010 ).
Whether MRD- negative remissio ns wi th non-chem o regimens will  also translate into improved 
clinical outcom es in MCL is not y et known. The prognostic significance of MRD negat ivity by 
flow cy tometry and clo noSEQ will be assessed. The correl ation between assays and the 
correl ation between peripheral blood and bone marrow MRD findings will also be det ermined.
1.4.7 Rationale for Treatment -naive Open -label Arm, Inclusion of Patients with a TP53 
Mutation and Exclusion of Blastoid Variant
In the AIM study  that included 24 patients with relapsed/refractory  MCL (23 pati ents) or 
treatm ent-naive MCL with a TP53 mut ation (1 patient), patients were treated open -label wit h 
ibrutinib 560 mg and venetoclax 400 mg (Tam 2018 ). Pati ents had a m edian age of 68 y ears and 
had received 0 -6 prior lines of therapy. Fift y percent of pati ents (n=12) had aberrations o f 
TP53. The complete response rate according to PET was 62% at Week 16 (primary  endpoint) 
and 71% overall. For patients with a TP53 mutation, the CR rate was 50% with and without PET, 
and the ORR was 58% without PET and 50% with PET. MRD clearance was confirmed by flow 
cytometry in 67% of patients. In a time -to-event analysis, 78% of the patients with a response 
were estimated to have an ongo ing response at 15 mo nths (Tam 2018). Tum or lysis syndro me 
occurred in 2 patients. Commo n side effects were generally low grade and included diarrhea (in 
83% of patients), fat igue (in 75%), and nausea or vomit ing (in 71%). In this study  and co mpared 
to historical controls, treatment with ibrut inib and venetoclax was consis tent wi th improved 
outcom es in patients with MCL who had been predicted to have poor outcomes with current 
therapy  (Tam 2018 ). Based on these encouraging results including 1 treatment -naive MCL 
patient wi th a TP53 m utation wh o responded, i t is of interest to explore the combinat ion of 
ibrutinib and venetoclax in treatment -naive MCL in patients that are ≥65 years of age and 
transpl ant-ineligible and in pat ients with a TP53 mutati on. In treatm ent-naive MCL, the standard 
of care for pati ents that are ≥65 years of age and transplant -ineligible is BR or a variet y of other 
options based on fit ness level. The reported overall response rates with different therapeutic 
approaches for treatment -naive MCL patients with varying fit ness l evels (BR, R -CHOP, 
VR-CHOP, VR -CAP, FCR, R -CHOP/R -DHAP, R -Hyper CVAD) vary  from 75 –94% ( Flinn 
2014, Lenz 2005, Robak 2015, Kluin -
Nelemans 2012, Hermine 2016, Rummel 2014, Chen 
2017, Merli 2012, Rummel 2013, Rummel 2017 ); the corresponding CR rates vary  from 35 –
72%, and for BR, one of the most commo nly used therapi es used in the transplant -ineligible and 
less fit treatment -naive MCL populat ion, are approximately  around 50% ( Flinn 2014, Rummel 
2005, Rummel 2014, Chen 2017, Rummel 2017 ). Based on the encouraging results in pat ients 
with a TP53 m utation, it is of interest to explore the combinat ion of ibrutinib and venetoclax in 
treatm ent-naive MCL in patients with a TP53 mutation, which is a popu lation that i s chem o-
insensit ive and therefore has limited treatment options ( Eskel und 2017, Delfau- Larue 2015, 
Halldorsdottir 2011, Ferrero 2017, Obr 2018 ). For patients with a TP53 mutation, the available 
literature focuses on PFS and OS outcomes ( Eskelund 2017, Delfau -Larue 2015, 
Halldorsdottir 2011, Ferrero 2017, Obr 2018 ), and CR rates are underreported; it is hypothesized 
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 41that CR rates for MCL with a TP53 mutation are below the CR rates aro und 50% reported for 
BR in treatment -naive MCL. In the AIM study  (Tam 2018 ), the CR rate for subjects with TP53 
aberrat ions (mutations and delet ions, n=12) is 50%; in the PHILEMON study , where R/R MCL 
patients received a comb ination o f ibrutinib, rituximab and lenalido mide, similar proportions of 
patients wi th and wi thout a TP53 m utation had an overall response and CR; when correcting for 
other prognostic factors, no PFS difference was seen between pat ients with and wi thout a TP53 
mutati on (Jerkeman 2018 ). These encouragi ng data support the use of ibrutinib and venetoclax in 
patients wi th a TP53 m utation.
The rando mized portion for R/R MCL has a PFS endpo int. For treatment -naive MCL, the 
endpo int of CR rate was chosen, also considering the small sample size (n=75). Durable CRs 
may represent clinical benefit and can be assessed earlier (compared to PFS).
In summary, exploring the combinat ion of ibrut inib and venetoclax in treatment -naive MCL 
patients with or wi thout a TP53 mutation is of interest with the goal to explore CR rates and 
other efficacy and safet y param eters that can be achieved wit h this combinat ion in co mpar ison 
with histori cal CR rates and efficacy  and safet y data. 
The R/R MCL populat ion in this study  is inclusive of MCL patients with blastoid variant; 
blastoid variant and MCL with a TP53 mutation are considered high -risk MCL populations. 
Since favorable outcomes in younger/fit/transplant -eligible pat ients with blastoi d variant were 
observed wit h high -dose chemotherapy, high -dose consoli dation and stem  cell transplant 
(Dreyling 2018 ), contrasting y oung/fi t/transplant -eligible patients with TP53 mutations who do 
not benefit fro m intensive chemotherapy  and o ften relapse early ( Eskelund 2017, 
Delfau -Larue 2015), MCL patients with blastoid variant are excluded fro m the open -label 
treatm ent-naive arm, and the focus is on the population with a TP53 mutation as the high -risk 
group fo r treatm ent-naive subjects. 
1.4.8 Sample Size Considerations for Treatment -naive Open -label Arm Including 
Patients with a TP53 Mutation
A sample size o f 75 treatment -naive subjects is needed to exclude a 35% CR rate at a 1
-sided 
significance l evel of 0.025 wi thapproximately  80% power, assuming a target CR rate of 51%.
For the subpopulat ion with a TP53 m utation, a sample size of 48 subjects is needed to exclude a 
25% CR rate with approximately 80% power, assuming a target CR rate of 45%. The TP53 
popul ation coul d be a mix of treatment -naive MCL subjects and/or R/R MCL subjects with a 
TP53 m utation.
Based on a historical CR rate of approximately 50% with BR ( Flinn 2014, Rummel 2005, 
Rummel 2014, Chen 2017, Rummel 2017 ) in transpl ant-ineligible treatment -naive MCL 
subjects, the success criteria were set at excluding a CR rate of 40% for the transplant -ineligible 
treatm ent-naive MCL patients ≥65 years. Since the CR rates for MCL patients with TP53 
mutati ons are est imated to be lower (Eskelund 2017), the success criteria were set at excluding a 
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 4225% CR rate for the MCL patients with a TP53 mutation. In combinat ion, for the entire cohort of 
75 treatment -naive MCL patients, which contain at least one third of patients (n=25) wi th a TP53 
mutati on, the success criteria were set at excluding a 35% CR rate.
2STUDY OBJECTIVES
2.1 Safety Run -in Period
2.1.1 Primary Objective
To evaluate the occurrence of TLS and DLTs wit h the concurrent administration of ibrut inib and 
venetocla x.
2.1.2 Secondary Objectives
To evaluate response (partial and co mplete response), PFS, DOR, and OS.
2.2 Randomization Phase
2.2.1 Primary Objective
To evaluate whether the combinat ion of ibrut inib and venetocl ax will result in prolongat ion of 
PFS com pared to ibrutinib and pl acebo in subjects with relapsed or refractory  MCL.
2.2.2 Secondary Objectives
To evaluate whether the combinat ion of ibrut inib and venetocl ax will increase the 
CR rate, the overall response rate (ORR), the minimal residual disease (MRD) 
negat ive remissio n rate in subjects who were MRD posit ive at screening and
achieve CR, OS, DOR, and time -to-next treatment (TTNT) compared to ibrut inib 
and placebo.
To evaluate the frequency, severit y, and rel atedness of AEs; frequency, severit y and 
management of TLS; AEs re quiring dose reducti ons and/or discontinuation of study  
drug, or l eading to death.
To determine the PK of ibrut inib and venetoclax.
To evaluate whether the combinat ion of ibrut inib and venetocl ax will improve 
qualit y of life using a Health- related quali ty of life questi onnai re (FACT -Lym) 
compared to ibrutinib and placebo.
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 432.2.3 Exploratory Objectives 
To determine the prognostic significance of MRD negat ive remissio n by co mpar ing 
the correlat ion to the efficacy outcomes in the two treatment arms.
To evaluate whet her the combinat ion of ibrut inib and venetocl ax will decrease 
MRD posi tive relapse in subjects who achieve MRD negat ive remissio n compared 
to ibrut inib and placebo.
To evaluate the correlat ion of MRD negative remission in blood vs. bone marrow.
To evaluate the correlat ion of MRD negative remission determined by flow 
cytometry and clo noSEQ.
To evaluate PFS2: time from rando mizat ion to death or next disease progression 
(defined as the earliest of disease progression after the first subsequent ant i-cancer 
therapy or start of the second subsequent therapy ).
To identify alterat ions in genes or proteins associated with sensit ivity or resistance 
to the ibrutinib and venetocl ax combinat ion.
To evaluate patient -reported outcomes as measured by  European Organisat ion for 
Research and Treatment of Cancer Qualit y of Life Quest ionnaire EuroQoL Five -
Dimension (EQ -5D- 5L)
To evaluate medical resource utilization (MRU) (eg, requirements of 
hospi talizati ons, em ergency department visits, transfusions, and use of 
hematopoiet ic growth factors)
2.3 Treatment -naive Open -label Arm
2.3.1 Primary Objective
To evaluate the complete response (CR) rate with the co mbinat ion of ibrutinib and venetoclax in 
subjects wi th treatm ent-naive MCL
2.3.2 Secondary Objectives
To evaluate the overall response rate (OR R), the duration of response (DOR) and 
durati on of  CR 
To evaluate the minimal residual disease (MRD) -negative remissio n rate in subjects 
who were MRD posit ive at screening and achieve CR
To evaluate progression -free survival (PFS), overall survival (OS), and time -to-next 
treatm ent (TTNT) wi th the combinat ion of ibrut inib and venetoclax
To evaluate the frequency, severit y, and rel atedness of adverse events (AEs); 
frequency , severi ty and m anagement of TLS; AEs requiring dose reductions and/or 
discontinuat ionof study  drug, or leading to death
To determine the pharmacokinet ics (PK) of ibrutinib and venetoclax
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 442.3.3 Exploratory Objectives
To evaluate bio markers in relat ionship to efficacy outcomes
To evaluate whether the combinat ion of ibrut inib and venetocl ax will i mprove 
qualit y of life using a healt h-related qualit y of life questionnaire (EQ -5D- 5L)
3STUDY DESIGN 
3.1 Overview of Study Design
This Phase 3 mult inational, rando mized, double -blind study  is designed to compare the efficacy  
and safet y of the combinat ion of ib rutinib and venetoclax vs. ibrut inib and placebo in subjects 
with MCL.
Approximately  up to 287 subj ects wi th R/R MCL will be enro lled.
A separate open -label arm is designed to explore the efficacy  and safet y of the combinat ion of 
ibrutinib and venetoclax i n subjects with treatment -naive MCL.
In the treatm ent-naive open -label arm, approximately 75 subjects will be enrolled and treated 
with ibrutinib560mg and venetoclax 400 mg. Among them, approximately 50 subjects 
≥ 65 years and approximately 25 subjects w ith a TP53 mutation will be enrolled. Treatm ent-
naive MCL pat ients will use the same dose and schedule as established in the Safet y Run-in for 
the Rando mizat ion Phase of the study . Therefore, there will be no Safet y Run-in for the 
treatm ent-naive cohort.
3.1.1 Safety Run -in Period
The study  will start wi th an open -label Safet y Run-in Period to evaluate the occurrence of TLS 
and DLTs wit h the concurrent administration of ibrutinib and venetoclax. TLS and DLT 
occurrence will be assessed during the venetoclax Ramp -up Peri od for a minimum  of 5 weeks.
Up to 27 subjects may be enro lledduring the Safety  Run -in Period ( Figure 6).
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 45Figure 6. Study Schematic –Safety Run -in Period
PD = progressive disease; WC = withdrawal of consent
Tumor Lysis Syndrome (TLS) Categories
Two TLS risk categories will be evaluated separately and in parallel:
Increased ri sk for TLS –Subjects with high tumor burden ( at least one l esion 
>
10cm; or at least one lesio n >5 cm and circulat ing lymphocy tes 
>25,000 cells/mm3) and/or wi th baseline creat inine clearance (CrCl) < 60 m L/min. 
During the Safety  Run -in Period, subjects at increased risk for TLS will be 
hospi talize d for a minimum o f 24 hours (and up to 48 hours at the discretion o f the 
investigator) at the start of the 20 mg ramp -up dose and again at the start of the 
50mg ramp -up dose of venetoclax for monitoring and prophylaxis o f TLS.
Low ri sk for TLS –Subjects not m eeting the criteria described above.
TLS events are defined as follows: 
Clinical TLS –any event that m eets Howard criteria ( Appendix G) with the 
following except ions: 
oFor the purpose of TLS assessment during the Safety  Run -in Period, only those 
increases in serum creat inine > 1.0 m g/dL fro m pre-treatm ent baseline will be 
considered clinical TLS.
oIn subjects with renal dysfunct ion at baseline (CrCl < 60 mL/min), clinical TLS 
is defined as the presence of laboratory  TLS pl us either seizures, cardiac 
dysrhythmia, or death. 
Laboratory  TLS –any event that meets Howard criteria (Appendix G) for laboratory  
TLS, that does not resolve wit hin 72 hours despite protocol required management.
Dose- Limiting Toxicity (DLT)
A DLT is defined as any G rade 3 or hi gher non -TLS AE at l east possibly related to study  drug 
(ibrutinib and/or venetoclax) and occurring during the DLT assessment period with the fo llowing 
clarifications:
                
  
 
  
         
               
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 47Subjects at Low Risk for TLS
Evaluation of TLS
Three addit ional subjects will be dosed if 1 out of 6 subjects at low risk for TLS experiences a 
laboratory  TLS event and no subjects experience a clinical TLS event. If 0 out of 6 or ≤1 out of 
9subjects experience a laboratory  TLS event and no subjects experience a clinical TLS event, 
the Rando mizat ion Phase will start using the standard Ramp -up Schedule for subjects at low risk 
for TLS.
If ≥2 out of 6 -9 subjects at low risk for TLS experience a laboratory  TLS event, or any  subject 
experiences a clinical TLS event, the Rando mization Phase will start with a 4 -week ibrutinib 
lead-in followed by the standard Ramp -up Schedule ( Figure 7) for subjects in both TLS risk 
categori es.
Evaluation of DLTs
With respect to DLTs, if < 2 out of 6 or < 3 out of 9 subjects experience DLT(s) during the DLT 
assessment period, the Rando mization Phase will commence using the standard Ramp -
up 
Schedule for subjects at low risk for TLS ( Figure 7). However, if ≥3 out of 9 subjects e xperience 
DLT(s), the Rando mizat ion Phase will co mmence with a 4
-week ibrutinib lead- in followed by  
the standard Ramp- up Schedule for subjects in both TLS risk categories ( Figure 7).
The Safet y Review Co mmittee (SRC) will evaluate TLS and DLT data after 6 -9 subjects in the 
low TLS risk category  have co mpleted the TLS/DLT assessment period (the Ramp -up Peri od 
with a minimum  of 5 weeks). Members of SRC wi ll include the Sponsor (Medical Monitor or 
designee, Drug Safet y Representative and Biostatistician) as well as participat ing invest igators.
Subjects at Increased Risk for TLS
Evaluation of TLS
With respect to TLS only, if < 3 out of the 12 subjects at inc reased ri sk for TLS experience a 
laboratory  TLS event and no subjects experience a clinical TLS event, enrollment of 
increased- risk TLS subjects to the Rando mizat ion Phase will commence using the standard 
Ramp-up Schedule for subjects at increased risk fo rTLS ( Figure 7).
However, if ≥3 out of the 12 increased risk subjects experience a laboratory  TLS event or any  of 
these subjects experience a clinica l TLS event, at least 6 subjects at increased risk for TLS 
shoul d be treated wi th the 4 -week ibrut inib lead-in and assessed for safet y in eit her in an external 
study  or wi thin this study . If 
≤2 out of these 6 subjects experience a laboratory  TLS event and
no subjects experience a clinical TLS event, the Rando mizat ion Phase will co mmence wit h a 
4-week ibrutinib lead -in followed by  the standard Ram p-up Schedule for subjects at increased 
risk of TLS ( Figure 7).
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 48Evaluation of DLTs
With respect to DLTs, if < 4 out of the 12 subjects at increased risk for TLS experience DLT(s) 
during the DLT assessment period, the Rando mization Phase will commence using the st andard 
Ramp-up Schedule . However, if ≥4 out of the 12 subjects experience DLT(s), the 
Randomization Phase will commence with a 4 -week ibrutinib lead
-in followed by  the standard 
Ramp-up Schedule for subjects at increased risk o f TLS.
The SRC will evaluate TLS and DLT data after all 12 subjects in the increased TLS risk category  
have co mpleted the TLS and DLT assessment period prior to the Rando mizat ion Phase, and if 
requi red, after an addit ional 6 subjects have co mpleted the TLS and DLT assessment period (t he 
Ramp-up Peri od wi th a minimum of 5 weeks) after the 4 -week ibrutinib lead -in.
Subjects in either TLS risk category  who experience a laboratory  or clinical TLS event will be
managed according to standard inst itutional pract ice.
For subjects who experienc e laboratory  TLS, dosing of venetoclax will be withheld per protocol 
and may  be resumed when all laboratory  abnorm alities have returned to baseline. Dose reduction 
of venetoclax is not allowed for subjects enrolled in the Safet y Run-in Period. Once venetoc lax 
dosing is resumed, the applicable ramp -up week will re -start at the same dose level.
Those subjects incurring clinical TLS (regardless of TLS risk category ) must be docum ented and 
discussed wi th the study  medical m onitor to determine whether the risk-b enefi t rati o justifies the 
subject remaining on study .
Subjects will be treated with ibrut inib and venetoclax for approximately 104 weeks fo llowed by  
ibrutinib mo notherapy  until  PD, unacceptable toxicit y or wi thdrawal  of consent. Venetoclax will 
be discont inued after 104 weeks of treatment regardless of response assessment.
Subjects who discont inue study  treatm ent for any  reason will be followed for progression (if not 
progressed before treatment discont inuat ion), subsequent ant i-cancer therapy  and survival status 
until study  closure.
3.1.2 Randomization Phase
The Rando mizat ion Phase portion of the study  will f ollow a rando mized, double -blind design. 
Ibrutinib and venetoclax/placebo will be administered using the Ramp -up Schedule that was 
determined to be appropri ate for each TLS risk category . The Data Monitoring Committee 
(DMC) will review the safety  recommendat ions made by  the SRC and will be responsible for 
giving recommendat ions on continuing, modifying, or stopping the Rando mizat ion Phase of the 
trial (Figure 8).
Subject eligibilit y will be determined up to 28 days prior to randomizat ion. Approximately 
260eligible subjects will be rando mized at a 1:1 ratio to ibrutinib andvenetoclax or ibrutinib and 
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 49placebo. Rando mizat ion will be stratified by  number of pri or lines of therapy , ECOG PS, and by  
TLS ri sk category .
Figure 8. Randomization Phase Schematic
Initially, subjects at increased risk of TLS will be hospitalized for a minimum o f 24 hours (and 
up to 48 hours at the discretion of the invest igator) at the start of the 20 mg ramp -up dose and 
again at the start of the 50 mg ramp -up dose of venetoclax for monitoring and prophylaxis of 
TLS. The DMC will review unblinded safe ty data during the course of the study  to determine 
whether continued hospitalization o f these subjects during ramp -up rem ains warranted.
Subjects will be treated with eit her ibrutinib and venetoclax or ibrutinib and placebo for 
approximately  104 weeks, fo llowed by  ibrutinib monotherapy  until PD, unacceptable toxicit y or 
withdrawal  of consent. Venetocl ax/placebo will be discont inued after 104 weeks of treatment 
regardl ess of response assessment.
Subjects who discont inue study  treatm ent for any  reason will b e followed for progressi on (if not 
progressed before treatment discont inuat ion), subsequent ant i
-cancer therapy, and survival status 
until study  closure.
The independent Data Monitoring Committee (DMC) will review unblinded safet y data 
including all deaths and any  progressi on associ ated wi th safety 6-9 months after init iation of the 
Randomization Phase to evaluate the safety  of the combinat ion of ibrut inib and venetoclax and to 
confirm cont
inued dosing with the combinat ion is warranted. In addit ion, the DMC will review 
TLS data in the course of the study  to ascertain whether the continued hospitalizat ion of subjects 
with high tum or burden and/or creatinine clearance < 60 m L/min during ramp -up is needed. The 
make -up of  the DMC, responsibilit ies, authorit ies, and procedure will be detailed in a separate 
DMC charter.
The rati onale for the study  concept i s provi ded in Secti on 1.4.
 
 
 
      
    
  
            
    
   
   
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 51CT and PET or PET/CT: A CT scan (wit h contrast unless contraindicated) of the neck, chest, 
abdo men, and pelvis and any  other disease si tes (eg, extremit y) and a PET scan are required for 
the pretreatment tumor assessment within 28 days of the 1stdose. Thereafter, CT scans will be 
done for t umor assessments on Week 13 Day  1 (±7 day s); every  12 weeks for the rem ainder of 
the 1styear; every  16 weeks during the 2ndand 3rdyears; and every  24 weeks thereafter unt il PD. 
PET or PET/CT is mandatory  for all  subjects at the Week 13 visit (+/- 7 days ), the Week 25 visit 
(+/-7 day s) for subj ects in SD or PR who di d not achieve CR at Week 13, and at the 1 -year visit 
(Week 49 +/ -7 days) for all subjects, as well as at any other time point to confirm a CR. Other 
PET or PET/CT scans that are NOT mandator y can be performed wit hin a 30 -day window of the 
visit. For MRI refer to Section 7.1.3.2 .
Subjects who discont inue study  treatm ent for any  reason will be fo llowed for disease 
progression, subsequent anticancer therapy , and survival status until study  closure.
4SUBJECT SELECTION
4.1 Eligibility Criteria for SRI and Randomization Phase
4.1.1 Inclusion Criteria
Prior to enrollment, each potential subject must satisfy all o f the following inclusio n criteria. 
These criteria must continue to be met by the subject prior to first dose of study treatment.
Disease- Related
1.Pathol ogically  confirmed MCL (tum or tissue), wi th docum entati on of  either overexpressio n 
of cyclin D1 in associat ion with other rel evant markers (eg, CD19, CD20, PAX5, CD5) or 
evidence of t(11;14), as assessed by cytogenet ics, fluorescent in situ hybridizat ion (FISH), or 
polymerase chain react ion (PCR)
A report fro m the local laboratory  is acceptab le if available; however, it must be 
reviewed and approved by the central pathology  laboratory  to verify  the above 
criteria pri or to randomizat ion (for Randomizat ion Phase subjects only ).
If the report from the local laboratory  is not available pri or to ra ndomization (for 
Randomization Phase subjects only ), the tum or block or slides m ust be sent to the 
central  pathol ogy laboratory  for confirmat ion of the MCL diagnosis.
2.At least 1 measurable site of disease that is ≥2.0 cm  in the l ongest di ameter and m easurable 
in 2 perpendicular dimensions per CT
3.At least 1, but no more than 5, prior treatment regimens for MCL including at least 1 prior 
rituximab/ant i-CD20 containing regimen
4.Failure to achieve at least partial response (PR) with, or documented dise ase progression 
after, the m ost recent treatment regimen
5.Subjects m ust have adequate fresh or paraffin embedded tissue ( Secti on 7.1.3.4 ).
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 52Laborat ory
6.Adequate hematologic funct ion independent of transfusion and growth factor support for at 
least 7 day s prior to fi rst dose (Safet y Run-in Perio d) or to randomization (for the 
Randomization Phase), with the except ion of pegylated G -CSF (pegfilgrastim ) and 
darbepoeit in which require at least 14 days prior to the first dose (Safet y Run-in Period) or to 
rando mizat ion (for the Rando mizat ion Phase), defined as: 
Absolute neutrophil count (ANC) > 1000 cells/mm3(1.0x 109/L)
Platelet coun t >50,000 cells/mm3(50x 109/L)
Hem oglobin > 8.0 g/dL
Note: Subjects in the Rando mizat ion Phase with bone marrow involvement may be enro lled 
without m eeting the above hematologic function criteria after documented di scussi on wi th the 
medical mo nitor.
7.Adequate hepat ic and renal  function defined as:
Serum  aspartate transaminase (AST) or alanine transaminase (ALT) ≤3.0xupper 
limit of normal (ULN)
Estimated Creatinine Clearance (CrCl) ≥30 m L/min (Cockcroft -Gaul t)
Bilirubin ≤1.5 x ULN (unless bilirubin rise is due to Gilbert’s syndro me or of 
non-hepat ic origin)
8.Prothrombin t ime (PT)/International normal rat io (INR) < 1.5 x upper limit of normal (ULN) 
and PTT (activated partial thromboplast in time [aPTT]) < 1.5 x ULN (unless abnormalit ies 
are unrelated to coagulopath y or bleeding disorder). When treated with warfarin or other 
vitamin K antagoni sts, then INR ≤3.0.
Demographic
9.Men and wo men ≥18 years of age
10.Eastern Cooperative Oncology Group (ECOG) performance status (PS) of ≤ 2
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 53Ethical/Other
11. Mal e and femal e subjects of reproductive potent ial who agree to use both a highly  effect ive 
method of birth control (eg, implants, injectables, combined oral contraceptives, some 
intrauterine devices [IUDs], complete abst inence3, or sterilized partner) and a barrier met hod 
(eg, condoms, cervical ring, sponge, etc) during the period of therapy  and f or 90 day s after 
the last dose of study  drug.
4.1.2 Exclusion Criteria
To be enrolled in the study , potenti al subjects m ust meet NONE of the fo llowing exclusio n 
criteria ( These crite ria must continue to be not met by  the subject until first dose of study  
treatm ent):
Disease- Related
1.History  or current evi dence of central nervous system lympho ma
Concurrent Conditions
2.Concurrent enrollment in another therapeutic investigat ional study or pri or therapy  with 
ibrutinib or other BTK inhibitors
3.Prior treatm ent wi th venetoclax or other BCL2 inhibitors
4.Anticancer therapy  including chemotherapy , radi otherapy, small mo lecule and 
investigat ional agents ≤ 21days (or at l east 5 drug half-lives, whichever is shorter) prior to 
first administrati on of  study  treatm ent and/or m onocl onal ant ibody  ≤3weeks (or at least 
5drug half -lives, whichever is shorter) prior to receiving the first dose of study  drug
5.History  of other m alignancies, e xcept: 
Malignancy  treated wi th curative intent and with no known active disease present 
for ≥ 3years before the first dose of study  drug and felt to be at low risk for 
recurrence by treating physician
Adequately treated non -melanoma skin cancer or lent igo maligna wit hout evidence 
of disease
Adequately treated carcinoma in situ without evidence o f disease
6.Vaccinated with live, attenuated vaccines within 4 weeks of the first dose of study  drug
                                               
3Complete abstinence is a highly effective method only if defined as refraining from heterosexual intercourse 
during the entire period of risk associated with the study treatments. The reliability of sexual abstinence needs to be 
evaluated in relation to the duratio n of the clinical trial and the preferred and usual lifestyle of the subject. 
http://www hma.eu/fileadmin/dateien/Human_Medicines/01 
About_HMA/Working_Groups/CTFG/2014_09_HMA_CTFG_Contraception.pdf
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 547.Clinically significant infect ion requiring IV sy stemic tre atment that was com pleted ≤ 14 days 
before the first dose of study  drug
8.Any uncontrolled act ive systemic infect ion
9.Unreso lved toxicit ies from prior anti cancer therapy , defined as having not resolved to 
Commo n Termino logy Criteria f or Adverse Event ( CTCAE, v4.03 ), Grade 0 or 1, or to the 
levels dictated in the inclusio n/exclusio n criteria wit h the except ion of alopecia
10.Known bleeding disorders (eg, von Willebrand’s disease or hemophilia)
11.History  of stroke or intra cranial hemorrhage wit hin 6 m onths pri or to enrollment
12.Prior stem  cell transplant that requi res ongoing immunosuppressive therapy  or clinical graft 
vs host di sease (GVHD)
13.Known history  of human immunodeficiency  virus (HIV) or active wit h hepat itis C virus 
(HCV) or hepat itis B virus (HBV). Subjects who are positive for hepatit is B core antibody, 
hepat itis B surface antigen (HBsAg), or hepatit is C antibody must have a negative 
polymerase chain react ion (PCR) result before enrollment. Those who are PCR positive will 
be excluded.
14.Major surgery  within 4 weeks of the first dose of study  drug.
15.Any life -threatening illness, medical condit ion, or organ sy stem  dysfunct ion that, in the 
investigator’s opinion, could co mpro mise the subject’s safet y or put the study  outcom es at 
undue risk
16.Current ly act ive, clinically significant cardiovascular disease, such as uncontrolled 
arrhy thmia or Cl ass 3 or 4 congest ive heart failure as defined by the New York Heart 
Associ ation Functional Classificat ion; or a his tory of myocardial infarct ion, unstable angina, 
or acute coronary  syndrom e within 6 mo nths prior to randomizat ion
17.Unable to swallow capsules or tablets, or malabsorption syndrome, disease significant ly 
affect ing gastrointest inal funct ion, or resection of the stom ach or sm all bowel , symptom atic 
inflammatory  bowel  disease or ulcerative co litis, or partial or complete bowel obstruction
18.Treatment with any o f the following within 7 days prior to the first dose of study  drug:
moderate or strong cy tochrom eP450 3A (CYP3A) inhibitors (see Appendix Dfor 
examples)
moderate or strong CYP3A inducers (see Appendix Dfor examples) 
19.Administrati on or consum ption of any o f the following within 3 days prior to the first dose 
of study  drug:
grapefruit or grapefruit products
Seville oranges (including marmalade containing Seville ora nges)
star frui t
20.Known allergy  to xanthine oxi dase inhibitors and/or rasburicase for subjects with known risk 
factors (as defined by  high tum or burden and/or diminished renal funct ion, as detailed in 
“Study  Design” section above) for TLS
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 5521.Subjects with chronic liver disease wit h hepat ic impai rment Child -Pugh class B or C 
(Appendix F)
22.Female subject who is pregnant, breastfeeding or is considering beco ming pregnant during 
the study  or for approximately 90 days after the last dose of study  drug
23.Male subject who is considering fathering a child or donating sperm during the study  or for 
approximately  90 days after the last dose of study  drug
24.Unwilling or unable to participate in all required study  evaluat ions and procedures
25.Unable to understand the purpose and risks of the study  and to provi de a signed and dated 
inform ed consent form  (ICF) and authori zation to use protected health information 
(inaccordance with nat ional and local subject privacy regulat ions)
26.Known hypersensit ivity to the active ingredient or other components of one or more study  
drugs
4.2 Eligibility Criteria for the Treatment -naive Open -label Arm
4.2.1 Inclusion Criteria for the Treatment -naive Open -label Arm
1.Pathol ogically confirmed treatm ent-naive MCL (tumor tissue), with documentation of eit her 
overexpressio n of cyclin D1 in associat ion with other rel evant m arkers (eg, CD19, CD20, 
PAX5, CD5) or evidence o f t(11;14), as assessed by cy togeneti cs, fluorescent in situ 
hybridizat ion (FISH), or polymerase chain react ion (PCR)
A report fro m the local laboratory  is acceptable if available; however, it must be 
reviewed and approved by the central pathology  laboratory  to verify  the above 
criteria pri or to enrollment
If the report from the local laboratory  is not available, a tum or block or slides must 
be sent to the central pathology  laboratory  for confirmati on of  the MCL diagnosis 
prior to enrollment
2.Men and wo men ≥18 years of age wi th a TP53 mutati on4
3.At least 1 measurable site of disease that is ≥2.0 cm  in the l ongest di ameter and m easurable 
in 2 perpendicular dimensions per CT
4. Subjects must have adequate fresh or paraffin -embedded ti ssue
5.Eastern Cooperative Oncology Group (ECOG) performance status (PS) of ≤ 2
6.Adequate hematol ogic function independent of transfusion and growth factor sup port for at 
least 7 day s prior to fi rst dose, wi th the except ion of pegylated G -CSF (pegfilgrastim) and 
darbepoeit in which require at least 14 days prior to the first dose defined as: 
Absolute neutrophil count (ANC) > 1000 cells/mm3(1.0x 109/L)
                                               
4TP53 test by local or central lab
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 56Plateletcoun t >50,000 cells/mm3(50x 109/L)
Hem oglobin > 8.0 g/dL
7.Adequate hepat ic and renal funct ion defined as:
Serum  aspartate transaminase (AST) or alanine transaminase (ALT) ≤3.0xupper 
limit of normal (ULN)
Estimated Creatinine Clearance (CrCl) ≥ 30 mL/min (Cockcroft -Gaul t)
Bilirubin ≤ 1.5 x ULN (unless bilirubin rise is due to Gilbert’s syndrome or of 
non-hepat ic origin)
8.Prothrombin t ime (PT) or In ternati onal norm al ratio (INR) < 1.5 x upper limit of normal 
(ULN) and PTT (activated partial thromboplastin time [aPTT]) < 1.5 x ULN (unless 
abnorm alities are unrelated to coagulopathy  or bl eeding disorder). When treated with 
warfarin or other vitamin K antagonists, then INR ≤3.0
9. Male and female subjects of reproductive potential who agree to use both a highly effective 
method of birth control (eg, implants, injectables, combined oral contraceptives, some 
intrauterine devices [IUDs], complete abst inence5, or sterilized partner) and a barrier method 
(eg, condoms, cervical ring, sponge, etc) duri ng the period of therapy  and f or 90 day s after 
the last dose of study  drug
4.2.2 Exclusion Criteria for the Treatment -naive Open -label Arm
1.Blastoi d variant of MCL
2.History  or current evi dence of central nervous system lympho ma
3.Concurrent enrollment in an other therapeutic investigat ional study  or pri or therapy , including 
ibrutinib or other BTK inhibitors
4.Prior treatm ent wi th venetoclax or other BCL2 inhibitors
5.History  of other m alignancies, except:
Malignancy  treated wi th curative intent and with no known active disease present 
for ≥ 3years before the first dose of study  drug and felt to be at low risk for 
recurrence by treating physician
Adequately treated non -melanoma skin cancer or lent igo maligna wit hout evidence 
of disease
Adequately treated car cinoma in situ without evidence o f disease
                                               
5Complete abstinence is a highly effective method only if defined as refraining from heterosexual intercourse 
during the entire period of risk associated with the study treatments. The reliability of sexual abstinence needs to be 
evaluated in relation to the duration of the cl inical trial and the preferred and usual lifestyle of the subject. 
http://www hma.eu/fileadmin/dateien/Human_Medicines/01 
About_HMA/Working_Groups/CTFG/2014_09_HMA_CTFG_Contraception.pdf
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 576.Vaccinated with live, attenuated vaccines within 4 weeks of the first dose of study  drug
7.Clinically significant infect ion requiring IV sy stemic treatment that was completed ≤ 14 days 
before the first dose of study  drug
8.Any uncontrolled act ive systemic infect ion
9. Known bleeding disorders (eg, von Willebrand’s disease or hemophilia)
10.History  of stroke or intracranial hemorrhage wit hin 6 m onths pri or to enrollment
11.Known history  of human immunodeficie ncy virus (HIV) or active wit h hepat itis C virus 
(HCV) or hepat itis B virus (HBV). Subjects who are positive for hepatit is B core antibody, or 
hepat itis C ant ibody  must have a negat ive polymerase chain react ion (PCR) result before 
enrollment. Those who are hepat itis B surface ant igen (HBsAg) or PCR posit ive will be 
excluded.
12.Major surgery  within 4 weeks of the first dose of study  drug.
13.Any life -threatening illness, medical condit ion, or organ sy stem  dysfunct ion that, in the 
investigator’s opinion, could com promise the subject’s safet y or put the study  outcom es at 
undue risk
14.Current ly act ive, clinically significant cardiovascular disease, such as uncontrolled 
arrhy thmia or Cl ass 3 or 4 congest ive heart failure as defined by the New York Heart 
Association Functional Classificat ion; or a history  of myocardial infarct ion, unstable angina, 
or acute coronary  syndrom e within 6 mo nths prior to randomizat ion
15.Unable to swallow capsules or tablets, or malabsorption syndrome, disease significant ly 
affect ing gastrointest inal funct ion, or resection of the stomach or small bowel, symptomat ic 
inflammatory  bowel  disease or ulcerative co litis, or partial or complete bowel obstruction
16.Treatment with any o f the following within 7 days prior to the first dose of study  drug:
Moderate or strong cy tochrom e P450 3A (CYP3A) inhibitors ( Appendix D)
Moderate or strong CYP3A inducers ( Appendix D)
17.Administrati on or consum ption of any o f the following within 3 days prior to the first dose 
of study  drug:
grapefruit or grapefruit products
Seville oranges (including marmalade containing Seville oranges)
star frui t
18.Known allergy  to xanthine oxi dase inhibitors and/or rasburicase for subjects with known risk 
factors (as defined by  high tum or burden and/or diminished renal funct ion, as detailed in 
“Study  Design” section above) for TLS
19.Subjects with chronic liver disease wit h hepat ic impai rment Child -Pugh class B or C
20.Female subject who is pregnant, breastfeeding or is considering beco ming pregnant during 
the study  or for approximately 90 days after the last dose of study  drug
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 5821. M ale subject who is considering fathering a child or donating sperm during the study  or for 
approximately  90 days after the last dose of study  drug
22.Unwilling or unable to participate in all required study  evaluat ions and procedures
23.Unable to underst and the purpose and risks of the study  and to provi de a signed and dated 
inform ed consent form  (ICF) and authori zation to use protected health information 
(inaccordance with nat ional and local subject privacy regulat ions)
24.Known hypersensit ivity to the active ingredient or other components of one or more study  
drugs
5TREATMENT OF SUBJECT S
5.1 Treatment Allocation and Blinding
5.1.1 Safety Run -in Period
Up to 27 subjects may be enro lled during the Safety Run -in Period. Init ially, 6-9 subjects at low 
risk for TLS and 12 subjects at increased risk for TLS will receive ibrut inib at 560 mg once daily 
and open -label venetoclax at a starting dose of 20 mg once daily and gradually ramped up to a 
target dose of 400 mg once daily over a 5- week peri od. TLS events and DLT oc currence will be 
assessed during the venetoclax Ramp -up Peri od for a minimum of 5 weeks. Depending on the 
occurrence of TLS events and DLTs, a minimum of 6 addit ional subjects at increased risk for 
TLS m ay be treated wi th the 4 -week ibrutinib lead -in durin g the Safet y Run-in Period.
Subjects dosed in the Safet y Run-in Period will cont inue on open -label ibrut inib at 560 mg once 
daily  and open -label venetoclax at a target dose of 400 mg for up to approximately 104 weeks, 
followed by ibrut inib monotherapy  until disease progression, unacceptable toxicit y or 
withdrawal  of consent.
5.1.2 Randomization Phase
The Rando mizat ion Phase portion of the study  will f ollow a rando mized, double -blind design. 
After wri tten inform ed consent has been obtained and eligibilit y has been established, the study  
site will  obtain the subject’s ident ificat ion number and treatment assignment fro m the Interactive 
Response Techno logy (IRT) Sy stem .
5.1.2.1 Randomization
Approximately  260 eligible subjects will be randomized at a 1:1 ratio to ibrutinib an d venetoclax 
or ibrutinib and placebo treatment arms. Rando mization will be stratified by number of prior 
lines o f therapy  (1-2, ≥
3), ECOG PS (0- 1, 2), and by TLS category  (low risk, increased risk for 
TLS). Subjects will be dosed within 3 days of randomi zation.
Subjects will cont inue treatment with either ibrutinib and venetoclax or ibrut inib and placebo for 
at least 104 weeks, fo llowed by ibrut inib monotherapy  until PD, unacceptable toxicit y or 
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 59withdrawal  of consent. Venetocl ax/placebo will be discont inued after 104 weeks of treatment, 
regardl ess of response assessment.
A stratified, permuted -block rando mizat ion will be implemented in order to obtain a balanced 
assignment to each treatment within levels of the stratificat ion factors.
5.1.2.2 Blinding
Subjects, in vestigators, and the Sponsor’s study team members will remain blinded to treatment 
assignment. The investigator will not be provided with rando mizat ion codes nor the treatment 
received. The codes will be maintained within the IRT Sy stem , which has the func tionali ty to 
allow the investigator to break the blind for an individual subject if necessary to appropriately 
manage or treat the subject. Data that may potentially unblind the treatment assignment (ie, study  
drug pl asma concentrations) will be handled wi th speci al care to ensure that the integrit y of the 
blind is maintained and the potential for bias is minimized.
Telephone contact with the Sponsor or its designee will be available 24 hours per day , 7days per 
week. In the event the blind is broken, the S ponsor must be informed as soon as possible. The 
date and time of the unblinding must be documented within the IRT System, in the appropriate 
section of the eCRF and in the source document. The confirmat ion received from the IRT 
System  indicat ing the code break must be retained with the subject's source documents in a 
secure m anner. A subject whose treatment assignment has been unblinded may cont inue the 
study  treatm ent if the subject is expected to continue to receive clinical benefit. The subject 
shoul d continue to return for scheduled study visits. The single -blind (i e, subject rem ains blinded 
to treatment assignment) should be maintained, provided the subject’s safet y is not 
compromised.
5.1.3 Replacement of Subjects
Subjects who miss ≥20% of  the planned doses of ibrutinib or venetoclax for reasons other than 
toxicity (eg, non -compliance, withdrawal o f consent, di sease progressi on) during the TLS and 
DLT assessment period (venetoclax ramp -up during the Safet y Run-in Period), or subjects who 
do not complete the TLS and DLT assessment period for any  reason other than TLS or a DLT 
will be replaced.
Randomized subjects will not be replaced in the Rando mizat ion Phase.
5.1.4 Treatment -naive Open -label Arm
In the treatm ent-naive open -label arm, approximately 75 subject s will be enrolled and treated 
with ibrutinib560mg and venetoclax 400 mg. Among them, approximately 50 subjects 
≥ 65 years and approximately 25 subjects with a TP53 mutation will be enrolled. Ibrutinib and 
venetoclax will be administered using the 5 -week ramp -up schedule.
Subject eligibilit y will be determined up to 28 days prior to the first dose of study  drug.
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 60After wri tten inform ed consent has been obtained and eligibilit y has been established, the study  
site will  obtain the subject’s ident ificat ion number fro m the Interactive Response Techno logy 
(IRT) System .
Subjects in the protocol -defined increased -risk for tum or lysis syndrome (TLS) group will be 
hospi talized for a minimum o f 24hours (and up to 48 hours at the discretion o f the invest igator) 
at the start of the 20 mg and 50 mg ramp- up dose of venetoclax for monitoring and prophylaxis 
of TLS; subjects in the low -risk for TLS group may be hospitalized at the discret ion of the 
investigator.
Subjects will be treated with ibrut inib and venetoclax for ap proximately 104 weeks (2 y ears), 
followed by ibrut inib monotherapy  until PD, unacceptable toxicit y or wi thdrawal of consent. 
Venetoclax will be discontinued after 104 weeks (2 years) of treatment, regardless of response 
assessment.
Subjects who discont inue study  treatm ent for any  reason will be followed for disease 
progression, subsequent anticancer therapy , and survival status until study  closure.
5.2 Study Treatment
5.2.1 SRI and Randomized Phase
Ibrutinib
Orally  once daily ibrut inib 560 mg (4 x 140 mg capsules OR 1 x 560 m g tabl et) 
continuously 
Note: Dose modificat ion of ibrut inib for AEs is specified in Section 5.3.1.4 , Secti on 5.3.1.6 , and 
Secti on 6.2.1.1 .
Important: If using tablets, please ensure that patients do not take more than one 560 mg tablet per 
day.
Venetoclax
Orally  once daily venetocl ax at a target dose of 400 mg (4 X 100 m g)
Note: Dose modificat ion of venetoclax/placebo for AEs is specified in Section 5.3.2.5 and 
Secti on 6.2.1.2 .
Placebo
Oral once daily matching place bo for venetoclax at a target dose of 400 mg 
(4X100 mg)
Note: Dose modificat ion of venetoclax/placebo for AEs is specified in Sections 5.3.2.5and 
Secti on6.2.1.2 .
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 615.2.2 Treatment -naive Open -label Cohort
Ibrutinib
Orally  once daily ibrut inib 560 mg (4 x 140 mg capsules OR 1 x 560 mg tablet) 
continuously 
Note: Dose modificat ion of ibrut inib for AEs is specified in Section 5.3.1.4 , Secti on 5.3.1.6 ,and 
Secti on 6.2.1.1 .
Important: If using tablets, please ensure that patients do not take more than one 560 mg 
tablet per day.
Venetoclax 
Orally  once daily venetocl ax at a target dose of 400 mg (4 X 100 m g) dos ed 
concurrent ly wit h ibrut inib
Note: Dose modificat ion of venetoclax/placebo for AEs is specified in Section 5.3.2.5 and 
Secti on 6.2.1.2 .
5.3 Study Medication
5.3.1 Ibrutinib
5.3.1.1 Formulation/Packaging/Storage
Ibrutinib is provided either as hard gelatin capsules each containing 140 mg o f ibrutinib, or as 
film coated tablets each containing 560 mg of ibrutinib. All formulat ion excipients are 
compendial and are commo nly used in oral  formulations. Refer to the ibrutinib IB for a list of 
excipients.
The ibrut inib capsules will be packaged in opaque high -densit y polyethylene pl astic bottles wit h 
labels bearing the appropriate label text as required by  governing regul atory  agencies and child -
resistant packaging. The ibrutinib tablets 560 mg will be packaged in blisters.
Refer to the Pharmacy Manual/site invest igational product manua l for addi tional guidance on 
dose m odificat ions for subjects on ibrut inib tablets, study drug storage, preparation and handling.
Study  drug l abels will contain information to meet the applicable regulatory  requi rements.
5.3.1.2 Dose and Administration
Ibrutinib 56 0 mg (4 x 140 m g capsules or 1 x 560 mg tablet) is administered orally  once daily. 
The ibrut inib capsules or tablet are/is to be taken wit h venetocl ax/placebo tabl ets at 
approximately  the same t ime each day wit h a m eal and water. The capsules or tablet sho uld be 
swallowed intact and subjects should not attempt to open capsules, break the tablet or disso lve 
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 62them in water. The use of strong CYP3A inhibitors/inducers, and grapefruit and Seville oranges 
shoul d be avoi ded for the duration of the study  (Appendix D).
If a dose i s not taken at the scheduled time, it can be taken as soon as possible on the same day  
with a return to the normal schedule the following day . The s ubject shoul d not take extra 
capsules to make up the missed dose.
For subjects starting wit h the concurrent administration of ibrut inib and venetoclax using the 
standard Ramp -up Schedule, ibrutinib will be delivered in the clinic on Days 1, 2 (all subjects ) 
and 3 (hospitalized subjects) of Weeks 1 and 2; on Days 1 of the remaining weeks during the 
venetoclax Ramp- up Peri od (see Secti on 8.2); and on the PK sample co llection day  (see 
Secti on7.1.4.1 and Secti on 7.1.4.2 ). Otherwise, ibrutinib dosing is typically done on an 
outpati ent basis.
Ibrutinib will be dispensed to subjects at each dispensing visit. Study  drug may  not be shi pped to 
the subject without a pproval fro m the Sponsor and may  not be di spensed to any one other than 
the subject. Unused ibrut inib dispensed during previous visits must be returned to the site and 
drug accountabilit y records ( Section 12.8) updated at each visit. Returned drug must not be 
redispensed to any one and m ust not be destroyed without prior written approval of Clinical 
Moni tor/CRA and /or the Sponsor. Study  drugs can only be destroy ed after full accountabilit y 
and reconciliat ion by the Clinical Monitor/CRA unless required by local inst itutional policy .
5.3.1.3 Overdose
There i s no specific experience in the management of ibrut inib overdose in pat ients. No MTD 
was reached in the Phase 1 study  in which subjects received up to 12.5 mg/kg/day  
(1400 mg/day). Healthy subjects were exposed up to a single dose of 1680 mg. One healt hy 
subject experienced reversible Grade 4 hepatic enzyme increases (AST and ALT) after a dose of 
1680 mg. Subjects who ingested more than the recommended dosage should be closely 
monitored and given appropriate supportive treatment.
Refer to Section 11.3 for further inform ation regarding special reporting situat ions as a result of 
overdose. 
5.3.1.4 Dose Modification for Adverse Reactions
Ibrutinib interruption and/or dose reduction may  be requi red for toxi cities rel ated to ibrutinib. 
The dose of study  drug m ust be modified according to the dose modificat ion gui dance in Table 1
and Table 2if any o f the following ibrut inib related toxicit ies occur:
Grade 3 or greater neutropenia wit h infect ion or fever
Grade 4 neutropenia (ANC < 500/µL) for more than 7 days. See Section 6.1for 
instructi ons regarding the use of growth factor support.
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 63Grade 3 thrombocy topeni a (platelets < 50,000/µL) in the presence of Grade ≥ 2 
bleeding
Grade 4 thrombocy topeni a (platelets < 25,000/µL)
Grade 3 or greater n on-hematol ogical toxi city (Note: Table 2recommendations for 
Grade 3 or greater cardiac failure and cardiac arrhyt hmias)
Grade 2 cardiac failure ( Table 2)
Any other Grade 4 or unmanageable Grade 3 toxicity
If clinically  indicated, the use of anticoagulants or ant iplatelet agents m ay be considered for the 
thromboprophylaxis o f atrial fibrillat ion (Secti on6.2.4 and Secti on 1.2.4.6 ). 
For other AEs including grade 2 AEs that are deemed per the invest igator potentially manageable 
by dose reduction, these can be managed with a one dose level dose reduction.
In the event that the invest igator feels deviat ion from the reco mmendat ions above is required, 
please consult the m edical m onitor to di scuss for approval .
Dose changes must be recorded in the Dose Administration eCRF.
Table 1. Ibrutinib Dose Modifications
Hematologic AEs
Occurrence Action to be Taken
First Withhold ibrutinib until recover y to an ANC ≥ 750/µL or platelets > 25,000/µL with no 
evidence of Grade ≥2 bleeding; may restart at original dose level
Subsequent Withhold ibrutinib until recover y to an ANC ≥ 750/µL or platelets > 25,000/µL with no 
evidence of Grade ≥2 bleeding; may restart at 1 dose level lower* (refer to Table 3)
Other Hematologic and Non-Hematologic AEs (for Events not Specified in Table 2)
Occurrence Action to be Taken
First Withhold ibrutinib until recover y to Grade ≤1 or baseline; may restart at original dose levela
Second Withhold ibrutinib until recover y to Grade ≤1 or baseline; restart at 1 dose level lower*
(3capsules [ie 420 mg daily]) (refer to Table 3)
Third Withhold ibrutinib until recover y to Grade ≤1 orbaseline; restart at 1 dose level lower
(2capsules [ie 280 mg daily]) (refer to Table 3)
Fourth Discontinue ibrutinib
aWhen resuming treatment, restart at the same or lower dose based on benefit -risk evaluation. If the toxicity reoccurs, reduce 
daily  dose by  140 mg.
* Dose reduction due to a TLS event or a DLT is not applicable for Safety Run -in subjects.
Note: Do not dose below 280 mg daily except in case of required concomitant administration of strong or moderate CYP3A 
inhibitors or moderate hepatic impairment; refer to Section 5.3.1.6 and Section 6.2.1 .
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 64Table 2. Ibrutinib Dose Modifications for Cardiac Failure or Cardiac Arrhythmias
Events Occurrence Action
Grade 2 cardiac failureFirst Hold study drug until recovery to Grade ≤ 1 or baseline; 
restart at 1 dose level lower (3 capsules [ie, 420 mg daily])
Second Hold study drug until recovery to Grade ≤ 1 or baseline; 
restart at 1 dose level lower (2 capsules [ie, 280 mg daily])
Third Discontinue study drug
Grade 3 cardiac 
arrhythmiasFirst Hold study drug until recovery to Grade ≤ 1 or baseline; 
restart at 1 dose level lower (3 capsules [ie, 420 mg daily])a
Second Discontinue study drug
Grade 3 or 4 cardiac failure
Grade 4 cardiac 
arrhythmiasFirst Discontinue study drug
aEvaluate the benefit -risk before resuming treatment.
Table 3. Ibrutinib Dose Reduction Levels
Starting Dose Level 560 mg
Dose Reduction Level 1 420 mg
Dose Reduction Level 2 280 mg
Dose Reduction Level 3 140 mg
Dose Reduction Level 4 Discontinue
For requi red dose m odificat ion for hepatic impairment refer to Secti on 5.3.1.6 and for 
concomitant treatment with CYP3A inhibitors refer to Secti on 6.2.1 .
5.3.1.5 Leukocytosis/Leukostasis
A high number of circulat ing white blood cells (> 400,000/µL) may confer increased risk of 
leukostasis; these subjects should be closely  monitored. Administer supportive care such as 
hydrat ion and/or leukapheresis as indicated. Ibrutinib may be tem porarily  held, and the m edical 
monitor shoul d be contacted.
5.3.1.6 Dose Modification for Hepatic Impaired Subjects
Ibrutinib is metabo lized in the liver, and therefore subjects with clinically signi ficant chroni c 
hepat ic impairment at the time of Screening (Child -Pugh class B or C) are excluded fro m study  
participat ion. See Appendix Ffor Child -Pugh cl assifica tion.
For subjects with exist ing chronic mild hepatic impairment (Child -Pugh class A) at 
enrollment, the starting dose has to be adjusted to a level o f 280 m g daily (two 
capsules).
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 65For subjects who develop mild hepat ic liver impairment while on study  (Child -Pugh 
classA), the recommended dose reduction for ibrutinib is to a level of 280 mg daily 
(two capsules) unless lower doses had already been implemented.
For subjects who develop moderate hepatic impairment while on study  (Child- Pugh 
class B), the r ecommended dose reduction is to a level of 140 mg daily (one 
capsule).
Subjects who develop severe hepat ic impairment (Child- Pugh cl ass C) m ust hol d 
study  drug unt il reso lved to moderate impairment (Child -Pugh cl ass B) or better.
Subjects who develop acute hepatic toxicit y with liver enzymes Grade 3 or higher while on study  
shoul d be managed per standard dose modificat ion gui delines in Section 5.3.1.4 .
5.3.2 Venetoclax
5.3.2.1 Formulation/Packaging/Storage
The individual study  drug information is presented in Table 4.
Table 4. Identity of Venetoclax/Placebo Drug Product
Study Drug Trademark FormulationRoute of 
Administration Manufacturer
Venetoclax/placebo N/A10 mg tablet
Film coatedOral AbbVie
Venetoclax/placebo N/A50 mg tablet
Film coatedOral AbbVie
Venetoclax/placebo N/A100 mg tablet
Film coatedOral AbbVie
Packaging and Labeling
The venetocl ax/placebo tablets will be packaged in blister packs during the init ial dose ramp -up 
period and in high densit y polyet hylene (HDPE) plastic bottles thereafter to accommodate the 
study  design. Each container will be labeled as required per country  requi rements. Labels m ust 
remain affixed to the container.
Storage and Disposition of Study Drug
The venetocl ax/placebo supplied in this study  is for investi gational use only , and must only be 
used wi thin this study . All study  drug m ust be m aintained under adequate securit y and stored 
under condit ions specified on the label until dispensed for subject use or returned to the Sponsor 
or representative.
The tablets must be stored at a controlled ro om temperature of 15° to 25°C (59° to 77°F).
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 665.3.2.2 Venetoclax Toxicity Management
Prophylaxis and Management of Tumor Lysis Syndrome 
Venetoclax can cause rapid reduct ion in tumor and thus poses a risk for TLS in the Ramp -up 
Period. Changes in electroly tes consi stent wi th TLS that require prompt management can occur 
as early as 6- 8 hours fo llowing the fi rst dose of venetoclax and at each dose increase. The risk of 
TLS is a continuum based on mult iple factors, including comorbidit ies. Subjects with high tumor 
burden are at a greater risk of TLS when init iating venetoclax. Reduced renal funct ion further 
increases the risk. The risk may decrease as tumor burden decreases with venetoclax treatment.
Tumor burden assessments, including radiographic evaluat ion (eg, CT sc an) shoul d be 
perform ed at Screening as well as blood chemistry assessments (creatinine, uric acid, potassium, 
phosphorus, calcium, and albumin, if available) in all subjects. Pre -exist ing abnormalit ies shoul d 
be corrected prior to init iation of treatment with venetocl ax.
The prophylaxis measures listed below should be followed and more intensive measures 
(including hospitalization) should be emplo yed as overall risk increases:
Hydration: Ensure adequate hy dration (1.5 -2 L) 48 hours prior to init iating ther apy with 
venetoclax and throughout the Ramp -up Peri od, especi ally on the first day  of each ram p-up dose. 
Administer intravenous (IV) fluids as indicated based on overall risk of TLS or for those who 
cannot m aintain adequate oral hydration.
Anti
-hyperuricem ic agents: Administer allopurinol within 72 hours prior to init iation of 
venetoclax; consider continuing through the Ramp -up Peri od. Rasburi case is recommended for 
subjects at high risk, especially those with high tumor burden.
Laboratory Assessments:
Pre-dose: Assess blood chemistries prior to init iating venetoclax to evaluate kidney funct ion and 
correct pre -exist ing abnormalit ies. Reassess blood chemistries before starting each subsequent 
ramp-up dose of venetoclax.
Post-dose: For hospitalized subjects, m onitor bl ood chemistri es 4, 8, 12, 24 and, as needed, 
48hours after the venetoclax dose. For outpatient subjects, monitor blood chemistries at 
6-8hours and at 24 hours after the venetoclax dose. Electrolyte abnormalit ies shoul d be 
corrected prompt ly (see Appendix Hfor Recommendat ions for Initial Management of 
Electrolyte Abnormalit ies and Prevent ion of Tum or Ly sis). The next dose of venetoclax should 
not be administered unt il the 24 -hour bl ood chemistry  resul ts have been evaluated. The same 
monitoring schedule shou ld be followed when starting each subsequent ramp -up dose.
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 67Hospitalization: Based on invest igator assessment, subjects with high tumor burden (at least one 
lesion > 10 cm; or at least one lesion > 5 cm  and circul ating lymphocy tes > 25,000 cells/mm3) 
and/or CrCl < 60 mL/min, are at greater risk of TLS and require hospitalization the first 
24-48hours of treatment at the 20 mg and the 50 mg ramp- up doses of venetoclax for more 
intensive prophylaxis and monitoring. Consider hospitalization for subsequent ramp -up doses 
based on reassessment of risk. During the course of the study , the DMC will review unblinded 
TLS data to determine whether continued hospitalization of these subjects is warranted.
5.3.2.3 Dose and Administration
Venetoclax/placebo tablets should be taken orally once daily  with a meal and water at 
approximately  the same t ime each day wit h ibrut inib capsules .Venetoclax/placebo tablets should 
be swallowed who le and not chewed, crushed, or broken prior to swallowing. If the subject 
misses a dose of venetocla x/placebo within 8 hours of the time it is usually  taken, the subject 
shoul d take the missed dose as soon as possible on the same day  and resume the norm al daily 
dosing schedule. If a subject misses a venetoclax/placebo dose by  more than 8 hours, the subje ct 
shoul d not take the missed dose and resume the usual dosing schedule the following day . The use 
of strong CYP3A inhibitors/inducers, and grapefruit and Seville oranges should be avo ided for 
the duration of the study  (Appendix D).
For subjects starting wit h the concurrent administration of ibrut inib and venetoclax using the 
standard Ramp -up Schedule, venetoclax/placebo will be delivered in the clinic on Days 1, 2 ( all 
subjects) and 3 (hospitalized subjects) of Weeks 1 and 2; on Day s 1 of the rem aining weeks 
during the Ramp -up Peri od (see Section 8.2); and on the PK sample co llection day  (see 
Secti on7.1.4.1 and Secti on 7.1.4.2 ). Otherwise, venetoclax dosing will be done on an outpatient 
basis. Subjects should strict ly adhere to the Ramp- up Schedule. In the event of TLS, dosing of 
venetoclax will be wit hheld and/or m odified per the protocol and may  be resumed at the 
investigator’s discret ion, when all laboratory  abnormali ties have returned to baseline. If 
venetoclax is resumed at the same dose level, the 7- day count shoul d be re -started. In cases of 
vomiting after tak ing venetoclax/placebo, no addit ional dose (tablets) should be taken that day. 
The next dose should be taken at the usual time the fo llowing day .
5.3.2.4 Overdose
There i s no specific antidote for venetoclax/placebo. For subjects who experience overdose, 
closely  monitor and provi de appropri ate supportive treatment; during the Ramp -up Peri od, 
interrupt venetocl ax/placebo and mo nitor carefully for signs and symptoms of TLS along with 
other toxicit ies. Based on the venetoclax (assume for placebo) large vo lume of distr ibution and 
extensive protein binding, dialysis is unlikely to result in significant removal o f venetoclax 
(assume for placebo).
Refer to Section 11.3 for further inform ation regarding special reporting situat ions as a result of 
overdose.
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 685.3.2.5 Dose Modification for Adverse Reactions
Venetoclax/placebo dosing interruption and/or dose reduction may be required. See Table 5for 
dose m odificat ions for hematologic and other toxicit ies related to venetoclax/placebo. For 
subjects who have had a dosing interruption greater than 1 week during the Ramp -upPeriod or
greater than 2 weeks when at target dose, reassess for risk of TLS to determine if reinit iation 
with a reduced dose i s necessary (eg, all or some levels o f the dose Ramp -up Schedule).
Dose reduction of venetoclax is not allowed for subjects enro lled in th e Safet y Run-in Period 
(see Secti on 3.1.1 ).
Table 5. Recommended Dose Modifications for Venetoclax/placebo -related 
Toxicities
Event Occurrence Action
Tumo r Lysis Sy ndrome
Blood chemistry changes 
or symptoms suggestive 
of TLSAny Withhold the next day’s dose. If resolved within 
24-48 hours of last dose, resume at the same dose.
For any  blood chemistry changes requiring more than 
48 hours to resolve, resume at a reduced dose* 
(seeTable 6) 
For any  events of clinical TLS, resume at a reduced dose 
following resolution (see Table 6)*
Non-Hematologic Toxicities
Grade 3 or 4 non -
hematologic toxicities 1stoccurrence Interrupt venetoclax/placebo
Once the toxicity has resolved to Grade 1 or baseline level, 
venetoclax/placebo therapy may be resumed at the same 
dose. No dose modification is required. 
2ndand subsequent 
occurrences Interrupt venetoclax/placebo.
Follow dose reduction guidelines in Table 6when resuming 
treatment with venetoclax/placebo after resolution. A larger 
dose reduction may occur at the discre tion of the 
investigator.*
Hematologic Toxicities
Grade 3 or 4 neutropenia 
with infection or fever; or 
Grade 4 hematologic 
toxicities (except 
lymphopenia) 1stoccurrence Interrupt venetoclax/placebo.
To reduce the infection risks associated with neutropenia, 
granulocyte -colon y stimulating factor (G -CSF) may be 
administered with venetoclax/placebo if clinically 
indicated. Once the toxicity has resolved to Grade 1 or 
baseline level, venetoclax/placebo may be resumed at the 
same dose. 
2ndand subsequent 
occurrence Interrupt venetoclax/placebo.
Consider using G -CSF as clinically indicated.
Follow dose reduction guidelines* in Table 6when 
resuming venetoclax/placebo after resolution. Additional 
dose reductions may occur at the discretion of the 
investigator
*Dose reduction due to a TLS event or a DLT is not applicable for Safety Run -in Period subjects. 
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 69Consider discontinuing venetoclax/placebo for subjects who require dose reductions to less than 
100 m g for m ore than 2 weeks.
If the dose of venetoclax/placebo is reduced, at the invest igator’s discretion, the dose of 
venetoclax/placebo may be re -escalated after 2 months of a dose reducti on in the absence of a 
recurrence of the toxicit y that led to the reduction. Dose changes must be recorded in the Dose 
Administrati on eCRF.
Table 6. Dose Modification for Toxicity During Venetoclax/placebo Treatment
Dose at Interruption Restart Dosea
400 mg 300 mg
300 mg 200 mg
200 mg 100 mg
aContinue the reduced dose for at least 1 week before increasing the dose. 
5.3.2.6 Dose Modification for Hepatic Impaired Subjects
No dose adjust ment is recommended in subjects wit h mild or moderate hepatic impairment based 
on resul ts of the populat ion pharmacokinetic analysis. A recommended dose has not been 
determined for subjects who develop severe hepatic impairment.
5.4 Criteria for Permanent Discontinuation of Study Drug
Invest igato rs are encouraged to keep a subject who is experiencing clinical benefit in the study 
unless significant toxicit y puts the subject at risk or routine noncompliance puts the study  
outcom es at risk. Subjects who discontinue either ibrutinib or venetoclax/pla cebo (but not both) 
for tolerabilit y issues may cont inue in the study  as long as they are receiving at l east one study  
drug. F or a com plete list of criteria for permanent discontinuat ion of study  treatm ent, refer to 
Secti on 9.2.
An End -of-Treatment Vi sit (Secti on 8.2.3 ) is required for all subjects except for those subjects 
who have withdrawn full consent.
6CONCOMITANT MEDICATI ONS/PROCEDURES
6.1 Permitted Concomitant Medications
Supportive medicat ions in accordance with standard practice (such as for emesis, diarrhea, etc.) 
are permitted.
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 70Usage of ant imicrobial prophylaxis in accordance with standard practice (eg, ASCO guidelines 
[Flowers 2013 ]) is permitted and should be considered in pat ients who are at increased risk for 
opportunist ic infect ions.
Use of neutrophil growth factors (filgrast im and pegfilgrastim) red blood cell growth factors 
(erythropoi etin) and transfusio n is permitted in accordance with inst itutional policy (eg, ASCO 
Guidelines [Smit h 2006 ]). 
In addit ion, short courses (≤ 14 days) of steroid treatment for non- cancer rel ated m edical  reasons 
(eg, j oint inflammat ion, asthma exacerbat ion, rash, antiemet ic use and infusio n reactions) at 
doses that are clinically  indicated are permitted.
6.2 Medications to be Us ed with Caution
6.2.1 CYP3A Inhibitors/Inducers
6.2.1.1 Concomitant Use with Ibrutinib
Ibrutinib is metabo lized primarily by CYP3A4. Avoid conco mitant use of systemic strong or 
moderate CYP3A inhibitors and consider alternat ive agents with less CYP3A inhibit ion.
If a strong CYP3A inhibitor must be used, reduce ibrutinib dose to 140 mg or 
withhol d treatm ent for the durati on of  inhibitor use. Subjects should be monitored 
for signs of  ibrutinib toxicit y.
If a moderate CYP3A inhibitor must be used, reduce ibrutinib to 140 mg for the 
durati on of  the inhibitor use. Avo id grapefruit and Seville oranges during 
ibrutinib/placebo treatment, as these contain moderate inhibitors of CYP3A (see 
Secti on 6.2.1.1 ).
No dose adjust ment is required in co mbinat ion with mild inhibitors.
Table 7summarizes the recommended dose modificati ons wi th moderate and strong CYP3A 
inhibitors. Avo id concomitant use of systemic strong CYP3A inducers (eg, carbamazepine, 
rifampin, phenyto in, and St. John’s Wort). Consider alternat ive agents with less CYP3A 
induct ion.
A list of commo n CYP3A in hibitors and inducers is provided in Appendix D. For further 
inform ation, please refer to the current ibrut inib IB and examples of inhibitors, inducers, and 
substr ates can be found at http://medicine.iupui.edu/clinpharm/ddis/main -table/. This website is 
continually  revised and shoul d be checked frequently  for updates.
6.2.1.2 Concomitant Use with Venetoclax/placebo
Concomitant use of venetoclax/placebo with strong CYP3A inh ibitors at init iation and during the 
Ramp-up Peri od increases the risk for TLS. Concomitant use of venetoclax/placebo with strong 
CYP3A inhibitors at init iation (7 day s prior to fi rst dose) and during the Ramp
-up Peri od is 
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 71contraindicated. For subjects who have completed the Ramp -up Peri od and are on a steady  daily  
dose of venetoclax/placebo, reduce the venetoclax/placebo dose by  at least 75% when strong 
CYP3A inhibitors must be used conco mitantly.
Avoid conco mitant use of moderate CYP3A inhibitors with ven etocl ax. Consider alternat ive 
treatm ents. If a m oderate CYP3A inhibitor must be used, reduce the doses of venetoclax/placebo 
by at least 50%. Moni tor subjects m ore cl osely  for signs of  toxicities. Table 7summarizes the 
recommended dose modificat ions wi th moderate and strong CYP3A inhibitors.
Resume the venetoclax/placebo dose that was used prior to init iating the CYP3A inhibitor 2 to 
3days after di scontinuat ion of the inhibitor.
Avoid conco mitant use of venetoclax/placebo with strong CYP3A inducers (eg, carbamazepine, 
phenyto in, rifampin, St. John’s Wort) or moderate CYP3A inducers (eg, bosentan, efavirenz, 
etravi rine, m odafinil , nafcillin). Consider a lternat ive treatments with less CYP3A induct ion.
A list of commo n CYP3A inhibitors and inducers is provided in Appendix D. For further 
inform ation, please refer to the current venetoclax IB.
A sample list of caut ionary medicat ions that fall into these categories is provided in Appendix D.
Table 7. Man agement of Potential Ibrutinib and Venetoclax/placebo Interactions 
with CYP3A Inhibitors
Venetoclax/placebo Ibrutinib
Inhibitors Initiation and 
Ramp -up PeriodTarget Daily Dose 
(After Ramp-up)At any  time
Strong CYP3A 
inhibito rContraindicated Avoid inhibitor use, consider 
alternative agent. If must be 
used, reduce the venetoclax 
dose by at least 75%Avoid inhibitor use, consider 
alternative agent. If must be used, 
withhold ibrutinib for duration of 
inhibito r use, or reduce ibrutinib to 
140 mg
Modera te CYP3A 
inhibito rAvoid inhibitor use, consider alternative agent. If 
must be used, reduce the venetoclax dose by at least 
50%Avoid inhibitor use, consider 
alternative agent. If must be used, 
reduce ibrutinib to 140 mg
6.2.2 Drugs that May have Their Plasma Concentration Altered by Ibrutinib
In vitro studies indicated that ibrut inib is a mild P -gp inhibitor. Ibrutinib is not expected to have 
systemic drug -drug interactions with P -gp substrates. However, it cannot be excluded that 
ibrutinib could inhibit intes tinal P-gp after a therapeutic dose. There is no clinical data available. 
Therefore, to avoid a potential interact ion in the GI tract, narrow therapeutic range P -gp 
substrates such as digoxin should be taken at least 6 hours before or after ibrut inib.
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 726.2.3 Drug s That May Have Their Plasma Concentrations Altered by Venetoclax
Venetoclax is a P -gp and BCRP substrate as well as a P -gp and BCRP inhibitor and weak 
OATP1B1 inhibitor in vitro . To avoid a potential interaction in the gastrointest inal tract, 
coadministra tion of  narrow therapeuti c index P -gp substrates such as digoxin wit h venetoclax 
shoul d be avoi ded. If a narrow therapeutic index P- gp substrate must be used, it should be taken 
at least 6 hours before venetoclax. 
A list of medications that are P- gp subst rates i s provided in Appendix D. For further informat ion, 
please refer to the current venetoclax IB.
6.2.4 Antiplatelet Agents and Anticoagulants
6.2.4.1 Concomitant Use with Ibrutinib
Use ibrut inib wit h caution in subjects requiring anticoagulants or medications that inhibit platelet 
funct ion, and supplements such as fish oil and vitamin E preparations should be avoided during 
treatm ent wi th ibrutinib. Bleeding events of any g rade, including bruising and petechiae, 
occurred in pat ients treated with ibrut inib and the mechanism for the bleeding events is not well 
understood. Subjects with congenital bleeding diathesis have not been studied. Ibrutinib should 
be held at least 3 to 7 days pre -and post -surgery , depending upon the type of surgery  and the ri sk 
of bleeding (see Section 6.3).
Subjects requiring the init iation of the rapeuti c ant icoagulat ion therapy  (eg, atri al fibrillat ion), 
consider the risks and benefits of cont inuing ibrut inib treatment. If therapeutic anticoagulat ion is 
clinically indicated, treatment with ibrut inib/placebo should be held and not be restarted unti l the 
subject is clinically stable and has no signs of bleeding. No dose reduction is required when 
study  drug i s restarted. Subj ects shoul d be observed cl osely for si gns and symptom s of bleeding.
6.2.4.2 Concomitant Use with Venetoclax
In a drug -drug interaction study  in three healthy subjects, administration o f a single 400 mg dose 
of venetoclax with 5 mg warfarin resulted in 18% to 28% increase in C maxand AUC ∞of 
R-warfarin and S -warfarin. Because venetoclax was not dosed to steady  state, i t is recommended 
thatthe internat ional norm alized rati o (INR) be m onitored cl osely  in subjects receiving warfarin.
6.2.5 Prohibited Concomitant Medications and Products for Ibrutinib and/or 
Venetoclax/placebo
Any non -study  protocol -related chemotherapy , anticancer immunotherapy , experimental  therapy , 
or radi otherapy  are prohibited while the subject is receiving ibrut inib treatment.
Corti costeroi ds for the treatm ent of  the underlying malignancy are prohibited (refer to 
Secti on6.1for further gui dance).
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 73The Sponsor must be notified in advance (or as soon as possible thereafter) of any instances in 
which prohibited therapies are administered.
Subjects m ay not consume gra pefruit or grapefruit products, Seville oranges (including 
marmalade containing Seville oranges) or star fruit within the 3 -day period pri or to the first 
ibrutinib and venetoclax administration and unt il the last day of treatment is co mpleted due to 
possib le CYP3A mediated metabo lic interacti on.
Do not administer live attenuated vaccines prior to, during, or after treatment with venetoclax. 
The safet y and efficacy  of immunizat ion with live or attenuated viral vaccines during or
following venetoclax therapy  have not been studied. Advise subjects that vaccinat ions may be 
less effect ive.
6.3 Guidelines for Ibrutinib Management with Surgeries or Procedures 
Ibrutinib may  increase ri sk of bleeding with invasive procedures or surgery . The fo llowing 
guidance shoul d be applied to the use of ibrut inib in the peri operative peri od for subjects who 
requi re surgi cal interventi on or an invasive procedure while receiving ibrut inib: 
6.3.1 Minor Surgical Procedures
For minor procedures (such as a central line placement, skin or needle biopsy, lumbar puncture 
[other than shunt reservoir access], thoracentesis, or paracentesis) ibrut inib shoul d be held for at 
least 3 days prior to the procedure and should not be restarted for at least 3 days after the 
procedure. For bone marrow biopsies that are perform ed while the subject is on ibrutinib, it is not 
necessary  to hol d ibrut inib.
6.3.2 Major Surgical Procedures
For any  surgery  or invasive procedure requiring sutures or staples for closure, ibrut inib shoul d be 
held at least 7 day s prior to the int ervent ion (except for emergency procedures) and should be 
held at least 7 day s after the procedure and restarted at the discret ion of the investigator when the 
surgi cal si te is reasonably healed without serosanguineous drainage or the need for drainage 
tubes.
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 747STUDY EVALUATIONS
7.1 Description of Procedures
7.1.1 Assessments
7.1.1.1 ICF
The subject must read, understand, and sign the Institutional Review Board/Research Ethics 
Board /Independent Ethics Committee (IRB/REB/IEC) approved ICF confirming his or her 
willingness to pa rticipate in this study  before any study -specific screening procedures are 
perform ed. Subjects in the US must also grant permissio n to use protected health informat ion per 
the Heal th Insurance Portabilit y and Accountability Act (HIPAA). In addit ion, subjec ts must si gn 
all approved ICF amendments per the site IRB/REB/IEC guidelines during the course of the 
study .
7.1.1.2 Confirm Eligibility
All necessary  procedures and evaluat ions must be performed to document that the subject meets 
all of the inclusion criteria and none of the exclusion criteria until first dose of study  drug 
(Secti on 4).
7.1.1.3 Medical History and Demographics
The subject’s relevant medical history  through review of medical records and by interview will 
be co llected and recorded. Concurrent medical signs and symptoms must be documented to 
establish baseline severit ies. A di sease history , including the date of init ial diagnosis and list of 
all prior a nticancer regimens, dates administered, and responses and DOR to these treatments, 
will also be recorded.
7.1.1.4 Prior and Concomitant Medications
All medications at least 14 day s prior to the first dose through 30 days after the last dose of study 
drug will be d ocum ented. 
7.1.1.5 Adverse Events
The accepted regulatory  defini tion for an AE i s provi ded in Section 11.1. The occurrence of an 
AE at the time the ICF is si gned unt il first dose should be recorded under medical history in the 
eCRF form. All medical occurrences after the first dose with study  drug/treatm ent until 30 days 
after the l ast dose of study  drug that m eet the AE definit ion must be recorded as AEs in t he 
eCRF. Laboratory  abnorm alities and changes in vit al signs are considered to be AEs only  if they  
resul t in dose reducti on or treatm ent di scont inuat ions, necessitate therapeutic medical 
intervent ion, meet protocol specific criteria or if the invest igator considers them to be AEs . 
Addit ional important requirements for AE and SAE reporting are explained in Secti on 11.4.
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 757.1.1.6 Physical Examination
The Screening and End -of-Treatm ent physical examinat ion will include, at a minimum, the 
general appearance o f the subject, height (Screening only) and weight, and examinat ion of the 
skin, eyes, ears, nose, throat, lungs, heart, abdomen, extremit ies, musculoske letal system , 
nervous system, and lymphat ic system.
A limited symptom -directed physical  examinat ion may be required at selected timepo ints as 
outlined in Section 8.
7.1.1.7 Eye-related Symptom Assessment
The subjects will be asked about ey e
-related symptoms.
If there are any eye -related symptom s of severi ty Grade ≥2 at Screening or if the subject 
develops any eye -related symptom s of severit y Grade ≥2 while on study  treatm ent, an 
ophthalmo logic evaluat ion/consult must be performed, and the outcome must be reported on the 
ophthalmo logic eCRF.
7.1.1.8 ECOG
The ECOG performance index is provided in Appendix C.
7.1.1.9 Vital Signs
Vital signs will  include bl ood pressure, heart rate, and body  temperature. Vi tal signs will be 
assessed after the subject has rested in the sitting posit ion for ≥3 minutes.
7.1.1.10 Tumor Lysis Syndrome (TLS) Risk Assessment
At Screening, all study  subjects will be assessed for risk of developing TLS. The risk of TLS is a 
continuum based on mult iple factors, including comorbidit ies. Subjects at increased risk are 
defined as having at least one lesio n >10 cm; or at least one lesio n >5 cm and circulating 
lymphocy tes > 25,000 cells/mm3and/or have reduced renal funct ion CrCl < 60 mL/min. The risk 
may decrease as tumor burden decreases with venetoclax treatment.
Blood chemistry  (creatinine, uri c acid, potassium, phosph orus, cal cium , and albumin if available) 
assessments will be performed in all subjects within 72 hours prior to init iating venetoclax 
treatm ent.
Subjects with high tumor burden at baseline and/or CrCl < 60 mL/min will be hospitalized 
during the first 24-48 hours of treatment at the 20 mg (Week 1) and the 50 mg (Week 2) 
venetoclax dose. Blood chemistry  (creatinine, uric acid, potassium, phosphorus, calcium, and 
albumin if available) should be monitored pre -dose and 4±1, 8±1, 12±1, 24±2 and, as needed, 
48±2 h ours after the venetoclax dose. (Hospitalizatio n for subjects l acking immediate access to a 
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 76facilit y capable of correcting TLS prompt ly or for subjects who are otherwise considered at risk 
for TLS should be discussed wit h the m edical mo nitor). For all othe r subjects, blood chemistry  
will be mo nitored pre -dose, 6 -8 and 24±2 hours after the venetoclax dose at the 20 mg and the 50 
mg dose levels.
During the remaining ramp -up weeks (weeks 3- 5), for subjects at increased risk for TLS at 
baseline, blood chemistri es will be m onitored at pre -dose and 6- 8 hours after each dose increase.
Appropriate venetoclax dosing and management of subjects throughout their study treatment is 
guided by  their individual risk for developing TLS. Risk -based TLS prophylaxis and 
managem ent m easures are described in Secti on 5.3.2.2 .
7.1.1.11 B-Symptoms
B-symptoms include fever > 38° C for at l east 3 consecut ive days, drenching night sweats o r 
weight loss > 10% since the last disease assessment.
7.1.2 Laboratory
All laboratory  tests will be collected by  local lab.
7.1.2.1 Hematology
Hem atology parameters will include a complete blood count: white blood cells, red blood cells, 
hemoglo bin, hematocrit, platele ts, neutrophils, lymphocy tes, m onocy tes, eosinophils, basophils.
7.1.2.2 Chemistry (Serum)
Blood chemistry  param eters will  include sodi um, potassi um, chloride, bl ood urea ni trogen 
(BUN)/Urea, creatinine, glucose, calcium, and albumin, if available, total protein, AST, ALT, 
alkaline phosphatase, total bilirubin, LDH, phosphorus, uric acid, magnesium and bicarbonate.
7.1.2.3 Coagulation Studies
Measurement of PT, INR and aPTT will be performed at Screening using a local laboratory . INR 
shoul d be f ollowed m ore cl osely  in subjects on warfarin therapy .
7.1.2.4 Hepatitis Serologies
Hepati tis serol ogies include hepat itis C ant ibody , hepatit is B surface ant igen, and hepat itisB 
core anti body . If hepati tis B core anti body , hepat itis B surface ant igen, or hepatit is C ant ibody  is 
positive, th en PCR to quantitate hepatit is B DNA or hepatit is C RNA must be performed and 
must be negat ive prior to randomizat ion/enro llment. This applies to the SRI and Rando mizat ion 
Phase only. Treatment -naive open -label arm subjects with a posit ive hepat itis B surf ace anti gen 
test are excluded fro m the trial.
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 777.1.2.5 Serum β2 -microglobulin
One blood sample(s) for β2- microglobulin will be taken during the screening period.
7.1.2.6 Urinalysis
Urinalysis includes pH, ketones, specific gravit y, bilirubin, protein, blood, and glucose.
7.1.2.7 Pregnancy Test
Serum  or urine pregnancy  test will  be requi red at Screening by  local laboratory  only  for wom en 
of childbearing potential. A serum or urine pregnancy test will also be performed on Day 1 prior 
to first dose. If posit ive, pregnancy must be rul ed out by  ultrasound, at least 3 weeks after a 
positive urine pregnancy test, to be eligible. This test may be performed more frequent ly if 
requi red by l ocal regulatory  authori ties.
7.1.3 Diagnostics/Procedures
7.1.3.1 ECG
A single 12- lead ECG will be done at Screening and at the EOT visit. Subjects should be in a 
supine posit ion and resting for at least 10 minutes before obtaining the ECG. During the 
treatm ent peri od, ECGs m ay be perf ormed at the investigator’s discret ion, parti cularly in subjects 
with arrhy thmic sympto ms (eg, palpitat ions, lightheadedness) or new onset dyspnea.
During visit s in which both ECGs and blood draws are performed, ECGs should be performed 
first.
Abnorm alities noted at the Screening ECG should be included in the medical history .
7.1.3.2 CT/MRI and PET
SRI and Randomized Phase
Pretreatment tumor assessment will be performed within 28 days before the first dose of study 
drug.
A CT scan (with contrast unless contraindicated) of the neck, chest, abdomen, and pelvis and any 
other disease sites and a PET scan are requi red for the pretreatment tumor assessment. CT scans 
with contrast will be done for tumor assessments on Week 13 Day  1 (±7 days); every  12weeks 
for the rem ainder of the first y ear; every  16 weeks during the second and third years; and every 
24 we eks thereafter until PD. In subjects with positive PET at baseline, PET or PET/CT is 
mandatory  to confirm a CR. Disease assessments may be repeated as clinically indicated to 
confirm response or progression.
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 78Lesio ns that have been irradiated cannot be incl uded in the tum or assessment unless unequivocal 
tumor progressi on has been docum ented in these lesions after radiat ion therapy . There m ust be 
radiographically  measurable disease at Screening (at least one lymph node ≥2.0cm in the 
longest di ameter). Up to 6 measurable lymph nodes (target lesio ns > 1.5 cm  in the l ongest 
diameter), cl early  measurable in 2 perpendicular dimensions, will be fo llowed as target lesio ns 
for each subject. Measurable sites of disease should be chosen such that they  are representati ve 
of the subject’s disease. In addit ion, select ion of target lesio ns should be from as disparate 
regions of the body  as possible when these areas are significant ly involved. If additional lesions 
are present but are not included in the target lesio n asses sment, they  can be added as non -target 
lesions and foll owed throughout the study .
Inform ation on extranodal invo lvement (eg, gastric or ocular disease) will also be recorded. 
Lesio ns in anatomical locat ions that are not well visualized by CT may be measure d by MRI 
instead and should cont inue to be measured by MRI until disease progression.
In the case where CT contrast is contraindicated, an alternat ive would be MRI of the abdo men 
and pelvis with MRI contrast and CT of the chest and neck without CT contrast . In this case, 
neck nodes cannot be used as target lesions.
NOTE: PET/CT hybrid scanners may  be used to acquire the required CT images only if the CT 
produced by  the scanner i s of diagnostic qualit y, adheres to the specified slice thickness/scan 
param eters, and includes the use of intravenous (IV) contrast. Addit ionally, the CT images must 
be separated from the PET data prior to submitting the data and cannot be transmitted as fused 
CT/PET images.
If using a hybrid machine to acquire both PET and CT, the P ET m ust be perform ed pri or to the 
CT wi th IV contrast as to not compromise PET results.
If a CT with contrast scan indicates suspected CR, a confirmatory  PET scan m ay be perf ormed 
within 30 days.
For subjects who remain stable with PR for > 6 months wit h residual lymph node l esions 
>1.5cm that remain relat ively unchanged, a PET scan may be performed to determine if CR has 
been achieved and MRD testing should be implemented.
De-ident ified copies of all scans and radio logy reports (including those fro m screening) m ust be 
provi ded to the Sponsor or designee (eg, central imaging vendor). At the Sponsor’s discret ion, 
the Sponsor or its designee may conduct an independent review of the invest igator responses.
Treatment -naive Open -label Arm
CT and PET or PET/CT scans (with contrast unless contraindicated) of the neck, chest, 
abdo men, and pelvis and any  other disease si tes (eg, extremit y) and a PET scan are required for 
the pretreatment tumor assessment within 28 days of the 1stdose. Thereafter, CT scans will be 
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 79done for tumor assessments on Week 13 Day  1 (±7 day s); every  12 weeks for the rem ainder of 
the 1styear; every  16 weeks during the 2ndand 3rdyears; and every  24 weeks thereafter unt il PD. 
PET or PET/CT is mandatory  for all  subjects at the Week 13 visit ( +/-7 days), the Week 25 visi t 
(+/-7 day s) for subj ects in SD or PR who di d not achieve CR at Week 13, and at the 1 -year visit 
(Week 49 +/ -7 days) for all subjects, as well as at any other time point to confirm a CR. Other 
PET or PET/CT scans that are NO T mandatory  can be perform ed wi thin a 30 -day window of the 
visit. For MRI refer to Section 7.1.3.2 .
7.1.3.3 Endoscopy
Endoscopy  is opti onal at baseline but i s requi red and m ust be negat ive to confirm CR (preferably 
within 30 days of the init ial docum entati on of  CR) in subjects with known endoscopy -positive 
GI invo lvement at baseline.
7.1.3.4 Tumor Tissue
Approximately  20 slides of fresh or m ost recent dated FFPE archival tumor biopsy t issue will be 
collected at study  entry  and eval uated f or biomarker assessment. An optional fresh tumor biopsy  
may be collected at the time of disease progression.
Confirmation o f MCL diagnosis is required prior to enrollment; a repor t from the local 
laboratory  is acceptable. The diagnosis of MCL from the local laboratory  must include 
morphol ogy and expressi on of  either cyclin D1 in associat ion with other rel evant m arkers 
(eg,CD20 and CD5) or evidence of t(11;14)(q13;q32) as assessed by cy togeneti cs or fluorescent 
in situ hybridizat ion (FISH). The report containing this informat ion must be sent to the central 
laboratory  and the sponsor for confirmat ion of the diagnosis prior to enrollment.
For subjects who do not have this report avail able, the form alin-fixed paraffin embedded (FFPE) 
tumor tissue block or slides must be sent to the central laboratory  and confirmat ion of MCL 
diagnosis m ust be obtained from  the central  laboratory  prior to enrollment.
7.1.3.5 Bone Marrow Biopsies for Evaluation of Bone Marrow Involvement
A unilateral bone marrow biopsy must be collected at Screening up to 28 day s prior to the first 
administration of study  drug to be evaluated for bone marrow involvement, unless prior bone 
marrow bi opsy  is obtained within 90 days pr ior to study  treatm ent. Addi tional bone marrow 
biopsy will be co llected in subjects with documented CR.
Bone m arrow involvement must be assessed locally  prior to enrollment. A l ocal pathol ogy report 
must be available for review. If a local patho logy report is not available, bone marrow 
involvement will be assessed at the central lab. For subjects that meet CR criteria, if a local 
pathol ogy report is not available, a bone marrow biopsy  will need to be tested to ensure there is 
no lympho ma involvement in the bone marrow to confirm CR.
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 80If the subject’s physical examination findings, laboratory evaluations, radiographic 
evaluations and endoscopy  (if applicable) suggest that CR has been achieved in all other 
response parameters, a bone marrow biopsy  must be obtai ned for subjects with bone marrow 
involvement at baseline (by standard pathology ) to confirm the CR. If the response parameters 
indicate a suspected CR, a bone marrow biopsy  may be collected wi thin 30 days to confirm CR.
7.1.3.6 Bone Marrow Aspirate and Peripheral Blood for Minimal Residual Disease 
(MRD) Assessment
Minimal residual disease assessment will be performed by  flow cy tometry at Screening for every  
subject to detect a dominant clone in peripheral blood or bone marrow aspirate. MRD negativit y 
will be asses sed by  flow cy tometry  both in the peripheral blood and the bone marrow aspirate 
collected at documented CR. Thereafter subjects should be fo llowed wi th peripheral  blood MRD 
analyses by  flow cy tometry  every  12 weeks (±7 days) for the remaining first y ear; e very 
16weeks during the second and third years; and every  24 weeks thereafter until PD. 
MRD -negat ive remissio n is defined as undetectable MRD at documented CR in subjects who 
were MRD posit ive at screening as assessed by flo w cy tometry in bone marrow (BM) aspirate 
and/or peripheral blood and a consecut ive peripheral blood sample 12 weeks later.
If the MRD assessment is positive in bone marrow at CR, a repeat bone marrow aspirate is 
requi red 24 weeks l ater if the subject remains in CR to evaluate MRD status in the bone marrow.
If peripheral blood beco mes posit ive for MRD, a bone marrow sample will not be necessary; 
however, equivocal cases should be discussed with the medical mo nitor to determine the need 
for repeat bone marrow testing .
MRD -positive relapse is defined as a detectable increase in disease after a MRD -negat ive 
remission, as assessed by flo w cy tometry of a peripheral blood or BM aspirate sample.
7.1.3.7 Bone Marrow Aspirate and Peripheral Blood for Biomarker Assessment
Bone m arrow aspi rates and peri phera l blood sam ples will  be stored for expl oratory  biomarker 
analysis. ClonoSEQ (Adaptive Biotechno logies), a hi ghly sensi tive and exploratory  MRD 
detection assay, will also be used for retrospective assessment of MRD in a subset of collected 
samples of bone m arrow and peri pheral  blood to com pare MRD negat ivity as determined by  
flow cy tometry. If the Cl onoSeq technol ogy assay  is not available for use or a technically 
superi or assay  for MCL MRD has emerged at the time of testing, an alternative molecular MRD 
assay wi th equivalent or better analy tical performance may  be used for analysis.
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 817.1.4 Pharmacokinetics/Biomarkers
7.1.4.1 Pharmacokinetics for Safety Run -in and Randomization Phase
Ibrutinib and venetoclax should be dosed together at the same time wit h 8 ounces of water a nd a 
meal. It is ant icipated that steady  state will be reached after 1 week of administration of the 
highest venetoclax dose. Ibrutinib and venetoclax PK samples will be co llected at steady state on 
the PK days as shown in Table 8at the tim e points listed in Table 9.
Table 8. Ibrutinib and Venetoclax PK Samples Schedule at the Target Dose
Dosing Schedule PK Day
Standard ramp-up Week 6 Day 1
Pharmacokinet ics of ibrutinib and venetoclax when dosed in combinat ion will be determined at 
time- points specified in Table 9below.
Table 9. Pharmacokinetic Sample Schedule for Ibrutinib and Venetoclax or 
placebo on the PK Days
Study DrugsPre-
dose 
PKaDosebTime after ibrutinib and venetoclax dose
1 hour
(± 15 
min)2 hour 
(± 15 min)4 hour 
(± 30 min)6 hour
(± 30 min)8 hour
(± 1 h)
Ibrutinib and 
Venetoclax or 
Placebo*X X X X X X X
aPredose samples should be collected 30 minutes prior to the administration of ibrutinib and venetoclax or placebo 
bIbrutinib/venetoclax or placebo should be dosed the same time within 30 minutes after completion of the meal.
Example: 
Predose PK 7:00 a m
Breakfast 7:00 to 7:30 am
Dose 7:30 am
1 hr PK 8:30 am
2 hr PK 9:30 am 
4 hr PK 11:30 am
6 hr PK 1:30 pm
8 hr PK 3:30 pm
*Unscheduled PK sampling schedule based on Medical Monitor request, e.g. dose modification (at least 7 days after dose
modification)
Refer to the laboratory  binder for instructions on collect ing and processing these samples. On the 
day of the sampling visit, the clinical staff will instruct the subject to not take a dose before 
arrival at the clinic. Study  drug intake will be observed by clinic staff. The actual time (versus 
requested time) that each sample is drawn must be recorded using a 24 -hour format. The same 
clock shoul d be used for recording the time of dosing. In the event that medical management is 
needed, use of concomitant medicat ions should be recorded. In the case of ibrut inib or 
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 82venetoclax/placebo dose holds or modificat ions prior to the above time points, please consult 
with medical  monitor to determine the m ost appropri ate time at which to obtain PK bloo d 
samples.
For subjects who must start a moderate or strong CYP3A inhibitor while on treatment with 
ibrutinib or venetoclax, addit ional PK blood samples for the evaluat ion of ibrut inib and 
venetoclax exposure is requested at least one week after the init iation of  the concomitant CYP3A 
inhibitor. PK samples will be collected at the time points described above.
7.1.4.2 Pharmacokinetics Treatment -naive Open -label Arm
Ibrutinib and venetoclax should be dosed together at the same time wit h 8 ounces of water and a 
meal. It is ant icipated that steady  state will be reached after 1 week of administration of the 
highest venetoclax dose. Ibrutinib and venetoclax PK samples will be co llected at steady state on 
the PK days as shown at the time po ints listed in Table 10.
Table 10. Pharmacokinetic Sample Schedule for Treatment -naive Open -label Arm
Study Arm WeekStudy 
Day PredoseaTime Point Postdose
Doseb1h
(± 15 
min)2h
(±15min)4h
(± 30 
min)6h
(±30 
min)8h
(±1 h)
Treatment -
naive 
Open -
label*4 7 X X X X X X X
6 1 X X X X X X X
13 & 
beyond(+/-7 
days)X X X X
aPredose samples should be collected 30 minutes prior to the administration of ibrutinib and venetoclax 
bIbrutinib and venetoclax should be dosed the same time within 30 minutes after completion of the meal.
*Unscheduled PK sampling schedule based on Med ical Monitor request, e.g. dose modification (at least 7 days after dose 
modification)
Refer to the laboratory  binder for instructions on collect ing and processing these samples. On the 
day of the sampling visit, the clinical staff will instruct the subje ct to not take a dose before 
arrival at the clinic. Study  drug intake will be observed by clinic staff. The actual time (versus 
requested time) that each sample is drawn must be recorded using a 24 -hour format. The same 
clock shoul d be used for recording t he time of dosing. In the event that medical management is 
needed, use of concomitant medicat ions should be recorded. In the case of ibrut inib or 
venetoclax dose holds or modificat ions prior to the above time po ints, please consult with 
medical mo nitor to determine the most appropriate time at which to obtain PK blood samples.
For subjects who must start a moderate or strong CYP3A inhibitor while on treatment with 
ibrutinib or venetoclax, addit ional PK blood samples for evaluat ion of ibrut inib and venetocla x 
exposure is requested at least one week after the init iation of the concomitant CYP3A inhibitor. 
PK samples will be co llected at the time points described above.
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 837.1.4.3 Exploratory Biomarkers
Blood sam ples and a buccal swab will be collected and sent to the central laboratory at selected 
time points specified in the Schedule of Assessments ( Appendix Aand Appendix B).
Approximately  20 slides of fresh or m ost recent dated FFPE archival tumor biopsy  tissue will be 
collected at study  entry . An opti onal fresh tum or biopsy  may be collected at the time of disease 
progression. A bone marrow aspirate and a bone marrow biopsy will be co llected based on 
Secti on 7.1.3.5 and Secti on 7.1.3.6 . Tum or cells from  peripheral bl ood, bone m arrow and/or 
tumor tissue m ay be studi ed for genomic alterat ions, as well as gene and/or protein expressio n 
profiling. Non -cancer cell genes derived from the buccal swab will only be used as a control for 
the cancer gene mutation analysis. In addit ion to the markers known to be invo lved in MCL 
prognosi s, inhibit ion of BCR signaling and BCL -2 pathway s may  also be explored. These efforts 
may identify bio markers that could support the understanding of the disease or assist with future 
development of treatment options.
Bone m arrow aspi rate and peripheral blood samples will be stored for exploratory  biomarker 
analysis by  clonoSEQ. Samples collected in this s tudy may be stored at a bi oreposi tory for up to 
10 years (or according to local regulat ions) for addit ional research as new assays are developed 
for ibrutinib, venetoclax and MCL. Samples will only  be used to better understand the effects 
ibrutinib and ven etocl ax in MCL; sensit ivity and/or resistance to the invest igational treatment 
regimen in this study .
The research may begin at any  time during the study  or the post- study  storage peri od. Stored 
samples will be coded throughout the sample storage and analy sis process, and will not be 
labeled wit h personal ident ifiers.
7.1.5 Patient -Reported Outcomes
7.1.5.1 FACT -Lym for Safety Run -in and Randomization Phase
The FACT -Lym quest ionnaires ( Appendix I) will  be administered in this study . The FACT -Lym 
was ori ginally  devel oped to assess funct ional status and well -being o f patients wi th NHL 
(Erem enco 2004 ). Reliabilit y and validi ty have been assessed in NHL ( Webster 2005 ) and more 
recent ly construct validit y has been supported in subjects with relapsed/refractory  MCL 
(Carter 2008).
The FACT -Lym consists of the Funct ional Assessment of Chronic Illnes s Therapy  
-General 
(FACT -G) and a lympho ma-specific addit ional concerns subscale (Lym).
Responses to all items are rated on a 5 -point scale ranging from 0 “not at all” to 4 “very much”. 
The recall period is the past 7 day s. The lympho ma subscale includes 15 items and scores range 
from 0 to 60. Two summary  scores m ay also be calcul ated: the FACT -Lym total  score (FACT -G 
plus Lym) and the FACT -Lym trial outcom e index (TOI) score (physical well -being+funct ional 
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 84well-being+lympho ma). Higher scores represent bet ter funct ional status and well -being for all 
subscales and summary scales.
The subscale of most interest in this study  will be the Lym subscale. Carter ( Carter 2008) and 
Cella et al . (Cella 2005 ) reported a minimal important change score for the Lym subscale in a 
relapsed/refractory  MCL popul ation range fro m approximately  2.9 to 5.4. Therefore, a 5 -point 
change in the Lym subscale was selected as a conservat ive est imate of clinically meaningful 
deteri oration in lympho ma symptoms. Time to complete the FACT -Lym is approximately 7 to 
12 minutes. All translat ions not currently  available will be com pleted according to best practice 
guidelines for translat ing PRO instruments to the local language(s) ( Wild 2005 ).
The FACT -Lym quest ionnaire ( Appendix I) will be administered at the beginning o f the clinic 
visits prior to any  procedures or phy sician interact ions to prevent influencing subject 
percepti ons. The quest ionnaires will be administered on Week 1 Day  1, Week 13 Day 1 
(±7days); every  4 weeks for the rem ainder of the first year; every  8 weeks during the second and 
third years; and every  12 weeks thereafter unt il disease progressi on.
7.1.5.2 EQ-5D- 5L for SRI, Randomization Phase and Treatment -naive Open -label Arm
The EQ -5D- 5L (Appendix J) is a stand ardized instrum ent used to m easure healt h outcome 
(EuroQol  Group 1990 ) and consists of a 5 -item questi onnai re and a “thermometer” visual analog 
scale ranging fro m 0 (worst imaginable healt h state) to 100 (best imaginable health state). The 
scores for the 5 dimensio ns are used to compute a single ut ility score ranging from 0 to 1, 
represent ing the general healt h status of the individual. The 5 dimensio ns evaluated are mobilit y, 
self-care, usual act ivities, pain/disco mfort, and anxiet y/depressi on. The questionnaire will be 
administered on the same visit schedule as the FACT- Lym.
7.1.6 Medical Resource Utilization (MRU)
Medical resource utilizat ion including hospitalizat ions, emergency department visits, and 
hematopoiet ic growth fac tor use will be collected for each treatment arm throughout the study 
treatm ent peri od.
7.2 Efficacy Evaluations
7.2.1 Overall Response Assessments
Overall response assessments will include physical examinat ions, recording of symptoms, 
hematol ogical test resul ts, bo ne marrow aspirate or bone marrow biopsy, CT/PET radio logical 
evaluat ions and endoscopy  per the schedule of assessments ( Appendix Aand Appendix B). 
Response assessments will be performed according to the Revised Criteria for Response 
Assessment of Malignant Lympho ma(Cheson 2014 ), as assessed by investigators ( Appendix E) 
until disease progression or withdrawal o f consent fro m the study .
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 857.2.2 Survival
After progression, survival status will be assessed approximately  every  12 weeks until death, 
withdrawal  by subject, or study terminated by  Sponsor, whi chever com es first. Data on the 
subsequent lines of ant icancer therapy will be captured. Survival sweeps will be conducted at the 
time of the final analysis . All subjects who are on study  and not known to have died prior to the 
survival sweep will be contacted at that time.
7.3 Sample Collection and Handling
The actual  dates and times of sample co llection must be recorded in source documents for 
transcri ption to the eCRF or laboratory  requisi tion form. Refer to the Schedule of Assessments 
(Appendix Aand Appendix B) for the timing and frequency of all sample collect ions.
Instructi ons for the collect ion, handling, and shipment of samples are found in the Laboratory  
Manual.
8STUDY PROCEDURES
8.1 Screening Phase
Screening procedures will be performed up to 28 days before the first dose of ibrutinib and 
venetoclax/placebo, unless otherwise specified, and may  be perform ed over m ore than 1 visit. 
All subjects m ust first read, understand, and sign the IRB/REB/IEC- approved ICF before any 
study -specific screening procedures are performed. After signing the ICF, Screening, and being 
deem ed eligible for entry , subjects will be enrolled in the study .
8.1.1 Screening/Consenting Visit
The fo llowing procedures will be performed at t he Screening Visit within 28 days prior to 
enrollment unless otherwise noted:
Review of eligibilit y criteria
Medical history  including demographic information and prior treatments for MCL 
(if applicable)
Collect ion of patho logy report for cy togeneti cs/FISH documenting MCL diagnosis 
(if available)
Collect ion of approximately  20 slides of fresh or most recent dated FFPE archival 
tumor biopsy  tissue, OR tumor biopsy  obtained by  core needl e biopsy  prior to 
rando mizat ion
Docum ent bone m arrow disease involvement (bone marrow biopsy  must be 
obtained at Screening or up to 90 days before the first dose of study  drug for disease 
confirmat ion)
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 86Record concomitant medicat ions (including chemo therapy , radi ation, over -the-
counter drugs, vitamins, and herbs)
Perform  a com plete physical examinat ion, including height (may  use pri or hei ght 
measurement if available in source documents), weight and examinat ion of the skin, 
eyes, ears, nose, throat, lungs, heart, abdomen, extremit ies, musculoskeletal system, 
lymphat ic system, and nervous system
B-symptom  assessment
Obtain vital signs (including blood pressure, heart rate, and body  temperature) after 
the subject has rested in the sitting posit ion for ≥3 minutes.
Evaluat ion of ECOG PS
Determinat ion of Medical Resource Utilizat ion (M RU)
Obtain a single 12 -lead ECG after the subject has been in a supine posit ion and 
resting for at least 10 minutes.
AEs (record as Medical History  on eCRF)
Obtain bone marrow biopsy  and aspirate (wi thin 28 day s prior to fi rst dose) as 
described in Secti on7.1.3.5
Obtain blood specimens for the fo llowing laboratory  tests
oHem atology
oBlood chemistry  (including creatinine clearance)
oCoagulation panel (PT/INR, aPTT)
oHepati tis Serol ogies
oSerum  β2-microglobul in
oUrinalysis
oObtain serum or urine pregnancy test for women of childbearing potential only
Imaging by CT and/or other modalit y as described in Secti on 7.1.3.2 .
TLS ri sk assessment and prophylaxis wit hin 72 hours of first dose of venetoclax
oSerum  creatinine, uri c acid, potassium, phosphorus, calcium, and albumin, if available
oDeterminat ion of level o f risk and need for hospitalizat ion
oHydration: subject education
oPrescri ption of allopurino l (and rasburi case for hi gh risk subjects)
8.2 Treatment Phase
Following com pletion of the Screening Visit and once eligibilit y has been confirmed (per 
inclusio n/excl usion criteria), subjects will init iate study  treatm ent (see Secti on 5.2for ibrutinib 
and venetoclax dosing).
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 87Refer to the Schedule of Assessments ( Appendix Aand Appendix B) for a com plete list of 
procedures to be performed at each scheduled study visit.
8.2.1 Treatment Visits for Standard Ramp -up Schedule for SRI, Randomization Phase, 
and Treatment -naive (TN) Open -label Arm
8.2.1.1 Week 1 Day 1 and Week 2 Day 1
Pre-dose (within 72 hours prior to the first venetoclax dose and before each dose increase)
Confirmation o f eligibilit y (per inclusio n/exclusio n criteria) at week 1 only.
Update m edical history  at week 1 only
AEs
Conco mitant m edicat ions (including chemotherapy, radiat ion, over -the-counter 
drugs, vitamins, and herbs)
Physical examinat ion
Vital signs
ECOG PS (Week 1 Day  1 only)
PRO at week 1 only
Determinat ion of Medical Resource Utilizat ion (MRU)
TLS ri sk assessment and prophylaxis
Hospitalization o f subjects wi th high tum or burden
Laboratory  Tests
oHem atology
oBlood chemistry
oSerum  or urine pregnancy  test (f or wom en of childbearing potential only ) 
(Week 1 Day 1 only)
oMRD peripheral blood (Week 1 Day 1 only)
oBiomarker bl oodsample (Week 1 Day  1 only)
oBuccal Swab (Week 1 Day  1 only)
Dosing –Week 1 Day 1 and Week 2 Day 1
The dose of venetoclax or placebo should not be administered until the blood chemistry  resul ts 
have been evaluated.
In-clinic administration of venetoclax or placebo with a meal
In-clinic administration of ibrut inib
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 88Post-dose
For hospitalized subjects, serum creat inine, uric acid, potassium, phosphorus, 
calcium, and albumin, if available should be monit ored at 4±1, 8±1, 12±1 hours, 
after the venetocl ax/placebo dose.
For all outpatient subjects, serum creat inine, uric acid, potassium, phosphorus, 
calcium, and albumin, if available should be monit ored at 6 -8 hours after the 
venetoclax/placebo dose.
Any changes in these parameters should be managed prompt ly and tr eatment 
modified before any further venetoclax/placebo is administered.
8.2.1.2 Week 1 Day 2 and Week 2 Day 2
Pre-dose
AEs
Concomitant medicat ions (including chemotherapy, radiat ion, over -the-counter 
drugs, vitamins, and herbs)
Vital signs
Laboratory  Tests
oBlood c hemistry  (creatinine, uri c acid, potassium, phosphorus, calcium, and 
albumin, if available) 
TLS ri sk assessment and prophylaxis
Determinat ion of Medical Resource Utilizat ion (MRU)
Dosing –Week 1 Day 2 and Week 2 Day 2
The dose of venetoclax/placebo shoul d not be administered until the 24 -hour bl ood chemistry  
monitoring results have been evaluated.
 In-clinic administration of venetoclax/placebo with a meal
 In-clinic administration of ibrut inib
8.2.1.3 Week 1 Day 3 and Week 2 Day 3 (Hospitalized Subjects Only)
Pre-dose
AEs
Concomitant medicat ions (including chemotherapy, radiat ion, over -the-counter 
drugs, vitamins, and herbs)
Laboratory  Tests
oBlood chemistry  monitoring (creatinine, uric acid, potassium, phosphorus, 
calcium, and albumin, if available)
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 89TLS ri sk as sessment and prophylaxis
Determinat ion of Medical Resource Utilizat ion (MRU)
Dosing –Week 1 Day 3 and Week 2 Day 3
The dose of venetoclax/placebo should not be administered until the blood chemistry  monitoring 
resul ts have been evaluated.
In-clinic admini strati on of  venetocl ax/placebo wi th a meal
In-clinic administration of ibrut inib
Dosing –Week 1 Day 3 and Week 2 Day 3
The dose of venetoclax or placebo should not be administered until the blood chemistry  
monitoring results have been evaluated.
In-clinic administrati on of  venetocl ax or placebo with a meal
In-clinic administration of ibrut inib
8.2.1.4 Weeks 3, 4, and 5 Day 1 for Standard Ramp -up Schedule
Pre-dose
AEs
Concomitant medicat ions (including chemotherapy, radiat ion, over -the-counter 
drugs, vitamins, and herbs)
Physical examinat ion
Vital signs
ECOG PS (Week 3 Day  1 only)
Determinat ion of Medical Resource Utilizat ion (MRU)
TLS ri sk assessment and prophylaxis
Laboratory  Tests
oHem atology
oBlood chemistry
Pharmacokinet ics (only for TN open -label arm , on Week 4 Day 7). Pre -dose (± 30 min);
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 90Dosing
The dose of venetoclax or placebo should not be administered until the blood chemistry  resul ts 
have been evaluated.
In-clinic administration of venetoclax or placebo with a meal
In-clinic administration of ibrut inib
Post-dose
Blood chemistry  monitoring (creatinine, uric acid, potassium, phosphorus, calcium, 
and albumin, if available) 
Post-dose 1 hour (±15 min), 2 hours (±15 min), 4 hours (±30 min), 6 hours 
(±30 min) and 8 hours (±1 hour) after the administration of ibrut inib and venetoclax
oFor subjects with high tumor burden, serum creat inine, uric acid, potassium, 
phosphorus, calcium, and albumin, if available should be monitored at 6 -8hours 
after the start of the venetoclax or placebo dose at each ramp- up dose l evel. A ny 
changes in these parameters should be managed prompt ly and treatment 
modified before any further venetoclax or placebo is administered.
8.2.1.5 Week 6 Day 1
Pre-dose
AEs
Concomitant medicat ions (including chemotherapy, radiat ion, over -the-counter 
drugs, vitamin s, and herbs)
Physical examinat ion
Vital signs
ECOG PS
Determinat ion of Medical Resource Utilizat ion (MRU)
TLS ri sk assessment and prophylaxis
Laboratory  Tests
oHem atology
oBlood chemistry
oPK samples for ibrutinib and venetoclax or placebo 
Dosing 
In-clinic administrati on of  venetocl ax or placebo with a meal
In-clinic administration of ibrut inib
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 91Post-dose
PK samples for ibrutinib and venetoclax or placebo 1 hour (±15 min), 2 hours 
(±15 min), 4 hours (±30 min), 6 hours (±30 min) and 8 hours (±1 hour) after th e 
administration of ibrutinib and venetoclax or placebo (see Secti on 7.1.4 )
8.2.1.6 Week 8 Day 1 (± 1 Day) and Week 10 Day 1 (± 1 Day)
AEs
Concomitant medicat ions (including chemotherapy, radiat ion, over -the-counter 
drugs, vitamins, and herbs)
Physical examinat ion
Vital sign s
Determinat ion of Medical Resource Utilizat ion (MRU)
TLS ri sk assessment and prophylaxis
Laboratory  Tests
oHem atology
oBlood chemistry
Dosing
In-clinic administration of venetoclax or placebo with a meal
In-clinic administration of ibrut inib
8.2.1.7 Week 13 and beyond (±7 Days)
AEs
Concomitant medicat ions (including chemotherapy, radiat ion, over -the-counter 
drugs, vitamins, and herbs)
PRO at response assessment visits (see Secti on 7.1.5 for all t imepo ints 
[Appendix I])
Physical examinat ion
Vital signs
ECOG PS
Determinat ion of Medical Resource Utilizat ion (MRU)
TLS ri sk assessment and prophylaxis
Response Assessments
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 92For TN open -label arm only
oWeek 13 mandatory  PET scan for all subjects.
oWeek 25 mandatory  PET scan for subjects in SD and PR at Week 13.
oWeek 49, mandatory  PET scan for all subjects
Laboratory  Tests
oHem atology
oBlood chemistry
For TN open -label arm only
oWeek 13 Day  1: Pharm acokinetics. Pre -dose (±30 min); Post -dose 1 hour 
(±15 min), 2 hours (±15 min) after the administration of ibrut inib and 
venetoclax
After Week 13, clinic visits are scheduled every  4 weeks for one y ear; every  8 weeks during the 
second and third y ears; and every  12 weeks thereafter until treatment discont inuat ion. At each 
clinic visit subject should be supplied wit h enough study  drug to l ast unt il the next clinic visit.
8.2.2 Response Evaluation 
Response assessment visits should occur on Week 13 Day  1, then every  12 weeks for the first 
year; every  16 weeks during the second and third years; and every  24 weeks thereafter unt il PD. 
In addit ion, response assessments can be performed as clinically indicated to confirm response or 
progression.
CT/PET/MRI/endoscopy
Overall response assessment
B-symptoms
Laboratory  Tests
oHem atology
oMRD BMA (at CR only)
oBiomarker BMA (at CR only)
oMRD peripheral blood
oBiomarker peri pheral  blood
oBone m arrow bi opsy  (at CR only, if baseline is posit ive for lympho ma or 
missing)
Determinat ion of Medical Resource Utilizat ion (MRU)
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 938.2.3 End-of-Treatment Visit 
AEs
Concomitant medicat ions (including chemotherapy, radiat ion, over -the-counter 
drugs, vitamins, and herbs)
ECG
Determinat ion of Medical Resource Utilizat ion (MRU)
Laboratory  Tests
oHem atology
oBlood chemistry
oUrinalysis
oSerum  or urine pregnancy  test f or wom en of childbearing potential only
oMRD peripheral blood
oBiomarker bl ood
Physical Exam
Vital signs
8.3 Follow -up Phase
Once a subject has co mpleted the End -of-Treatm ent Visi t, they  will enter the Follow -up Phase.
8.3.1 Response Follow -up
Subjects who discont inue treatment for reasons other than PD will participate in the response 
follow-up. From  the time o f first dose (Safet y Run-in Pe riod and TN open -label arm) or 
rando mizat ion (for Randomizat ion Phase), these subjects will be fo llowed every  12weeks for the 
first year; every  16 weeks during the second and third y ears; and every  24weeks thereafter until 
PD. Once subjects progress (for subjects who have not withdrawn consent), they will start the 
Long -term Follow-up.
8.3.2 Long -term Follow- up
Subjects in Long -term Follow-up will be contacted approximately every  12 weeks (±14 days) by  
clinic visit or telephone to assess survival and the use of alternat ive ant icancer therapy. Subjects 
will be contacted until death, subject withdrawal, or study termination by the Sponsor, whichever 
occurs first.
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 949SUBJECT COMPLETION A ND WITHDRAWAL
9.1 Completion
A subject will be considered to have co mpleted the study ,if he or she has died before the end of 
the study , has not been lost to fo llow up, or has not withdrawn consent before the end of the 
study .
9.2 Withdrawal from Study Treatment
Study  treatm ent will be discont inued in the event of any of the fo llowing events:
Progressive disease including clinical progression
Unacceptable toxicit y: an intercurrent illness or AE that prevents further ibrutinib or 
venetoclax administration
Withdrawal o f consent for treatment by  subject
Invest igator decisio n (such as chronic nonco mpliance, significant protocol 
deviat ion, clinical deterioration, or best interest of the subject)
Study  terminat ion by Sponsor
Subject beco mes pregnant
All subjects, regardless of reason for discont inuat ion of study  treatm ent will undergo an 
End-of-Treatm ent Visi t and, if applicable, be follo wed for progression and survival.
The invest igator should notify the Sponsor within 24 hours if a subject discont inues study  
treatm ent (ibrutinib and/or venetoclax/placebo) due to disease progression and should provide
docum entati on of  disease progressi on for revi ew by  the m edical m onitor. If  a subject shows 
signs of  disease progressi on on physical examinat ion or laboratory assessment, the subject may 
continue study  treatm ent unt il disease progression is confirmed. Thes e subjects should stay  in the 
study  to be followed for survival.
9.3 Withdrawal from Study
Withdrawal fro m study  (including all fo llow-up) will  occur under the following circumstances:
Withdrawal o f consent for fo llow-up observat ion by the subject
Lost to foll ow-up
Study  terminat ion by Sponsor
Death
If a subject is lost to follow -up, every  reasonable effort shoul d be made by  the study  site 
personnel to contact the subject. The measures taken to fo llow up shoul d be docum ented.
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 95When a subject withdraws before completing the study, the fo llowing information should be 
docum ented in the source documents:
Reason for withdrawal;
Whether the subject withdraws full consent (ie, withdraws consent to treatment and 
all further contact) or partial consent (ie, withdraws c onsent to treatment but agrees 
to parti cipate in follow -up visits).
10STATISTICAL METHODS AND ANALYSIS 
Statistical analysis will be done by the Sponsor or under the authority o f the Sponsor. A general 
descript ion of the statist ical methods to be used to ana lyze the efficacy  and safet y data is outlined 
below. Specific details including alpha allocat ion, study  power considerat ion, secondary  
endpo int ranking, analysis populat ions, and detailed analysis plan will be provided in a separate 
Statistical Analysis Pl an (SAP). The SAP may supersede the protocol specifics, provided 
modificati ons to the protocol  are j ustified and clearly documented.
The study  consists of an open -label Safet y Run-in porti on and a double -blind Rando mizat ion 
Phase porti on for subj ects wi th relapsed/refractory  MCL. The Safet y Run-in porti on is to 
evaluate the occurrence of TLS and DLTs wit h the concurrent administration of ibrutinib and 
venetoclax. The double -blind porti on is to eval uate the efficacy and safet y of the combinat ion of 
ibrutinib and venetocl ax in co mpar ison to the combinat ion of ibrut inib and placebo. Endpoints 
from the Safet y Run-in Period will be summarized descript ively and separately fro m the 
Randomization Phase data. Endpoints fro m the Rando mizat ion Phase portion will be 
summarized and analyzed as described in the later sect ions.
The study  includes a separate open -label arm for treatment -naive subjects: A total of 
approximately  75 subjects, wi th approximately  50 subjects ≥65 years of age and approximately 
25 subjects with a TP53 m utation. Endpoints for the Treatment -naive Open -label arm will be 
summarized and analyzed as described in Section 10.5.2 .
10.1 Analysis Population
10.1.1 Safety Run -in Period Evaluable Population
Subjects who miss ≥20% of  the planned doses of ibrutinib or venetoclax for reasons other than 
toxicity (eg, non -compliance, withdrawal o f consent, di sease progressi on) during the TLS and 
DLT assessment period, or subjects who do not complete the TLS and DLT assessment period for 
any reason other than TLS or a DLT will be considered non -evaluable and will  need to be 
replaced.
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 9610.1.2 Safety Population
The Safet y Popul ation consists of all subjects treated with at least one dose of any study  drug 
(ibrutinib or venetoclax) in the double -blind porti on. The safet y popul ation will be used for the 
analysis of safet y data.
Subjects receiving at least one dose of study  drug in the Treatm ent-naive Open -label arm will be 
included in t he All-Treated popul ation described in Secti on 10.2.5 .
10.1.3 Intent -to-Treat Population in Randomization Phase
The Intent -to-Treat (ITT) Populat ion consists of all subjects randomized into the Randomizat ion 
Phase porti on of  the study , with subjects grouped according to the treatment assigned at 
rando mizat ion. It will be used for the analysis of Rando mizat ion Phase efficacy  data.
10.1.4 All-Treated Population for Tre atment -naive Open -label Arm
The All -Treated Popul ation for the open -label arm consists of treatm ent-naive subjects who 
received at least one dose of study  drug (ibrutinib or venetoclax) and will be used as the primary  
popul ation for the efficacy  and safet yanalyses.
10.1.5 Additional Analysis Population
Addit ional analysis populat ions will be defined in the SAP.
10.2 Endpoints
10.2.1 Safety Run -in Period
Frequency of TLS and DLTs
Frequency, severit y, and relatedness of AEs
Frequency of AEs causing study  drug discont inuatio n, or dose reductions or leading 
to death
Response (CR, PR), DOR, and PFS
OS
Unless indicated otherwise, the safet y and efficacy data from the Safet y Run-in porti on will be 
summarized descript ively including all treated subjects and separately fro m the doubl e-blind 
porti on of  the study . Details will be specified in the SAP. 
10.2.2 Random ization Phase Primary Endpoint
The primary  efficacy  endpoint of the Rando mizat ion Phase portion of this study  is PFS, defined 
as the duration fro m the date of rando mizat ion to the date of invest igator -assessed disease 
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 97progression using the Revised Response Criteria for Malignant Lymphoma ( Cheson 2014), or 
death fro m any cause, whichever occurs first.
10.2.3 Randomization Phase Secondary Endpoints 
Efficacy:
Com plete response rate (CR) based on the best overall response per invest igator 
assessment according to the Revised Response Criteria for Malignant Lympho ma 
(Cheson
2014).
Overall response rate (ORR), defined as CR or PR per invest igator assessment 
according to the Revised Response Criteria for Malignant Lympho ma 
(Cheson
2014).
MRD -negat ive remissio n rate in subjects who achieve CR per invest igator 
assessment. A MRD -negative remissio n is defined as undetectable MRD at 
docum ented CR in subjects who were MRD posit ive at screening as assessed by 
flow cy tometry in bone marrow and/or peripheral blood, with requirement of 
confirmat ion of MRD negativit y in the subsequent peripheral blood 12 weeks later. 
OS, defined as the time fro m rando mizat ion to death fro m any cause.
DOR , defined for subjects who achieve an overall response as the time fro m the 
first occurrence of response (CR or PR) to disease progression or death, whichever 
occurs first.
TTNT, defined as the duration from the date of randomizat ion to the start date of 
any ant i
-lympho ma treatment subsequent to study treatment.
Safety:
Frequency, severit y, and relatedness of AEs
Frequency, severit y and management of TLS
Frequency of AEs requiring discontinuat ion of study  drug or dose reductions, or 
leading to death
Pharmac okinetics:
Pharmacokinet ics of ibrutinib at steady state
Pharmacokinet ics of venetoclax at steady  state
Patient Reported Outcomes (PRO):
Time to worsening in FACT -Lym subscale of the healt h-related qualit y of life 
questionnaire (FACT -Lym)
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 9810.2.4 Randomization Phase Exploratory Endpoints
Patient-reported outcomes by EQ -5D-5L
Medical resource utilizat ion (MRU)
10.2.5 Treatment -naive Open -label Arm Primary Endpoint
The primary  efficacy  endpoint of the treatment -naive open- label arm is the co mplete response 
(CR) rate based on the best overall response according to the Revised Response Criteria for 
Malignant Lympho ma (Cheson 2014).
10.2.6 Treatment -Naive Open -Label Arm Secondary Endpoints
Overall response rate (ORR), defined as CR or PR according to the Revised 
Response Criteria for Malignant Lympho ma (Cheson 2014)
Durati on of  Response (DOR), defined for subjects who achieve an overall response 
as the time from the first occurrence of response (CR or PR) to disease progression 
or death, whichever occurs first
Durati on of  CR, defined for subjects who achieve CR as the time from the first 
occurrence of CR to disease progression or death, whichever occurs first
MRD -negat ive remissio n rate in subjects who were MRD posit ive at screening and
achieve CR. MRD -
negative remissio n is defined the same as described in 
Secti on10.2.3 .
PFS, defined as the time fro m the date of the first dose of study  treatm ent to th e date 
of disease progressi on using the Revised Response Criteria for Malignant 
Lympho ma (Cheson 2014), or death fro m any cause, whichever occurs first
OS, defined as the time fro m the date of the first dose of study  treatm ent to death 
from any cause
TTNT, defined as the duration from the date of the first dose of study  treatment to 
the start date of any ant i
-lympho ma treatment subsequent to study treatment
10.2.7 Treatment -naive Open -label Arm Exploratory Endpoints
Ident ification of biomarkers that are predict ive of response (or resistance) to study 
treatm ent
Patient-reported outcome by EQ -5D-5L
10.3 Sample Size Determination (Randomization Phase)
The Rando mizat ion Phase sample size will be powered based on the primary endpo int of PFS. 
Approximately  260 subjects will be randomized at a 1:1 ratio.
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 99The null hypothesis is hazard ratio (HR) ≥1 for the ibrutinib and venetoclax group relat ive to 
ibrutinib and placebo group. The alternat ive hypothesis is HR < 1.
With a targeted HR of 0.61 (cor responding to an improvement in median PFS from 14 months to 
23 m onths), 134 PFS events will provide at least 80% power at a 1 -sided overall significance 
level of 0.025. Assuming an enro llment rate of approximately 10 -11 subjects per month (a rough 
estimat e based on 3 pieces of enro llment rates), the accrual is projected to complete 
approximately  21 m onths from the first subject in. Detailed project ion of the enrollment schedule 
will be provided in a separate document. The actual length of the study  and the time to the final 
analysis will depend on the actual enrollment rate and the number of events that occur.
The sample size and power calculations for the study are based on a 1 -sided log -rank test for PFS and 
were calculated using the software package, Eas t 6.4.1 (Cy tel Software Corp, Cambridge, MA).
OS will be analyzed at the time of the primary analysis of PFS when the superiority boundary for 
PFS is crossed. It is anticipated that 112 and 155 OS events in total will be observed at the interim 
analy sis (at ~40 months) and at the final analysis (at ~57 months), respectively. This is based on the 
assumption that the median OS for the ibrutinib and placebo group is approximately 30 months 
(estimated based on data from subjects treated with ibrutinib monothera py in MCL3001), and the 
hazard ratio is 0.65 (corresponding to a median OS of 46.2 months for the ibrutinib and venetoclax 
group). With 155 OS events, the study has ~76% power at a 1-sided overall significance level of 
0.025. At the interim analysis, if 11 2 OS events are observed, the information fraction will be 72.3%. 
The 1 -sided alpha spending is 0.008 at the interim analy sis based on a group sequential design with 
Lan-Demets spending function with O’Brien -Fleming boundary. This will ensure control of th e 
overall type I error for the study. The exact alpha boundary will be calculated using the actual 
number of events observed at the interim analysis.
The calculations for OS are based on the software package, East 6.5 (Cytel Software Corp, 
Cambridge, MA).
10.4 Sample Size Determination (Treatment -naive Open -label Arm)
A sample size o f 75 treatment -naive subjects is needed to exclude a 35% CR rate at a 1- sided 
significance l evel of 0.025 wi th approximately  80% power, assuming a target CR rate of 51%.
For the subp opulation with a TP53 m utation, a sample size of 48 subjects is needed to exclude a 
25% CR rate with approximately 80% power, assuming a target CR rate of 45%. The TP53 
popul ation could be a mix of treatment -naive MCL subjects and/or R/R MCL subjects with a 
TP53 m utation.
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 10010.5 Efficacy Analysis 
10.5.1 Randomization Phase
10.5.1.1 Analysis for Primary Efficacy Endpoint
The primary  efficacy  endpoint of the Rando mizat ion Phase portion of this study  is PFS, defined 
as the duration fro m the date of rando mizat ion to the date of invest igator -assessed disease 
progression using the Revised Response Criteria for Malignant Lymphoma ( Cheson 2014), or 
death fro m any cause, whichever occurs first. PFS will be compared between treatment arms 
using the strati fied l og rank test. The HR for PFS will be estimated using a stratified Cox 
proporti onal hazards model. The 95% CI for the HR will be provided. The stratification factors 
will be the same as the rando mizat ion stratification factors: prior lines of therapy
,ECOG PS, and 
the TLS categories. The stratification factors will be obtained at the time of rando mizat ion. 
Kaplan Meier estimates and associated plot will be generated. The median PFS for each 
treatm ent arm  and the associ ated 95% CI will be constructed us ing the Brookmeyer -Crowl ey 
methodol ogy (Brookm eyer 1982 ).
10.5.1.2 Analysis for Secondary Efficacy Endpoints
Details o f the analysis methods, models, and mult iplicit y adjust ments to control the overall 
Type1 error rate will be specif ied in the SAP.
10.5.1.2.1 Complete Response Rate
CR rate i s the proportion of subjects with CR as the best overall response by the time of analysis.
The CR rate will be co mpared between treatment arms using stratified Cochran -Mantel -Haenszel 
(CMH) test. The differen ce in CR rate between treatment arms and its 95% CI will be calculated 
using the normal approximat ion to the bino mial distribut ion.
10.5.1.2.2 Overall Response Rate
Overall response rate (ORR) is the proportion of subjects with CR or PR. The analysis methods 
for ORR will be the same as those described in Secti on 10.5.1.2.1 .
10.5.1.2.3 Minimal Residual Disease -Negative Remission Rate
The MRD -negat ive remissio n rate in subj ects who were MRD posit ive at screening and achieve 
a CR will be calculated. The analysis methods of MRD -negat ive remissio n rate will be the same 
as those described in Section10.5.1.2.1 .
10.5.1.2.4 Overall Survival
The interim analysis for OS will be conducted at the primary analysis o f PFS. Details for the 
interim and final analyses for OS will be specified in the SAP.
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 101In the Rando mizat ion Phase, OS will be co mpared between treatment arms using the stratified 
log rank test. All deaths will be considered as an event. Data for subjects who have not died by  
the time o f analysis will be censored at the date of last contact. Methods for comparison of OS 
between treatment arms will be the same as the methods for the primary  efficacy  endpoint of 
PFS. 
10.5.1.2.5 Duration of Response
In the Rando mizat ion Phase, DOR will be summarized using Kaplan -Meier est imates for 
subjects who achieve an overall  response. The censoring rule for DOR is the same as PFS.
10.5.1.2.6 Time -to-next Treatment
In the Rando mizat ion Phase, Time -to-next Treatment will be co mpared between treatment arms. 
Methods for comparison of TTNT between treatment arms will be the same as th e methods for 
the primary  efficacy endpoint of PFS.
10.5.1.2.7 Time to Worsening in FACT -Lym Subscale
In the Rando mizat ion Phase, time to worsening in FACT -Lym subscale of the healt h-related 
qualit y of life quest ionnaire (FACT -Lym) will be compared between treatment arms. Methods 
for com parison will be the same as the methods for the primary  efficacy  endpoint of PFS as 
appropriate.
10.5.2 Treatment -naive Open -label Arm
Analyses in the fo llowing sect ions will be conducted for treatment -naive subjects enro lled in the 
open -label arm. In addi tion, analyses on the subjects with a TP53 mutation will be conducted; 
R/R MCL subjects with a TP53 mutation may  be included in the analyses. Analysis details will 
be specified in the SAP.
10.5.2.1 Analysis for the Primary Efficacy Endpoint
The primar y efficacy  endpoint of the treatment -naive open- label arm is the CR rate, defined as 
the proporti on of  subjects wi th a CR as the best overall response using the Revised Response 
Criteria for Malignant Lympho ma (Cheson 2014 ). 
The CR rate will be est imated, and the 95% CI will be calculated based on exact bino mial 
distribut ion.
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 10210.5.2.2 Analysis for Secondary Efficacy Endpoints
10.5.2.2.1 Analyses of ORR, DOR, Duration of CR, and MRD -Negative Remission Rate
The analysis method for the ORR and the MRD -negative remissio n rate will be the same as those 
described for the CR rate.
DOR and the duration of CR will be summarized using Kaplan -Meier est imates for subjects who 
achieve a response. 
10.5.2.2.2 Analyses of PFS, OS, and TTNT
Kaplan -Meier estimates will be provi ded for PFS, OS, and TTNT. Censoring conventions will be 
provi ded in the SAP.
10.6 Safety Analysis
The safet y variables to be analyzed include exposure of study  drugs, AEs, and clinical laboratory  
test results (hematology  and chemistry ). In general, continu ous variables will be summarized 
using descript ive statist ics (n, m ean, m edian, standard deviation, standard error and range). 
Categorical variables will be summarized using frequencies and percentages. No formal 
statist ical test ing is planned. 
Adverse Ev ents
Adverse event parameters to be evaluated are SOC, preferred terms, incidence, and intensit y of 
AEs; the relat ionship of AEs to study  treatm ent; and the acti on taken wi th respect to study  
treatm ent due to AEs.
The verbat im terms used in the eCRF by inv estigators to ident ify AEs will be coded using the 
Medical Dict ionary for Regulatory  Activities (MedDRA).
Treatment -emergent period is defined as the period of time fro m the first dose of study  treatm ent, 
until the earlier of:
Thirtydays fo llowing the l ast dose of ibrut inib or venetoclax, whichever occurs 
later
OR
The start date of a new ant icancer therapy .
The TEAEs are those events that:
Are not present prior to the treatment -emergent period and occur during the 
treatm ent-emergent period,
The onset dates are missing and end dates are during the treatment -emergent peri od,
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 103Are considered related to study  drug by  the invest igator regardless of the start dates 
of the events, or
Are present prior to the treatment -emergent period but worsen in severit y during t he 
treatm ent-emergent period or are subsequent ly considered related to study  drug by  
the invest igator.
All treatment -emergent AEs will be included in the analysis. For each AE, the number and 
percentage of subjects who experience at least one occurrence of the given event will be 
summarized. The number and percent of subjects with TEAEs will be summarized according to 
intensity (CTCAE, v4.03 ) and drug relationship, as well as categorized by system organ class 
and preferred ter m. For analysis, only  AEs wi th a causal relat ionship of “possibly  related” and 
“related” will be considered as related to study  drug. Summaries, list ings, datasets, or subject 
narratives may  be provi ded, as appropri ate, for those subjects who die, who disc ontinue 
treatm ent due to an AE, or who experience a severe adverse react ion or a SAE.
Clinical Laboratory Tests
Laboratory  tests will  be summarized separately for hematology  and serum chemistry . All 
laboratory  values will be graded using the CTCAE v4.03 . The worst toxicit y grade for sel ected 
laboratory  tests will be tabulated.
10.7 Pharmacokinetic Analysis
10.7.1 Ibrutinib
Ibrutinib and PCI -45227 bioanalyt ical data will be used in a nonco mpart mental PK analysis. 
Plasma concentrations below the lowest quantifiable concentration will be treated as zero in the 
summary statist ics. All subjects and samples excluded fro m the analysis will be clearly 
docum ented in the PK report.
Descript ive statistics will be used to summarize ibrutinib and PCI-45227 concentrations at each 
sampling t ime point (including, but not limited to: C max, Tmax, AUC last, and t 1/2) at each dosing 
interval .
10.7.2 Venetoclax
Venetoclax bioanalyt ical data will be used in a noncompart mental PK analysis. Plasma 
concentrations belo w the l owest quantifiable concentration will be treated as zero in the 
summary statist ics. All subjects and samples excluded fro m the analysis will be clearly 
docum ented in the PK report.
Descript ive statistics will be used to summarize venetoclax concentr ations at each sampling time 
point and PK parameters (including, but not limited to: C max, Tmax, and AUC) at each dosing 
interval .
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 10410.8 Biomarker Analyses 
Biomarker exploratory  analyses are planned to ident ify biomarkers that are predict ive of 
response (or re sistance) to ibrutinib and venetoclax treatment. Descript ive statist ics will be used 
to summarize these exploratory  endpoints.
11ADVERSE EVENT REPORT ING 
Timely, accurate, and complete reporting and analysis o f safet y information fro m clinical studies 
are cr ucial for the protection of subjects, invest igators, and the Sponsor, and are mandated by 
regul atory  agencies worl dwide. The Sponsor has established Standard Operating Procedures in 
conformit y with regul atory  requi rements worl dwide to ensure appropriate re porting of safety  
inform ation; all clinical studies conducted by  the Sponsor or i ts affiliates will be conducted in 
accordance with those procedures.
11.1 Definitions 
11.1.1 Adverse Events
An AE is any  untoward m edical occurrence in a subject administered a pharmaceu tical product 
and which does not necessarily have a causal relat ionship wit h this treatm ent. An AE can 
therefore be any  unfavorable and unintended sign (including a clinically significant abnormal 
laboratory  finding, for example), symptom, or disease tempo rally associated wi th the use of an 
investigat ional study  drug, whether or not considered related to the study  drug ( ICH-E2A 1995 ).
For the purposes of this clinical study , AEs include events which are either new or represent
detectable exacerbations of pre -exist ing condit ions.
The term  “disease progression” should not be reported as an AE term. As an example, 
"worsening of underlying disease" or the clinical diagnosis that is associated with disease 
progression should be repo rted.
Adverse events may include, but are not limited to:
Subject ive or object ive symptoms provided by the subject and/or observed by the 
investigator or study  staff including laboratory  abnorm alities of clinical significance
Any AEs experienced by the sub ject through the complet ion of final study  
procedures
AEs not previously observed in the subject that emerge during the protocol -
specified AE reporting period, including signs or symptoms associated with the 
underlying disease that were not present before the AE reporting period 
Com plicat ions that occur as a result of protocol -mandated intervent ions 
(eg,invasive procedures such as biopsies).
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 105The fo llowing are NOT considered AEs:
Pre-existing condition: A pre -existing condit ion (documented on the medical 
history  CRF) i s not considered an AE unless the severit y, frequency, or character of 
the event worsens during the study  period.
Per protocol, pre -planned, or elective hospitalization: Per
-protocol 
hospi talizati ons f or TLS prophylaxis and management are not considered SAEs, 
unless a hospitalizat ion is prolonged beyo nd 3 days due to an AE. A hospitalization 
planned before signing the ICF is not considered an SAE, but rather a therapeutic 
intervent ion. However, if during the pre -planned hospi talizati on an event occurs, 
which prolongs the hospitalizat ion or m eets any  other SAE cri teria, the event will be 
considered an SAE. Surgeries or intervent ions that were under considerat ion, but 
not performed before enro llment in the study , will not be considered serious if they 
are perform ed after enrollment in the study  for a condi tion that has not changed 
from its baseline level. Elective hospitalizations for social reasons, so lely for the 
administration of chemotherapy , or due to l ong travel distances, are also not SAEs.
Diagnostic Testing and Procedures: Testing and procedures should not be 
reported as AEs or SAEs, but rather the cause for the test or procedure should be 
reported.
Asymptomatic Treatment -related Lymphocytosis: This event shoul d also not be 
considered an AE. Subjects with treatment -related lymphocy tosis shoul d remain on 
study  treatm ent and continue with all study -related procedures.
11.1.2 Serious Adverse Events
A SAE based on Internat ional Conference on Harmo nisat ion (ICH) and EU Guidelines on 
Pharmacovigilance for Medi cinal Products for Human Use is any  untoward m edical occurrence 
that at any  dose:
Results in death (ie, the AE actually  causes or l eads to death)
Is life -threatening. Life -threatening i s defined as an AE in which the subject was at 
risk of death at the time o f the event. It does not refer to an event which 
hypotheti cally  might have caused death if it were more severe. If eit her the 
investigator or the Sponsor believes that an AE meets the definit ion of life -
threatening, it will be considered life -threatening.
Requi res in -patient hospi talizat ion >24 hours or prolongation o f exist ing 
hospi talizati on
Results in persistent or significant disabilit y/incapacit y (ie, the AE resul ts in 
substant ial disrupt ion of the subject’s abilit y to conduct normal life f uncti ons)
Is a congenital ano maly/birth defect
Is an important medical event that may not result in death, be immediately 
life-threatening or require hospitalizat ion, but may  be considered an SAE when, 
based upon appropriate medical judgment, the event may jeopardi ze the subject or 
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 106subject may require intervention to prevent one of the other outcomes listed in this 
definit ion. Examples of such events are intensive treatment in an emergency  
departm ent or at hom e for allergi c bronchospasm, blood dyscrasias, o r convulsio n 
that does not result in hospitalizat ion; or development of drug dependency  or drug 
abuse
Given that the invest igator’s perspective may be informed by having actually observed the event, 
and the Sponsor is likely to have broader knowledge of th e drug and its effects to inform its 
evaluat ion of the significance of the event, if either the Sponsor or the investigator believes that 
the event is serious, the event will be considered serious.
11.1.3 Severity Criteria (Grade 1 -5)
Definit ions found in the Co mmon Termino logy Cri teria f or Adverse Events versio n 4.03 
(CTCAE v4.03 ) will be used for grading the severity  (intensit y). The CTCAE v4.03 displays 
Grades 1 through 5 with unique clinical descript ions of severit y for each refe renced AE. Shoul d 
a subject experience any AE not listed in the CTCAE v4.03, the fo llowing grading system should 
be used to assess severit y:
Grade 1 (Mild AE) –experiences which are usually transient, requiring no special 
treatm ent, and not interfering wi th the subject’s daily  activi ties
Grade 2 (Moderate AE) –experiences which introduce some level of inconvenience 
or concern to the subject, and which may interfere with daily act ivities, but are 
usually ameliorated by  simple therapeut ic measures
Grade 3 ( Severe AE) –experiences which are unacceptable or intolerable, 
significant ly interrupt the subject’s usual daily  activi ty, and requi re systemic drug 
therapy  or other treatm ent
Grade 4 (Life -threatening or disabling AE) –experiences which cause the subjec t to 
be in imminent danger of death
Grade 5 (Death related to AE) – experiences which result in subject death
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 10711.1.4 Causality (Attribution)
The invest igator is to assess the causal relation (ie, whether there is a reasonable possibilit y that 
the study  medicat ioncaused the event) using the following definit ions:
Not Related: Another cause of the AE is more plausible; a temporal sequence cannot be 
established wit h the onset of the AE and administration of the 
investigat ional product; or, a causal relationship is considered bio logically  
implausible.
Unlikely: The current knowledge or information about the AE indicates that a 
relationship to the invest igational product is unlikely.
Possibly 
Related:There i s a clinically  plausible t ime sequence between onset of the AE and 
administration of the investigat ional product, but the AE could also be 
attributed to concurrent or underlying disease, or the use of other drugs or 
procedures. Possibly  related shoul d be used when the invest igational 
product is one of several b iologically  plausible AE causes.
Related: The AE is clearly related to use of the invest igational product.
11.2 Unexpected Adverse Events
An “unexpected” AE is an AE that is not listed in the ibrut inib IB/package insert or is not listed 
at the specificit y or severit y that has been observed. For example, hepatic necrosis would be 
“unexpected” (by  virtue of  greater severit y) if the ibrutinib IB referred only  to el evated hepat ic 
enzymes or hepatitis. Similarly, cerebral thro mboembo lism and cerebral vasculit is wou ld be 
“unexpected” (by  virtue of  greater specificit y) if the ibrutinib IB/package insert listed only 
cerebral vascular accidents. "Unexpected" also refers to AEs that are ment ioned in the 
ibrutinib IB as occurring with a class of drugs or as ant icipated fr om the pharmaco logical 
properties of the drug, but are not specifically mentioned as occurring wit h the study  drug under 
investigat ion.
11.3 Special Reporting Situations
Speci al reporting situat ion on a Sponsor study  may requi re expedi ted reporting and/or safet y 
evaluat ion include, but are not limited to:
Overdose of any study  drug
Suspected abuse/misuse of a study  drug
Inadvertent or accidental exposure to a study  drug
Medicat ion error invo lving a product (with or without subject exposure to the study 
drug, eg, name confusio n)
If any special reporting situat ion meets the criteria of an AE, it should be reported on the Serious 
Adverse Event Report Form. Please report all overdoses on a SAE form regardless of the 
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 108outcom e. The Seri ous Adverse Event Report Form shou ld be sent via email or fax to 
Pharmacyclics LLC Drug Safet y or desi gnee wi thin 24 hours of awareness.
11.4 Documenting and Reporting of Adverse Events and Serious Adverse Events by 
Investigators
11.4.1 Assessment of Adverse Events
Invest igators will assess the occurrence of AEs and SAEs at all subject evaluat ion timepoints 
during the study . All AEs and SAEs, whether volunteered by  the subject, discovered by study  
personnel during questioning, detected through physical examinat ion, clinically significant 
laborato ry test, or other m eans, will be recorded in the subject’s medical record and on the AEs 
CRF and, when applicable, on the Serious Adverse Event Report Form.
Each recorded AE or SAE will be described by it s durati on (ie, start and end dates), severit y, 
regulatory seriousness cri teria (if applicable), suspected relat ionship to the invest igational 
product, and any  actions taken.
11.4.2 Adverse Event Reporting Period
All AEs whether serious or non -serious, will be documented fro m the time the signed and dated 
ICF is o btained unt il 30 days fo llowing the l ast dose of study  drug. SAEs will be reported to the 
Sponsor Drug Safet y via an SAE reporting form and will be recorded in the eCRF fro m the time 
of ICF signing. Non -serious AEs will be recorded in the source documents from the time of ICF 
signing and will be recorded in the eCRF from the first dose of study  drug.
Serious adverse events reported after 30 day s following the last dose of study  drug shoul d also be 
reported if considered related to study  drug. Resoluti on inf ormation after 30 day s shoul d be 
provi ded.
Progressive disease should NOT be reported as an event term, but instead symptoms/clinical 
signs of  disease progressi on m ay be reported (see Secti on 11.1.1 ).
All AEs, regardless of seriousness, severit y, or presumed rel ationship to study  drug, m ust be 
recorded using medical termino logy in the source document. All records will need to capture the 
details o f theduration and the severit y of each episode, the acti on taken wi th respect to the study  
drug, invest igator’s evaluation o f its relationship to the study drug, and the event outcome. 
Whenever possible, diagnoses should be given when signs and symptoms are du e to a commo n 
etiology (eg, cough, runny  nose, sneezing, sore throat, and head congest ion shoul d be reported as 
"upper respiratory  infecti on"). Invest igators must record in the CRF their opinio n concerning the 
relationship of the AE to study  therapy . All m easures requi red for AE m anagement m ust be 
recorded in the source document and reported according to Sponsor instructions.
All deaths should be reported with the primary  cause of death as the AE term, as death is 
typically  the outcom e of the event, not the event itself. Autopsy  and postm ortem  reports m ust be 
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 109forwarded to the Sponsor, or designee, as outlined above, if allowed per local regulatory  
guidelines.
If a death occurs within 30 days after the last dose of study  drug, the death m ust be reported to 
the Sponsor as a SAE. 
11.4.3 Expediting Reporting Requirements for Serious Adverse Events
All SAEs (init ial and fo llow-up inform ation) will be reported on the Serious Adverse Event 
Report F orm and sent vi a email  or fax to Pharm acyclics LLC Drug Safet y, or desi gnee , within 
24hours of the discovery  of the event or information. Pharmacyclics LLC may  request foll ow-up 
and other addit ional information fro m the investigator (eg, hospital admissio n/discharge notes 
and laboratory  resul ts). The contact inform ation (phone, email and fax) for Pharm acyclics LLC 
Drug Safet y can be found on the Serious Adverse Event Report Form and instructions.
All SAEs that have not resolved by the end of the study , or that have not resolved upon 
discontinuat ion of the subject's participat ion in the study, must be fo llowed unt il any of the 
following occurs:
The event resolves
The event stabilizes
The event returns to baseline, if a baseline value/status is available
The event can be attributed to agents other than the study  drug or to factors 
unrelated to study  conduct.
It becomes unlikely that any  addi tional information can be obtained (subject or 
healt h care practit ioner refusal to provide addit ional informat ion, lost to follow up 
after dem onstrati on of  due diligence wi th follow
-up efforts)
The Sponsor assum es responsibilit y for appropri ate reporting of AEs to the regulatory  authori ties 
and governing bodies according to the local regulations.
The invest igator (or Sponsor where required) must report these events to the appropriate 
Independent Et hics Committee/Inst itutional Review Board (IEC/IRB) that approved the protocol 
unless otherwise required and documented by the IEC/IRB .
11.4.4 Pregnancy
Before study  enrollment, subjects must agree to take appropriate measures to avoid pregnancy. 
However, should a pregnancy  occur in a female study  subject, consent to provide fo llow-up 
inform ation regarding the outcome of the pregnancy  and the healt h of the infant until 30 days o ld 
will be requested.
A female subject or female partner of a male subject must immedia tely inform  the invest igator if 
she becomes pregnant from the time of consent to 90 day s after the l ast dose of study  drug(s). 
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 110Any female subjects receiving study  drug(s) who become pregnant must immediately  
discontinue study  drug. The invest igator should counsel the subject, discussing any risks of 
continuing the pregnancy and any possible effects on the fetus.
Although pregnancy  itself is not regarded as an AE, the outcome will need to be documented. 
Any pregnancy  occurring in a female subject or female p artner of a male subject must be 
reported from the time of first dose up until 90 days after the last dose of study  drug(s). Any 
occurrence of pregnancy must be recorded on the Pregnancy Report Form Part I and sent via 
email or fax to Pharmacyclics LLC Dru g Safet y, or desi gnee, wi thin 24 hours of learning of the 
event. All pregnancies will be fo llowed f or outcome, which is defined as elective terminat ion of 
the pregnancy , miscarriage, or delivery  of the f etus. For pregnancies with an outcome o f live 
birth, the newborn infant will be fo llowed until 30 days old by  com pleting the Pregnancy Report 
Form  Part II. Any congenital anomaly /birth defect noted i n the infant m ust be reported as a SAE.
11.4.5 Other Malignancies
All new m alignant tum ors including solid tumors, sk in malignancies and hematologic 
malignancies will be reported for the duration of study  treatm ent and during any  
protocol -specified fo llow-up peri ods incl uding post -progression fo llow-up for OS. If observed, 
enter data in the corresponding eCRF.
11.4.6 Eye-Related Adverse Events
New or worsening eye -related symptom s that are Grade 2 or higher, or a symptom that was 
Grade 2 or higher at baseline and worsens should be evaluated by an ophthalmo logist, whose 
findings should be reported on the ophthalmo logic eCRF.
11.4.7 Adverse Events of Special Interest (AESI)
Specific AEs, or groups of AEs, will be fo llowed as part of standard safet y monitoring act ivities 
by the Sponsor. These events (regardless of seriousness) should be reported on the Serious 
Adverse Event Repor t Form  and sent vi a email  or fax to Pharm acyclics LLC Drug Safet y, or 
designee, within 24 hours of awareness.
11.4.7.1 Major Hemorrhage
Major hem orrhage is defined as any of the following:
Any treatment -emergent hem orrhagic AEs of Grade 3 or higher*
Any treatment -emergent serious adverse events of bleeding of any grade
Any treatment -emergent central nervous system hemorrhage/hematoma of any 
grade
*All hemorrhagic events requiring transfusion of red blood cells should be reported as Grade 3 or higher 
AE per CTCAE v4.03.
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 111Events meet ing the definit ion of major hemorrhage will be captured as an event of special 
interest according to Secti on 11.4.7 above.
12STUDY ADMINISTRATION AND INVESTIGATOR OB LIGATIONS
12.1 Regulatory and Ethical Compliance
This clinical study  was designed and will be implemented in accordance with the protocol, 
the ICH Harmonized Tripartite Guidelines for Good Clini cal Practi ces, wi th applicable local 
regul ations (including US Code of Federal Regulatio ns [CFR] Ti tle 21 and European Direct ive 
2001/20/EC), and with the ethical principles laid down in the Declarat ion of Helsinki.
12.2 Institutional Review Board (IRB), Research Ethics Board (REB) and Independent 
Ethics Committee (IEC) Approval
The invest igator will submit this protocol, the ICF, IB, and any other relevant supporting 
inform ation (eg, all advert ising materials or materials given to the subject during the study ) to the 
appropriate IRB/REB/IEC for review and approval before study  initiation. Amendments to the 
protocol  and ICF m ust al so be approved by  the IRB/REB/IEC before the implementation of 
changes in this study .
The invest igator is responsible for providing th e IRB/REB/IEC wi th any required informat ion 
before or during the study , such as SAE expedited reports or study  progress reports.
The IRB/REB/IEC must comply wit h current United States (US) regulat ions (§21 CFR 56) as 
well as country -specific nat ional regul ations and/or local laws.
The fo llowing docum ents m ust be provi ded to Pharm acyclics LLC or its authorized 
representative before entering subjects in this study: (1) a copy  of the IRB/REB/IEC l etter that 
grants formal approval; and (2) a copy  of the IRB/REB /IEC -approved ICF.
12.3 Informed Consent
The ICF and process must comply wit h the US regulat ions (§ 21CFR Part 50) as well as 
country -specific nat ional regulat ions and/or local laws. The ICF will document the study- specific 
inform ation the investigator or his/ her designee provides to the subject and the subject’s 
agreem ent to parti cipate.
The invest igator or designee (designee must be listed on the Delegat ion of Authorit y log) 
must explain in terms understandable to the subject the purpose and nature of the stu dy, 
study procedures, anticipated benefits, potential risks, possible AEs, and any  discomfort 
participat ion in the study may entail. This process must be documented in the subject’s source 
record. Each subject must provide a signed and dated ICF before any study -related (nonstandard 
of care) activit ies are performed. The original and any amended signed and dated consent forms 
must remain in each subject’s study  file at the study site and be available for verificat ion by 
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 112study  monitors at any  time. A copy  ofeach signed consent form must be given to the subject at 
the time that it is signed by  the subject.
12.4 Quality Control and Quality Assurance
Sponsor shall implement and maintain qualit y control  and qualit y assurance procedures to ensure 
that the study  is con ducted and data are generated, documented and reported in co mpliance wit h 
the protocol, GCP, and applicable regulatory  requirem ents. Thi s study  shall  be conducted in 
accordance with the provisio ns of the Declarat ion of Helsinki (October 2008) and all revis ions 
thereof, and in accordance wit h the Food and Drug Administration (FDA) regulat ions (21 CFR 
Parts 11, 50, 54, 56, and 312, Subpart D –Responsibilit ies of Sponsors and investigators) and 
with the ICH gui delines on GCP ( ICH-E6 1996).
12.5 Protected Subject Health Information Authorization
Inform ation on m aintaining subject confident iality in accordance to individual local and nat ional 
subject privacy regulat ions m ust be provi ded to each subject as part of the informed consent 
process (refer to Section 7.1.1.1 ), either as part of the ICF or as a separate signed document 
(forexample, in the US, a site -specific HIPAA consent may be used). The invest igator or 
designee must explain to each subject that for the evaluat ion of study  resul ts, the subject’s 
protected h ealth inform ation obtained during the study  may be shared wi th Pharmacyclics LLC 
and its designees, regulatory  agencies, and IRBs/REBs/IECs. As the study  Sponsor, 
Pharmacyclics LLC will not use the subject’s protected health information or disclose it to a
third party  without applicable subject authorizat ion. It i s the invest igator’s or designee’s 
responsibilit y to obtain written permissio n to use protected healt h informat ion from each subject. 
If a subject withdraws permissio n to use protected healt h infor mation, it is the invest igator’s 
responsibilit y to obtain the withdrawal request in writing fro m the subject andto ensure that no 
further data will be collected from the subject. Any data collected on the subject before 
withdrawal  will be used in the anal ysis o f study  resul ts.
During the review of source documents by  the m onitors or audi tors, the confident iality of the 
subject will be respected with strict adherence to professio nal standards and regulat ions.
12.6 Study Files and Record Retention
The invest igator must keep a record of allsubjects who have consented to enroll in the study . 
For those subjects subsequent ly excluded from enrollment, the reason(s) for exclusion is to be 
recorded.
The invest igator/study staff must maintain adequate and accurate records to enable the conduct 
of the study  to be fully docum ented and the study  data to be subsequent ly verified. Essent ial 
docum entati on includes, but is not limited to, the IB, signed protocols and amendments, 
IRB/REB/IEC approval letters (dated), regulatory approval letters (dated, where applicable), 
signed investi gator agreem ents (eg, Form  FDA 1572s or equivalent) and Financial Disclo sures, 
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 113signed ICFs (including subject confident iality information), drug dispensing and accountabilit y 
records, shipping records of invest igational product and study -related materi als, signed 
(electroni cally ), dated and com pleted case report form s (CRFs), and documentation of CRF 
correcti ons, SAE forms transmitted to Pharmacyclics LLC and notificat ion of SAEs and re lated 
reports, source documentation, normal laboratory  values, decoding procedures for blinded 
studi es, curri cula vi tae for study  staff, and all relevant correspondence and other documents 
pertaining to the conduct of the study .
All essential documentation will be retained by the invest igator for at least 2 years after the date 
the last marketing applicat ion is approved for the drug for the indication for which it is being 
investigated and unt il there are no pending or contemplated marketing applicat ions; o r, if no 
applicat ion is to be filed or if the application is not approved for such indication, unt il 2years 
after formal discont inuat ion of clinical development of the drug.
The invest igator must notify Pharmacyclics LLC and obtain written approval fro m 
Pharmacyclics LLC before destroying any  clinical  study  docum ents or images (eg, scan, 
radiograph, ECG tracing) at any  time. Shoul d an investi gator wi sh to assi gn the study  records to 
another party  or m ove them  to another l ocati on, advance wri tten noti ce wil l be given to 
Pharmacyclics LLC. Pharmacyclics LLC will inform the invest igator of the date that study  
records m ay be destroy ed or returned to Pharmacyclics LLC.
Pharmacyclics LLC must be notified in advance o f, and Pharmacyclics LLC m ust provi de 
express w ritten approval  of, any  change in the m aintenance of the foregoing documents if the 
investigator wishes to move study  records to another location or assign responsibilit y for record 
retenti on to another party . If the investi gator cannot guarantee the archi ving requi rements set 
forth herein at his or her study  site for all  such docum ents, speci al arrangements must be made 
between the invest igator and Pharmacyclics LLC to store such documents in sealed containers 
away  from the study  site, so that they  can be returned sealed to the investigator for audit 
purposes.
12.7 Case Report Forms and Record Maintenance
The CRFs will be used to collect the clinical study  data and m ust be com pleted for each enrolled 
subject with all required study  data accurately  recorded such that the informat ion matches the 
data contained in medical records (eg, physicians’ notes, nurses’ notes, clinic charts and other 
study -specific source documents). Authorized study  site personnel  (ie, listed on the Del egation of 
Authori ty log) will  com plete CRFs designed for this study  according to the complet ion 
guidelines that will be provided. The invest igator will ensure that the CRFs are accurate, 
complete, l egible, and com pleted wi thin a reasonable period of time. At all t imes, the 
investigator has fi nal responsibilit y for the accuracy  and authent icity of all clinical data.
The CRFs exist within an electronic data capture (EDC) sy stem  with controlled access managed 
by Pharmacyclics LLC or i ts authori zed representative for this study . Study  staff will  be 
appropriately  trained in the use of CRFs and application of electronic signatures before the start 
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 114of the study  and before being given access to the EDC system. Original data and any  changes of 
data will be recorded using the EDC system, with all changes tracked by  the system  and recorded 
in an el ectroni c audi t trail . The invest igator attests that the informat ion contained in the CRFs is 
true by  provi ding electronic signature within the EDC system. After database lock, the 
investigator will receive a copy of the subject data (eg, paper, CD, or other appropriate media) 
for archiving at the study  site.
12.8 Investigational Study Drug Accountability
Ibrutinib, venetoclax/placebo and any Pharmacyclics LLC supplied co mparator used must be 
kept i n a locked limi ted ac cess room . The study  drug m ust not be used outsi de the context of the 
protocol . Under no ci rcumstances shoul d the investi gator or other si te personnel supply ibrut inib, 
venetoclax/placebo or comparator to other invest igators, subjects, or clinics or allow supplies to 
be used other than as directed by  this protocol  without pri or authori zation from 
Pharmacyclics LLC.
Accountabilit y records for ibrutinib, venetoclax/placebo, and any Pharmacyclics LLC supplied 
comparator m ust be maintained and readily  available for regul ar inspect ion by representatives of 
Pharmacyclics and are open to inspect ions by regulatory  authori ties at any  time.
An Invest igational Drug Accountabilit y Log m ust be used for drug accountabilit y. For addi tional 
details on invest igational study  drug m anagement, pl ease refer to the Pharmacy Manual.
12.9 Study Monitoring/Audit Requirements
Representatives of Pharmacyclics LLC or i ts desi gnee will  monitor thi s study  until completion. 
Moni toring will be conducted through personal visits wit h the invest igator and si te staff, rem ote 
monitoring, as well as any appropriate communications by  mail, fax, em ail, or tel ephone. 
Thepurpose of monitoring is to ensure that the study  is conducted in co mpliance with the 
protocol , standard operating procedures (SOPs), an d other written instructions and regulatory  
guidelines, and to ensure the qualit y and integri ty of the data. This study  is also subject to 
reviews or audits.
To assure the accuracy  of data collected in the CRFs, it is mandatory  that the m onitor/audi tor 
have access to all original source documents, including all electronic medical records (EMR) at 
reasonable times and upon reasonable notice. If access to the EMR cannot be granted to the 
monitor, the si te must ensure that all certified copies of documents are available during 
monitoring visits for all screened and enro lled subjects. During the review o f source documents, 
every effort will be made to maintain the anonymit y and confident iality of all subjects during 
this clinical study . However, because of the e xperimental nature of this treatment, the 
investigator agrees to allow the IRB/REB/IEC, representatives of Pharmacyclics LLC, i ts 
designated agents and authorized emplo yees o f the appropriate Regulatory  Authori ty to inspect 
the facilit ies used in this stud y and, for purposes of verificat ion, allow direct access to the 
hospi tal or clinic records of all subjects enrolled into this study . A statem ent to this effect will be 
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 115included in the informed consent and permissio n form  authori zing the use of protected he alth 
inform ation.
Pharmacyclics LLC or i ts authori zed representati ve m ay perform an audi t at any  time during or 
after com pletion of this study . All study -related docum entati on m ust be m ade available to the 
designated auditor. In addit ion, a representative of the FDA or other Regulatory  Agencies may  
choose to inspect a study  site at any  time before, during, or after complet ion of the clinical study . 
In the event of such an inspect ion, Pharmacyclics LLC will be available to assist in the 
preparati on. All  pertinent study  data shoul d be m ade available as requested to the Regulatory  
Authori ty for verificat ion, audi t, or inspect ion purposes.
12.10 Investigator Responsibilities
A co mplete list of investigator responsibilit ies are outlined in the clinical trial research 
agreem ent and the invest igator agreements (eg, Statement of Investigator Form FDA 1572s or 
equivalent), both of which are signed by  the investigator before commencement of the study . In 
summary, the invest igator will conduct the study according to the curre nt protocol; will read and 
understand the IB; will obtain IRB/REB/IEC approval to conduct the study ; will  obtain informed 
consent from each study  partici pant; will  maintain and supply to the Sponsor or designee, 
auditors and regul atory  agencies adequate an d accurate records of study  activit y and drug 
accountabilit y for study -related m onitoring, audi ts, IRB/REB/IEC revi ews and regulatory  
inspections; will report SAEs to the Sponsor or designee and IRB/ REB/IEC according to the 
specifics outlined in this prot ocol; will  personally conduct or supervise the study; and will ensure 
that colleagues part icipating in the study are informed about their obligat ions in meeting the 
above co mmit ments.
12.11 Sponsor Responsibilities
A co mplete list of the Sponsor responsibilit ies is outlined in the clinical trial research agreement 
and in the laws and regulat ion of the country  in which the research is conducted. In summary , the 
Sponsor will select qualified investigators, provide them wit h the informat ion they  need to 
properly co nduct the study , ensure adequate monit oring of the study , conduct the study  in 
accordance with the general invest igational plan and protocols and prompt ly inform 
investigators, healt h and regulatory  agencies/authori ties as appropriate of significant new ad verse 
effects or risks wit h respect to the drug.
12.12 Financial Disclosure
A separate financial agreement will be made between each principal invest igator and 
Pharmacyclics LLC or i ts authori zed representati ve before the study  drug is delivered.
For thi s study , each investi gator and sub -invest igator (as designated on the invest igator 
agreem ents [eg, Form  FDA1572 or equivalent]) will provide a personally signed Financial 
Disclosure Form  in accordance wit h § 21 CFR 54. Each invest igator will notify 
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 116Pharmacyclics LLC or i ts authori zed representati ve of any relevant changes in financial 
disclosure inform ation during the conduct of the study  and f or 1 year after the study  has been 
completed.
12.13 Liability and Clinical Trial Insurance
In the event of a side effect or inj ury, appropri ate medical care as determined by  the 
investigator/designee will be provided.
The ICF will include a descript ion of treatm ent in the event of a study -related injury  and 
handling of the costs associated therewith, incorporating country -specific national regulat ions 
and/or local laws. Financial co mpensat ion for lost wages, di sabili ty or di scomfort due to the 
study  is not available.
Clinical trial insurance has been undertaken according to the laws of the countries where the 
study  will be conducte d. An insurance cert ificate will be made available to the participat ing sites 
at the time of study  initiation.
12.14 Protocol Amendments
Pharmacyclics LLC will init iate any  change to the protocol  in a protocol amendment document. 
Theamendment will  be submi ttedto the IRB/REB/IEC together with, if applicable, a revised 
model ICF. Wri tten documentati on of  IRB/REB/IEC and required site approval must be received 
by Pharmacyclics LLC before the amendment may take effect at each site. Addit ionally under 
this circumst ance, information on any  change in risk and/or change in scope must be provided to 
subjects al ready  actively participat ing in the study, and they must read, understand and sign each 
revised ICF confirming willingness to remain in the trial.
No other signif icant or consistent change in the study  procedures, except to eliminate an 
immediate hazard, shall be effected without the mutual agreement of the invest igator and 
Pharmacyclics LLC.
12.15 Publication of Study Results
Pharmacyclics LLC may use the results of this clinical study  in registrati on docum ents f or 
Regulatory  Authori ties in the US or abroad. The results may also be used for papers, abstracts, 
posters, or other material presented at scientific meetings or published in pro fessio nal journals or 
as part of an academic thesis by  an invest igator. In all cases, to avoid disclo sures that could 
jeopardi ze propri etary  rights and to ensure accuracy  of the data, Pharm acyclics LLC reserves the 
right to previ ew all  manuscripts and abstracts related to this study , allowing Pharm acyclics LLC 
sufficient time to make appropriate comments befo re submissio n for publicat ion.
In most cases, the investigators at the sites with the highest accruals of eligible subjects shall be 
listed as lead authors on manuscripts and reports o f study  resul ts. The medical  monitor, s tudy 
director and/or l ead statistician may also be included in the list of authors. This custom can be 
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 117adjusted upon m utual  agreement of the authors and Pharmacyclics LLC and in accordance wit h 
current standards for a uthorship as recorded in professio nal conference and journal submissio n 
instructi ons.
12.16 Study Discontinuation
The Sponsor reserves the right to terminate the study  at any  time. Should this be necessary, 
both the Sponsor and the invest igator will arrange dis continuat ion procedures. In terminat ing the 
study , the Sponsor and the invest igator will assure that adequate considerat ion is given to the 
protecti on of  the subjects’ interests .
12.17 Study Completion
The study  is expected to be completed approximately 5 y ears from the first subject enrolled, the 
time all subjects have exited the study  for any  reason, or study  terminati on at the Sponsor’s 
discreti on, whichever occurs first.
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 11813REFERENCES
Borner C. The Bcl -2 protein family: sensors and checkpoints for life -or-death decisions. 
Mol Immunol. 2003;39:615-47.
Brookmeyer R and Crowley J. A confidence interval for the median survival time. Biometrics. 1982;38: 
29-41.
Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. 
BrJHaematol. 2 004;127(1):3 -11.
Campo E and Rule S. Mantle cell lymphoma: evolving management strategies. Blood. 2015;125:48 -55.
Carter GC. Validation of the Functional Assessment of Cancer Therapy –Lymphoma (FACT -LYM) in 
Patients with Relapsed/Refractory Mantle Cell Ly mphoma. ASH 2008; San Francisco, California.
Cella D, Webster K, Cashy J, et al. Development of a measure of health -related quality of life for non -
Hodgkin’s lymphoma clinical research: the Functional Assessment of Cancer Therapy –Lymphoma 
(FACT -Lym). Blo od. ASH 2005, 106, Abstract 750.
Chang BY, Francesco M, De Rooij MF, et al. Egress of CD19(+)CD5(+) cells into peripheral blood 
following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients. 
Blood. 2013a;122:2412- 24. 
Chang BY, Francesco M, Steggerda S, et al. Ibrutinib Inhibits Malignant Cell Adhesion and Migration 
and Reduces Tumor Burden in Lymph Node and Bone Marrow in a Murine Model of Mantle Cell 
Dissemination and Progression. 2013b AACR: Abstract 923. 
Chen RW, Li H, Bernstein SH, et al. RB but not R -HCVAD is a feasible induction regimen prior to auto -
HCT in frontline MCL: results of SWOG Study S1106. Br J Haematol. 2017;176(5):759- 769. 
Child CG, Turcotte JG. “Surgery and portal hypertension”. In Child CG. T he liver and portal 
hypertension. Philadelphia:Saunders. 1964. pp. 50-64.
Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and 
response assessment of Hodgkin and non -Hodgkin lymphoma: the Lugano classification. 
JClin Oncol.2014;32(27):3059 -68.
Coiffier B, Altman A, Pui CH, et al. Guidelines for the management of pediatric and adult tumor lysis 
syndrome: an evidence -based review. J Clin Oncol.2008;26(16):2767-78.
Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03. Published June 14, 2010
Cory S and Adams JM. The Bcl -2 fam ily: regulators of the cellular life -or-death switch. Nature Reviews. 
Cancer. 2002;2:647-56.
Cory S, Huang DC, Adam JM. The Bcl -2 family: roles in cell survival and oncogenesi s. 
Oncogene. 2003;22:8590 -607.
Delfau -Larue MH, Klapper W, Berger F, et al. High -dose cytarabine does not overcome the adverse 
prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma. Blood. 2015;126(5):604 -11. 
Dreyling M, Jurczak W, Jerkema n M, et al. Ibrutinib versus temsirolimus in patients with relapsed or 
refractory mantle -cell lymphoma: an international, randomised, open -label, phase 3 study. 
Lancet. 2016;387:770 -8.
Dreyling M, Geisler C, Hermine O, et al. Newly diagnosed and relapsed m antle cell lymphoma: ESMO 
Clinical Practice Guidelines for diagnosis, treatment and follow -up. Annals Oncol. 2014;25 (Suppl 3): 
iii83–iii92.
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 119Dreyling M, Klapper W, Rule S. Blastoid and pleomorphic mantle cell lymphoma: still a diagnostic and 
therapeutic ch allenge! Blood. 2018;132(26):2722 -2729.
Dreyling M, Thieblemont C, Gallamini A, et al. ESMO Consensus conferences: guidelines on malignant 
lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T -cell lymphoma. 
Ann Oncol. 2013;24:857 -77.
Eremenco S, Webster K, Kutikova L, et al. Development and multilingual validation of the 
FACT -Lymphoma instrument. Quality of Life Research 2004; 13(9): 1501.
EuroQol Group. EuroQol -A new facility for the measurement of health -related quality of life. He alth 
Policy. 1990; 16: 199 -208.
Eskelund CW ,Dahl C, Hansen JW, et al. Tp53 mutations identify younger mantle cell lymphoma patients 
who do not benefit from intensive chemoimmunotherapy. Blood. Oct. 26;130(17):1903 -1910. 
Epub 2017 Aug 17.
Ferrero S, Rossi D, Bruscaggin A, et al. KMT2D and TP53 mutations predict poor PFS and OS in mantle 
cell lymphoma receiving high -dose therapy and ASCT: The Fondazione Italiana Linfomi (FIL) MCL0208 
Phase II Trial. Supplement: 14th International Conference on Malignant Lymp homa Palazzo dei 
Congr essi, Lugano (Switzerland), 14 –17 June, 2017; Volume35, IssueS2.
Flinn IW, van der Jagt R, Kahl BS, et al. Randomized trial of bendamustine -rituximab or R -CHOP/R -
CVP in first -line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014;123(19):2944-52.
Flowers CR, Seidenfeld J, Bow EJ, Karten C, et al. Antimicr obial prophylaxis and outpatient 
management of fever and neutropenia in adults treated for malignancy: American Society of Clinical 
Oncology clinical practice guideline . J Clin Oncol. 2013 Feb 20;31(6):794-810.
Gerecitano JF, Roberts AW, Seymour JF, et al. Phase 1 study of venetoclax (ABT -199 / GDC -0199) 
monotherapy in patients with relapsed/refractory Non -Hodgkin Lymphoma. ASH 2015. Abstract 254.
Ghielmini M and Zucca E . How I treat Mantle Cell Lymphoma. Blood. 2009;114:1469 -76.
Goy AandKahl B . Mantle cell lymphoma: the promise of new treatment options. Crit Rev Oncol 
Hematol. 2011;80:69 -86.
Halldórsdóttir AM, Lundin A, Murray F, et al. Impact of TP53 mutation and 17p deletion in mantle cell 
lymphoma. Leukemia. 2011;25(12) 904 -8.
Herman SE, Gordon AL, Hertlein E, et al. Bruton tyrosine kinase represents a promising therapeutic 
target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI -32765. Blood. 
2011;117:6287-96.
Hermine O, Hoster E, Walewski J, et al. Addition of high -dose cytarabine to immunochemotherapy 
befor e autologous stem -cell transplantation in patients aged 65 years or younger with mantle cell 
lymphoma (MCL Younger): a randomised, open -label, phase 3 trial of the European Mantle Cell 
Lymphoma Network. Lancet. 2016; 388(10044):565 -75.
Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced -stage 
mantle cell lymphoma. Blood. 2008;111:558 -65.
Howard SC, Jones DP, Pui C -H. The Tumor Lysis Syndrome. N Engl J Med 2011; 364:1844 -1854.
International Conference on Harmonisation (ICH) of Technical Requirements for Registration of 
Pharmaceuticals for Human Use: ICH Harmonised Tripartite Guideline: Guida nce for Good Clinical 
Practice (ICH -E6)(R1). June 1996.
International Conference on Harmonization (ICH) Guideline for Industry: Clinical Safety Data 
Management: Definitions and Standards for Expedited Reporting (ICH -E2A). March 1995.
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 120Investigator's Brochur e. Ibrutinib (PCI -32765) . Version 14: 10 December 2020. Pharmacyclics LLC; 
Janssen Research & Development, LLC.
Investigator’s Brochure. Venetoclax (ABT -199). Version 13: 13 January 2021. AbbVie Inc.
Jerkeman M, Eskelund CW, Hutchings M, et al. Ibrutinib, lenalidomide, and rituximab in relapsed or 
refractory mantle cell lymphoma (PHILEMON): a multicentre, open -label, single -arm, phase 2 trial. 
Lancet Haematol. 2018;5(3):e109 -e116.
Kluin -Nelemans HC, Hoster E, Hermine O, et al. Treatment of older patients with mantle -cell lymphoma. 
N Engl J Med. 2012;367(6):520 -31. 
Lennert K. Histopathology of non -Hodgkin’s lymphomas: based on the Kiel Classification. Berlin, 
Germany: Springer -Verlag. 1981.
Le Gouill S, Davies A, Bouabdallah K, et al. OAsIs: An international phase I trial of obinutuzumab, 
venetoclax plus ibrutinib in relapsed/refractory mantle cell lymphoma. ASCO 2016. Abstract TPS7583.
Lenz G, Dreyling M, Unterhalt M, et al. Current strategies in the treatment of advanced stage mantle cell 
lymphoma. Deutsch Med Wochenschr. 2004;129:2429 -33.
Lenz G, Dreyling M, Hoster E, et al. Immunochemotherapy with rituximab and cyclophosphamide, 
doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failu re, but 
not long -term outcome in patients with previously untreated mantle cell lymphoma: results of a 
prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol. 
2005;23(9):1984 -92.
Levin A, Warnock DG, Mehta RL, et al. Improving outcomes from acute kidney injury: report of an 
initiative. AmJ Kidney Dis 2007;50:1-4.
Merli F, Luminari S, Ilariucci F, et al. Rituximab plus HyperCVAD alternating with high dose cytarabine 
and methotrexate for the initial treatment of patient s with mantle cell lymphoma, a multicentre trial from 
Gruppo Italiano Studio Linfomi. Br J Haematol. 2012;156(3):346 -53.
National Cancer Institute (NCI). Common Terminology Criteria for Adverse Events. Version 4.03. 2010.
National comprehensive clinical ne twork clinical practice guidelines in oncology (NCCN guidelines). 
Non-Hodgkin’s Lymphomas, Version. 2. 2016.
Obr A, Procházka V, Jirkuvová A, et al. TP53 Mutation and Complex Karyotype Portends a Dismal 
Prognosis in Patients With Mantle Cell Lymphoma. Clin Lymphoma Myeloma Leuk. 
2018;18(11):762 -768. 
Oken, MM, Creech RH, Tormey DC, et al.: Toxicity And Response Criteria Of The Eastern Cooperative 
Oncology Group. Am J Clin Oncol. 5:649-55, 1982.
Pan Z, Scheerens H, Li SJ, et al. Discover y of selective irreve rsible inhibitors for Bruton's tyrosine kinase. 
ChemMedChem. 2007;2:58 -61.
Portell C, Axelrod M, Brett L, et al. Synergistic cytotoxicity of ibrutinib and the BCL2 antagonist, 
ABT -199(GDC -0199) in mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL): 
molecular analysis reveals mechanisms of target interactions. Blood 124: 509; ASH 2014, Oral Abstract.
Portell C, Chen RW, Wages N, et al. Initial Report of a Multi -Institution Phase I/Ib Study of Ibrutinib 
with Venetoclax in Relapsed or Refractory Mantle Cell Lymphoma. Poster Abstract 623, ASH 2016.
Pott C1, Hoster E, Delfau -Larue MH, et al. Molecular remission is an independent predictor of clinical 
outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL 
intergroup study. Blood. 2010;115:3215 -23.
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 121Pugh RN, Murray- Lyon IM, Dawson L, et al. “Transection of the oesophagus for bleeding oesophageal 
varices”. The British journal of surgery. 1973;60: 646 -9.
Robak T, Huang H, Jin J, et al. Bortezomib -based therapy for newly diagnosed mantle -cell lymphoma. 
NEngl J Med. 2015;372(10):944-53.
Robinson KS, Williams ME, van der Jagt RH, et al. Phase II multicenter study of bendamustine plus 
rituximab in patients with relapsed indolent B -cell and mantle cell non -Hodgkin's ly mphoma. 
JClin Oncol. 2008;26:4473-9.
Rule S, Dreyling M, Hess G, et al. Overall survival outcomes in patients with mantle -cell lymphoma 
(MCL) treated with ibrutinib in a pooled analysis of 370 patients from 3 international open -label studies. 
European Hem atology Association (EHA), Annual Meeting 2016, Copenhagen, Denmark, Abstract 
135194.
Rummel MJ, Al -Batran SE, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable 
toxicity profile in the treatment of mantle cell and low -grade non -Hodgkin's lymphoma. 
JClin Oncol. 2005;23:3383 -9.
Rummel MJ,Niederle N, Maschmeyer G, et al. Benda mustine plus rituximab versus chop plus rituximab 
as first -line treatment for patients with indolent and mantle -cell lymphomas: an open -label, multicentre, 
randomised, phase 3 non -inferiority trial. Lancet . 2013;381(9873):1203 -10.
Rummel MJ, Maschmeyer G, Ganser A, et al. Benda mustine plus rituximab (B -R) versus CHOP plus 
rituximab (CHOP -R) as first -line treatment in patients with indolent and mantle cell lympho moas (MCL) 
–7 year updated results from the StiL NHL1 study. Blood. 2014;124(21): 4407.
Rummel J, Maschmeyer G, Ganser A, et al. Bendamustine plus rituximab (B -R) versus CHOP plus 
rituximab (CHOP -R) as first -line treatment in patients with indolent lympho mas: nine -year updated 
results from the StiL NHL1 study. J Clin Oncol. 2017; 35:15_suppl, 7501.
Souers AJ1, Leverson JD, Boghaert ER, et al. ABT -199, ABT -199, a potent and selective BCL -2 
inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19(2):202 -8.
Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood 
cell growth factors: An evidence -based clinical practice guideline. J Clin Oncol. 2006;
24:3187 -205.
Tam CS, Roberts AW, Anderson MA, et al. Combination ibrutinib and venetoclax for the treatment of 
mantle cell lymphoma: primary endpoint assessment of the Phase 2 AIM study. 2017 International 
Conference on Malignant Lymphoma (ICML), Abstract 135.
Tam C, Roberts A, Anderson MA, et al. The combination of ibrutinib and venetoclax (ABT -199) rapidly 
achieves complete remissions in patients with relapsed / refractory mantle cell lymphoma: preliminary 
results of the phase II AIM study. Haematologica. 2016;101(s1):103.
Tam CS, Anderson MA, Po tt C, et al. Ibrutinib plus Venetoclax for the Treatment of Mantle -Cell 
Lymphoma. N Engl J Med. 2018;378(13):1211 -1223.
Webster K, Cashy J, Cella D, et al. Measuring quality of life (QOL) in patients with non -Hodgkin’s 
Lymphoma (NHL): The Functional Assess ment of Cancer Therapy -Lymphoma (FACT -Lym). Quality of 
Life Research, 2005;14(9), 1650.
Wild D, Grove A, Martin M, et al. Principles of Good Practice for the Translation and Cultural 
Adaptation Process for Patient -Reported Outcomes (PRO) Measures: Report of the ISPOR Task Force for 
Translation and Cultural Adaptation. Value In Health. 2005;8(2):94 -104.
Willis S, Day CL, Hinds MG, et al. The Bcl -2-regulated apoptotic pathway. J Cell Sci.2003; 
116(Pt 20):4053 -6.
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 122Zhao X1, Bodo J, Sun D, et al. Combination of ibrutinib with ABT -199: synergistic effects on 
proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT 
and BCL2 pathways. Br J Haematol. 2015;168:765 -8.
Zhao X1, Bodo J, Sun D, et al. Combination Of Ibrutinib With ABT -199, a BCL -2 Pathway Inhibitor: 
Effective Therapeutic Strategy In a Novel Mantle Cell Lymphoma Cell Line Model. ASH 2013. Abstract 
625.
Zhou Y, Wang H, Fang W, et al. Incidence trends of mantle cell lymphoma in the United States between 
1992 and 2 004. Cancer. 2008;113:791-8.
Zucca E, Stein H, Coiffier B. European Lymphoma Task Force (ELTF): report of the workshop on mantle 
cell lymphoma (MCL). Annals Oncol. 1994;5:507 -11.
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 12314APPENDICES
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 124Appendix A. Schedule of Assessments –Standard Ramp- up Schedule
Week 1 2 3 4 5 6 8 10Week 13 
& 
beyonda
(±7days)Response 
Assessmentb
(±7days)EOTc
(±7 
days)RFUdLTFUw
Day 1 2 3 1 2 3 1 1 1 11 (±1 
day)1 (±1 
day)(±14 days)
Study Drug Administration
Ibrutinib 560 mg daily Continuous ----
Venetoclax daily dose / placebo 20mg 50mg 100mg 200mg 400mg continuous target daily dose ----
ProcedureScreening
Day -28 to -1
Informed consent X
Medical 
history/demographic/prior 
treatmentX X
Confirm eligibility X X
Concomitant medicationseX X X X X X X X X X X X X X X
AEsfX X X X X X X X X X X X X X X
Physical examgX X X X X X X X X X X
Vital signs hX X X X X X X X X X X X X
ECOG X X X X X
ECGiX X
Disease Assessment
CT/PET/MRI/endoscopyjX X X
Tumor tissuekX (X)
Bone marrow biopsyxX (X)
B-symptoms X X X
Overall response 
assessmentm X X
MRD Bone marrow 
aspiratel X (X)
MRD assessment in 
bloodn X X X
TLS Risk AssessmentoX X X X X X X X X X X X X X
PROpX X
Medical resource 
utilization (MRU)Hospitalizations, emergency department visits, hematopoietic growth factor use to be documented throughout 
study  treatment period
Biomarker Bone marrow 
Aspiratel X (X)
Biomarker Peripheral BlooduX X X X
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 125Week 1 2 3 4 5 6 8 10 Week 13 
& 
beyonda
(±7days)Response 
Assessmentb
(±7days)EOTc
(±7 
days)RFUdLTFUw
Day 1 2 3 1 2 3 1 1 1 11 (±1 
day)1 (±1 
day)(±14 days)
Study Drug Administration
Ibrutinib 560 mg daily Continuous ----
Venetoclax daily dose / placebo 20mg 50mg 100mg 200mg 400mg continuous target daily dose ----
ProcedureScreening
Day -28 to -1
HematologyqX X X X X X X X X X X X
Blood chemistryrX X X X X X X X X X X X X X X
UrinalysissX X
Serum or Urine Pregnancy X X X
Hepatitis serologiestX
Coagulation panel X
Buccal Swab X
Serum β 2-microglobulin X
PK blood samplingvX
Survival status, incl. other 
malignanciesw X
Subsequent Anticancer Therapy X X
Abbreviations:
EOT = End -of-Treatment Visit; RFU = Response Follow -up Visit; LTFU = Long -term Follow up; PRO = patient -reported outcome;
Footnotes:
aAfter week 13, study drug dispensing visits are sche duled every 4 weeks for one year; every 8 weeks during the 2ndand 3rdyears; and every 12 weeks thereafter until treatment 
discontinuation.
bResponse assessment visits are scheduled on Week 13 Day 1 (± 7days); every 12 weeks for the remain derof the 1styear; every 16 weeks during the 2ndand 3rdyears, and every 
24 weeks thereafter until PD. In addition, response assessments can be performed as clinically indicated to confirm response or progression. 
cAn EOT visit will occur 30 days (±7) from the last dose of study drug or prior to the start of a new anticancer treatment.
dSubjects who discontinue for reasons other than PD will have follow -up response assessments (based on Week 1 Day 1 for a subject) every 12 weeks (± 14 days )from the 
1stdose for the 1styear; every 16 weeks (± 14 days) during the 2ndand 3rdyears; and every 24 weeks (± 14 days )thereafter until PD.
eConcomitant medications are collected from 30 days before thefirst dose through the 30 days after the last dose of study drug.
fSee Section 11for details regarding the reporting of AEs.
gA complete physical examination (at Screening and EOT) will include, at a minimum, the gene ral appearance of the subject, height (may use prior height measurement if 
available in source documents) and weight, and examination of the skin, eyes, ears, nose, throat, lungs, heart, abdomen, extr emities, musculoskeletal system, lymphatic system, 
and n ervous system. At other timepoints, a limited symptom -directed phy sical exam will be performed. The physical exam should include an eye -related sy mptom assessment.
hVital signs (blood pressure, heart rate, and body temperature) will be assessed after the subject has rested in the sitting position for ≥3 minutes.
iA single 12 -lead ECG will be done at Screening and at the EOT visit. Subjects should be in a supine position and resting for at least 10 minutes before obtaining the ECG. During 
the treatment per iod, ECG’s may be performed at the investigator’s discretion, particularly in subjects with arrhythmic symptoms (eg, palpitat ions, lightheadedness) or new 
onset dyspnea. 
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 126jCT and PET or PET/CT: A CT scan (with contrast unless contraindicated) of the neck, chest, abdomen, and pelvis and any other disease sites (eg, extremity) and a PET or 
PET/CT scan (CT should be of diagnostic quality) are required for the pretreatment tumor assessment within 28 days of the fir st dose. Thereafter, CT scans will be done for
tumor assessments on Week 13 Day 1 (±7 days); every 12 weeks for the remain derof the 1styear; every 16 weeks during the 2ndand 3rdyears; and every 24 weeks thereafter 
until PD. PET or PET/CT is mandatory to confirm a CR. For MRI refer to Section 7.1.3.2 .
kA total of up to 20 slides of fresh or the most recent dated FFPE archival tumor biopsy tissue will be required at study entr y. An optional tumor biopsy should be collected at the 
time of d isease progression if feasible.
lA unilateral bone marrow aspirate will be done at Screening or up to 28 days before the 1stadministration of study drug for MRD testing. A 2ndbone marrow aspirate will be 
performed in all subjects who achieve aCR. Subse quent bone marrow aspirates will be obtained as needed (ie, if MRD in BM at CR was positive, and subject remains CR) to 
confirm MRD -negative CR. 
mResponse assessments will be completed by the investigator using the Revised Response Criteria for Malignant Lymphoma ( Cheson 2014 ).
nBlood will be drawn for MRD assessments at baseline, at documented complete response and onwards every 12 weeks (± 7days) for the remain derof the 1styear; every 
16weeks during the 2ndand 3rdyears; and every 24 weeks thereafter until PD. 
oRisk of TLS is to be re -assessed prior to each venetoclax dose ramp -up. Administration of prophylaxes as needed is to occur within 72 hours of dosing. Subjects with high tumor 
burden at baseline may be hosp italized for a minimum of the first 24 hours of treatment (and up to 48 hours at the discretion of the investigator) at the s tart of the 20 mg (ramp -
up dose) and the 50 mg dose levels and blood chemistry (creatinine, uric acid, potassium, phosphorus, calci um, and albumin, if available) should be monitored pre -dose and 4±1, 
8±1, 12±1, 24±2 and as needed 48±2 hours after the venetoclax dose. Additionally, for high -risk TLS subjects, post -dose blood chemistries will be monitored at pre -dose and 
6-8 hours after the venetoclax dose during ramp up of the 100 mg, 200 mg and 400 mg dose levels. For all other subjects, blood chemistry will be monitored pre -dose, 6 -8 and 
24±2 hours after the venetoclax dose at the 20 mg and the 50 mg dose levels. 
pPRO questionnaires (FACT -Lym, EQ -
5D-5L) should be completed prior to any assessments, and before being clinically evaluated by the study nurse or physician. The 
questionnaires will be administered on Week 1 Day 1, Week 13 Day 1 (± 7 days); every  4 weeks for the remainder of the 1styear; every 8 weeks during the 2ndand 3rdyears; and 
every 12 weeks thereafter until disease progression.
qHematology includes complete blood count with differential and platelet counts. 
rBlood chemistry: Sodium, potassium, chloride, BUN, creat inine, glucose, calcium, total protein, albumin, AST, ALT, alkaline phosphatase, total bilirubin, LDH, phosphate, uric 
acid, urea, magnesium and bicarbonate. Serum creatinine, uric acid, potassium, phosphorus and calcium should be assessed with in 72 hours prior to the 1stvenetoclax dose and 
before each dose increase.
sUrinalysis: pH, ketones, specific gravity, bilirubin, protein, blood, and glucose. 
tHepatitis C antibody, hepatitis B surface antigen and hepatitis B core antibody will be evaluated. If he patitis B core antibody or hepatitis B surface antigen or Hepatitis C 
antibody is positive, then PCR to quantitate hepatitis B DNA or hepatitis C RNA must be performed. DNA PCR needs to be confir med negative (< 29U) prior to enrollment in 
subjects who are hepatitis B core antibody or hepatitis B surface antigen positive. For subjects who are hepatitis C antibody positive, hepati tis C PCR needs to be confirmed 
negative prior to enrollment.
uBlood biomarker samples will be drawn at baseline, at documented c omplete response and onwards every 12 weeks (± 7days) for the remain derof the 1styear; every 16 weeks 
during the 2ndand 3rdyears; and every 24 weeks thereafter until PD.
vPK samples will be drawn at protocol -specified timepoints: pre -dose (30min), 1hr (±15min), 2hrs (±15min), 4hrs (±30min), 6hrs (±30min), and 8hrs (±1hr) post dose.
wAfter progression, survival status, other malignancies and subsequent anticancer therapy will be collected approximately ever y 12 weeks (based on Week 1 Day 1 for a subjec t) 
until death, withdrawal by subject, loss to follow -up, or study terminated by Sponsor, whichever comes first.
xA unilateral bone marrow biopsy will be done at Screening or up to 28 days before the 1stadministration of study drug for standard pathology . A 2ndbone marrow biopsy will be 
performed in subjects with positive bone marrow involvement at baseline by standard pathology who achieve a CR.
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 127Appendix B. Schedule of Assessments –Treatm ent-naive Open -label Arm
Week 1 2 3 4 5 6 8 10Week 13 
& 
beyonda
(±7days)Response 
Assessmentb
(±7days)EOTc
(±7 
days)RFUdLTFUw
Day 1 2 3 1 2 3 1 1 7 1 11 (±1 
day)1 (±1 
day)(±14 days)
Study Drug Administration
Ibrutinib 560 mg daily Continuous ----
Venetoclax daily dose 20mg 50mg 100mg 200mg 400mg continuous target daily dose ----
ProcedureScreening
Day -28 to -1
Informed consent X
Medical history/ demographic/
central lab pathology report 
confirmation or tissue testX X
Confirm eligibility* X X
Concomitant medicationseX X X X X X X X X X X X X X X
AEsfX X X X X X X X X X X X X X X
Physical examgX X X X X X X X X X X
Vital signs hX X X X X X X X X X X X X
ECOG X X X X X
ECGiX X
Disease Assessment
CT/PET/MRI/endoscopyjX X X X
Tumor tissuekX (X)
Bone marrow biopsyxX (X)
B-symptoms X X X
Overall response assessmentmX X X
MRD Bone marrow aspiratelX (X)
MRD assessment in bloodnX X X
TLS Risk AssessmentoX X X X X X X X X X X X X X
PROpX X
Medical resource utilization 
(MRU)Hospitalizations, emergency department visits, hematopoietic growth factor use to be documented throughout study 
treatment period
Biomarker Bone marrow 
Aspiratel X (X)
Biomarker Peripheral BlooduX X X X
HematologyqX X X X X X X X X X X X
Blood chemistryrX X X X X X X X X X X X X X X
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 128Week 1 2 3 4 5 6 8 10 Week 13 
& 
beyonda
(±7days)Response 
Assessmentb
(±7days)EOTc
(±7 
days)RFUdLTFUw
Day 1 2 3 1 2 3 1 1 7 1 11 (±1 
day)1 (±1 
day)(±14 days)
Study Drug Administration
Ibrutinib 560 mg daily Continuous ----
Venetoclax daily dose 20mg 50mg 100mg 200mg 400mg continuous target daily dose ----
ProcedureScreening
Day -28 to -1
UrinalysissX X
Serum or Urine Pregnancy X X X
Hepatitis serologiestX
Coagulation panel X
Buccal Swab X
Serum β 2-microglobulin X
PK blood samplingvX X X
Survival status, incl. other 
malignanciesw X
Subsequent Anticancer Therapy X X
Abbreviations:
EOT = End -of-Treatment Visit; RFU = Response Follow -up Visit; LTFU = Long -term Follow up; PRO = patient -reported outcome; *TP53 mutation test by local or central lab
Footnotes:
aAfter week 13, study drug dispensing visits are scheduled every 4 weeks for 1 year; every 8 weeks during the 2nd and 3rd year s; and every 12 weeks thereafter until treatment 
discontinuation.
bResponse assessment visits are scheduled on We ek 13 Day 1 (± 7days); every 12 weeks for the remain derof the 1styear; every 16 weeks during the 2ndand 3rdyears, and every 
24 weeks thereafter until PD. In addition, response assessments can be performed as clinically indicated to confirm response or progression. PET scans will be performed at 
screening, at Week 13, Week 25, Week 49 and at suspected CR.
cAn EOT visit will occur 30 days (±7) from the last dose of study drug or prior to the start of a new anticancer treatment.
dSubjects who discontinue for reasons other than PD will have follow -up response assessments (based on Week 1 Day 1 for a subject) every 12 weeks (± 14 days) from the 
1stdose for the 1st year; every 16 weeks (± 14 days) during the 2nd and 3rd years; and every 24 weeks (± 14 days) thereafter until PD.
eConcomitant medications are collected from 30 days before 1st dose through the 30 days after the last dose of study drug.
fSee Section 11for details regarding the reporting of AEs.
gA complete physical examination (at Screening and EOT) will include, at a minimum, the general appearance of the subject, hei ght (may use prior height measurement if 
available in source documents ) and weight, and examination of the skin, eyes, ears, nose, throat, lungs, heart, abdomen, extremities, musculoskeletal syst em, lymphatic system, 
and nervous system. At other timepoints, a limited symptom -directed phy sical exam will be performed. The phys ical exam should include an eye -related sy mptom assessment.
hVital signs (blood pressure, heart rate, and body temperature) will be assessed after the subject has rested in the sitting p osition for ≥3 minutes.
IA single 12 -lead ECG will be done at Scree ning and at the EOT visit. Subjects should be in a supine position and resting for at least 10 minutes before obtaining the E CG. 
During the treatment period, ECG’s may be performed at the investigator’s discretion, particularly in subjects with arrhythmi c symptoms (eg, palpitations, lightheadedness) or 
new onset dyspnea. 
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 129jCT and PET or PET/CT: A CT scan (with contrast unless contraindicated) of the neck, chest, abdomen, and pelvis and any other disease sites (eg, extremity) and a PET or 
PET/CT scan (CT sh ould be of diagnostic quality) are required for the pretreatment tumor assessment within 28 days of the 1st dose. Thereafter, CT scans will be done for 
tumor assessments on Week 13 Day 1 (±7 days); every 12 weeks for the remain derof the 1st year; every 16 weeks during the 2nd and 3rd years; and every 24 weeks thereafter 
until PD. PET or PET/CT is mandatory for all subjects at the Week 13 visit (+/ -7 days), the Week 25 visit (+/ -7 days) for subjects in SD or PR who did not achieve CR at 
Week 13, and at th e 1-year visit (Week 49 +/ -7 days) for all subjects, as well as at any other time point to confirm a CR. Other PET or PET/CT scans that are NOT mandatory 
can be performed within a 30 -day window of the visit. For MRI refer to Section 7.1.3.2 .
kA total of up to 20 slides of fresh or the most recent dated FFPE archival tumor biopsy tissue will be required at study entr y. An optional tumor biopsy should be collected at the 
time of disease progression if feasible.
lA unilateral bone marrow aspirate will be done at Screening or up to 28 days before the 1stadministration of study drug for MRD testing. A 2ndbone marrow aspirate will be 
performed in all sub jects who achieve a CR. Subsequent bone marrow aspirates will be obtained as needed (ie, if MRD in BM at CR was positive, and subje ct remains CR) to 
confirm MRD -negative CR. 
mResponse assessments will be completed by the investigator using the Revised Re sponse Criteria for Malignant Lymphoma ( Cheson 2014 ).
nBlood will be drawn for MRD assessments at baseline, at documented complete response and onwards every 12 weeks (±7 days) for the remainder of the 1st year; every 
16weeks during the 2nd and 3rd years; and every 24 weeks thereafter until PD. 
oRisk of TLS is to be re -assessed prior to each venetoclax dose ramp -up. Administration of prophylaxes as needed is to occur within 72 hours of dosing. Subjects with high tumor 
burden at baseline may be hospitalized for a minimum of the first 24 hours of treatment (and up to 48 hours at the discretion of the investigator) at the start of the 20 mg (ramp -
up dose) and the 50 mg dose levels and blood chemistry (creatinine, uric acid, po tassium, phosphorus, calcium, and albumin, if available) should be monitored pre -dose and 4±1, 
8±1, 12±1, 24±2 and as needed 48±2 hours after the venetoclax dose. Additionally, for high risk TLS subjects, post -dose blood chemistries will be monitored at pr e-dose and 
6-8hours after the venetoclax dose during ramp up of the 100 mg, 200 mg and 400 mg dose levels. For all other subjects, blood ch emistry will be monitored pre -dose, 6 -8 and 
24±2 hours after the venetoclax dose at the 20 mg and the 50 mg dose lev els. 
pPRO questionnaires (EQ -
5D-5L) should be completed prior to any assessments, and before being clinically evaluated by the study nurse or physician. The questionnaires will be 
administered on Week 1 Day 1, Week 13 Day 1 (±7 days); every 4 weeks for t he remainder of the 1st year; every 8 weeks during the 2nd and 3rd years; and every 12 weeks 
thereafter until disease progression.
qHematology includes complete blood count with differential and platelet counts. 
rBlood chemistry: Sodium, potassium, chlo ride, BUN, creatinine, glucose, calcium, total protein, albumin, AST, ALT, alkaline phosphatase, total bilirubin, LDH, phosph ate, uric 
acid, urea, magnesium and bicarbonate. Serum creatinine, uric acid, potassium, phosphorus and calcium should be assessed within 72 hours prior to the first venetoclax dose and 
before each dose increase.
sUrinalysis: pH, ketones, specific gravity, bilirubin, protein, blood, and glucose. 
tHepatitis C antibody, hepatitis B surface antigen and hepatitis B core antibody will b e evaluated. If hepatitis B core antibody or hepatitis B surface antigen or Hepatitis C 
antibody is positive, then PCR to quantitate hepatitis B DNA or hepatitis C RNA must be performed. DNA PCR needs to be confir med negative (< 29U) prior to enrollment in 
subjects who are hepatitis B core antibody or hepatitis B surface antigen positive. For subjects who are hepatitis C antibody positive, hepatitis C PCR needs to be confirmed 
negative prior to enrollment. Subjects who are Hepatitis B surface antigen posi tive are excluded from the trial.
uBlood biomarker samples will be drawn at baseline, at documented complete response and onwards every 12 weeks (±7 days) for t he remainder of the 1styear; every 16 weeks 
during the 2ndand 3rdyears; and every 24 weeks t hereafter until PD.
vPK samples will be drawn at Week 4 Day 7 and Week 6 Day 1: pre -dose (±30min), 1hr (±15min), 2hrs (±15min), 4hrs (±30min), 6hrs (±30min), and 8hrs (±1hr) post dose. In 
addition, at Week 13: pre -dose (±30min), 1hr (±15min), 2hrs (±15min). Unscheduled PK sampling is allowed based on Medical Monitor request, e.g. dose modification (at least 
7 day s after dose modification)
wAfter progression, survival status, other malignancies and subsequent anticancer therapy will be collected approximat ely every  12 weeks (based on Week 1 Day 1 for a subject) 
until death, withdrawal by subject, loss to follow -up, or study terminated by Sponsor, whichever comes first.
xA unilateral bone marrow biopsy will be done at Screening or up to 28 days before the f irst administration of study drug for standard pathology. A second bone marrow biopsy 
will be performed in subjects with positive bone marrow involvement at baseline by standard pathology who achieve a CR. 
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 130Appendix C. ECOG Status Scores
Status Eastern Cooperative Oncology Group (ECOG) Performance Status**
0 Fully active, able to carry on all predisease perform ance without restriction.
1Restricted in physically strenuous activity but am bulatory and able to carry out work of a light or 
sedentary nature, eg, light housework, office work.
2Ambulatory and capable of all self -care, but unable to carry out any work activities. Up and 
about more than 50% of waking hours.
3 Capable of only limited self -care, confined to bed or chair more than 50% of waking hours.
4 Completely disabled. Cannot carry on any self -care. Totally confined to bed or chai r.
5 Dead.
**Oken MM, Creech RH, Tormey DC, et al: Toxicity And Response Criteria Of The Eastern Cooperative Oncology Group. 
AmJ Clin Oncol. 5:649 -655, 1982.
Available at: http://www.ecog.org/general/perf_stat html. Accessed January 4, 2008.
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 133Appendix E. Revised Criteria for Response Assessment for Ma lignant 
Lymphoma
SitePET -CT-based Response CT-based Response
Complete Metabolic Response
(CMR)Complete Radiologic Response
(ALL of the following)
Lymph nodes and 
extraly mphatic sitesScore 1, 2, or 3* with or without a residual 
mass o n 5PS**.
It is recognized that in Waldeyer’s ring or 
extranodal sites with high physiological 
uptake or with activation within spleen or 
marrow, eg, with chemotherapy or myeloid 
colony stimulating factors, uptake may be 
greater than normal mediastinum and/or 
liver. In th is circumstance, CMR may be 
inferred if uptake at sites of initial 
involvement is no greater than surrounding 
normal tissue even if the tissue has high 
physiological uptakeTarget nodes/nodal masses must regress 
to <1.5 cm in LDi
No extralymphatic sites o f disease
Non-measured lesion Not applicable Absent 
Organ enlargement Not applicable Regress to normal 
New lesions None None
Bone marrow No evidence of FDG -avid disease in 
marrowNormal by morphology; if indeterminate, 
IHC negative
Partial Metabolic Response (PMR) Partial Remission (PR) 
(ALL of the following)
Lymph nodes and 
extraly mphatic sitesScore 4,5** with reduced uptake compared 
with baseline and residual mass(es) of any 
size.
At interim these findings suggest responding 
disease 
Atend of treatment these findings indicate 
residual disease>50% decrease in SPD of up to 6 target 
measurable nodes and extranodal sites
(When a lesion is too small to measure on 
CT, assign 5mm x 5mm as the default 
value. When no longer visible, 0x0 mm
Fora node > 5mm x 5mm, but smaller 
than normal, use actual measurement for 
calculation.)
Non-measured lesion Not applicable Absent/no rmal, regressed, but no increase
Organ enlargement Not applicable Spleen must have regressed by > 50% in 
length beyond normal 
New lesions None None
Bone marrow Residual uptake higher than uptake in 
normal marrow but reduced compared with 
baseline (diffuse uptake compatible with 
reactive changes from chemotherapy 
allowed).
If there are persistent foc al changes in the 
marrow in the context of a nodal response, 
consideration should be given to further 
evaluation with MRI or biopsy, or an 
interval scanNot applicable
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 134No Metabolic Response (NMR) Stable disease
Target nodes/nodal 
masses, extranodal 
lesionsScore 4 or 5 with no significant change in 
FDG uptake from baseline, at interim or 
end of treatment.< 50% decrease from baseline in SPD of 
up to 6 dominant, measurable nodes and 
extranodal sites; no criteria for PD are met 
Non-measured 
lesionsNot applicable No increase consistent with progression
Organ enlargement Not applicable No increase consistent with progression
New lesions None None
Bone marrow No change from baseline Not applicable
Progressive Metabolic Disease (PMD) Progressive disease requires at least 
ONE of the following
Individual target 
nodes/nodal masses, 
Extranodal lesionsScore 4, 5 with an increase in intensity of 
uptake from baseline and/or
New FDG -avid foci consistent with 
lymphoma at interim or end of treatment
assessmentPPD Progression: 
An individual node must be abnormal 
with: LDi > 1.5 cm AND Increase by 
≥50% from PPD nadir AND an increase 
in LDi or SDi from nadir
0.5 cm for lesions <2 cm
1.0 cm for lesions > 2 cm 
In the setting of splenomegaly, the splenic 
length must increase by > 50% of the 
extent of its prior increase beyond baseline 
(eg, a 15 cm spleen must increase to 
> 16 cm). 
If no prio r splenomegaly, must increase by 
at least 2 cm from baseline
New or recurrent splenomegaly 
Non-measured 
lesionsNone New or clear progression of pre -existing 
non-measured lesions 
New lesions New FDG -avid foci consistent with 
lymphoma rather than another etiology, eg, 
infection, inflammation. If uncertain 
regarding etiology of new lesions, biopsy 
or interval scan may be considered.Regrowth of previously resolved lesions
A new node > 1.5 cm in any axis
A new extranodal site > 1.0 cm in any axis 
if less than 1.0 cm in any axis, its presence 
must be unequivocal and must be 
attributable to lymphoma.
Assessable disease of any size 
unequivocally attributable to lymphoma
Bone marrow New or recurrent FDG avid foci New or recurrent involvement
* Score 3 in many  patients indicates a good prognosis with standard treatment, especially if at 
the time o f an interim scan. However in trials invo lving PET where de -escalat ion is invest igated, 
it may be preferable to consider score 3 as inadequate response (to avoid under -treatm ent).
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 135SPD –sum of the product of the perpendicular diameters for mult iple lesio ns
LDi –Longest transverse d iameter of a lesio n
SDi –Shortest axis perpendicular to the LDi
PPD –Cross product of the LDi and perpendicular diameter
Measured dominant lesio ns –Up to 6 of the largest dominant nodes, nodal masses and 
extranodal lesio ns selected to be clearly measura ble in 2 diameters. Nodes should preferably be 
from disparate regions of the body , and shoul d include, where applicable, mediast inal and 
retroperitoneal areas. Non -nodal  lesions include those in solid organs, eg, liver, spleen, kidneys, 
lungs, etc, gastroi ntestinal invo lvement, cutaneous lesions of those noted on palpat ion.
Non-measured lesio ns –Any disease not selected as measured, dominant disease and truly 
assessable disease should be considered not measured. These sites include any nodes, nodal 
masses, and extranodal sites not selected as dominant, measurable or which do not meet the 
requi rements for m easurabilit y, but are still considered abnormal. As well as truly  assessable 
disease which is any  site of suspected di sease that would be difficult to fo llow quant itatively 
with measurement, including pleural effusio ns, ascites, bone lesio ns, leptom eningeal disease, 
abdo minal masses and other lesio ns that cannot be confirmed and fo llowed by  imaging.
In Waldeyer’s ring or in extranodal sites, eg, gastrointes tinal tract, liver, and bone marrow, FDG 
uptake m ay be greater than mediast inum with CMR, but should be no higher than surrounding 
norm al physi ologic uptake, eg, wi th marrow activati on due to chemotherapy  or myel oid growth 
factors.
**PET Five Point Scale ( 5-PS)
1. No uptake above background
2. Uptake < m ediast inum 
3. Uptake > m ediast inum, but < liver
4. Uptake moderately  > liver
5. Uptake markedly  higher than liver and/or new lesions
X. New areas of uptake unlikely to be related to lympho ma
Source: Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response 
assessment of Hodgkin and non -
Hodgkin lymphoma: the Lugano classification. J Clin Oncol.2014;32(27):3059 -68. 
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 136Appendix F. Child -Pugh Score for Subjects with Liver Impairment
Measure 1 point 2 points 3 points
Total bilirubin, μmol/L (mg/dL) <34 (< 2) 34- 50 (2 -3) >50 (> 3)
Serum albumin, g/L (g/dL) >35 (> 3.5) 28- 35 (2.8 -3.5) <28 (< 2.8)
PT/INR < 1.7 1.71-2.30 > 2.30
Ascites None Mild Moderate to Severe
Hepatic encephalopathy None Grade I -II (or suppressed 
with medication)Grade III -IV 
(or refractory)
Points Class
5-6 A
7-9 B
10-15 C
Source s:
Child CG, Turcotte JG. “Surgery and portal hypertension”. In Child CG. The liver and portal hypertension. 
Philadelphia:Saunders. 1964. pp. 50 -64.
Pugh RN, Murray -Lyon IM, Dawson L, et al. “Transection of the oesophagus for bleeding oesophageal varices”. The British 
journal of surgery, 1973;60: 646 -9.
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 137Appendix G. Howard Criteria for Laboratory and Clinical T LS*
(Howard etal,NEJM 2011)
Metabolic AbnormalityCriteria for Classification of 
Laboratory Tumor Lysis SyndromeCriteria for Classification of 
Clinical Tumor Lysis Syndrome
Hyperuricemia Uric acid > 8.0 mg/dL 
(475.8 μmol/liter) in adults or above 
the upper limit of the normal range for 
age in children
Hyperphosphatemia Phospho rus > 4.5 mg/dL 
(1.5mmol/liter) in adults or 
>6.5mg/dL (2.1 mmol/liter) in 
children
Hyperkalemia Potassium > 6.0 mmol/liter Cardiac dysrhythmia or sudden death 
probably or definitely caused by 
hyperkalemia
Hypocalcemia Corrected calcium < 7.0 mg/dL 
(1.75 mmol/liter) or ionized calcium 
<1.12 (0.3 mmol/liter)†Cardiac dysrhythmia, sudden death, 
seizure, neuromuscular irritabili ty 
(tetany , paresthesias, muscle twitching, 
carpopedal spasm, Trousseau’s sign, 
Chvostek’s sign, laryngospasm, or 
bronchospasm), hypotension, or heart 
failure probably or definitely caused by 
hypocalcemia
Acute kidney injury‡ Not applicable Increase in th e serum creatinine level of 
0.3 mg/dL (26.5 μmol/liter) (or a single 
value > 1.5 times the upper limit of the 
age-appropriate normal range if no 
baseline creatinine measurement is 
available) or the presence of oliguria, 
defined as an average urine output o f 
<0.5mL/kg/hr for 6 hr
*In laboratory TLS, two or more metabolic abnormalities must be present during the same 24 -hour period within 3 days 
before the start of therapy or up to 7 days afterward. Clinical TLS requires the presence of laboratory TLS plus an increased 
creatinine level, seizures, cardiac dysrhythmia, or death.
†The corrected calcium level in milligrams per deciliter = measured calcium level in milligrams per deciliter + 0.8 × 
(4−albumin in grams per deciliter).
‡Acute kidney injury is defined as an increase in the creatinine level of at least 0.3 mg per deciliter (26.5 μmol per liter) or a 
period of oliguria lasting 6 hours or more. By definition, if acute kidney injury is present, the patient has clinical TLS. D ata 
about acute kidne y injury  are from ( Levin 2007 ).
Note: Only  post -dose laboratory assessments will be considered when applying Howard Criteria for laboratory and clinical 
TLS.
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 138Appendix H. Recommendations for Initial Management of Electrolyte 
Abnor maliti es and Prevention of Tumor Lysis Syndrome (TLS)
Secti on 1: Fi rst Dose of Venetocl ax or Dose Escalation
Within the first 24 hours after either the first dose or dose escalat ion, if any 
laboratory  criteria bel ow are m et, the pati ent should be hospitalized for monitoring 
and the invest igator notified. No addit ional venetocl ax doses shoul d be administered 
until reso lution. A rapidly rising serum potassium is a medical emergency .
Nephro logy (or other acute dialysis service) should be contacted/consulted (per 
institutional standards to ensure emergency dialysis i s available) on admissio n for 
any subject hospitalized prophylact ically or in response to laboratory changes.
IV fluids (eg, D5 1/2 normal saline) should be init iated at a rate of at least 
1 mL/kg/hr rounded to the nearest 10 mL (target 150 to 200 mL/hr; not 
< 50 mL/hr). Modificat ion of fluid rate should also be considered for individuals 
with specific m edical  needs.
Moni tor for sym ptoms or si gns of TLS (eg, fever, chills, tachycardia, nausea, 
vomiting, d iarrhea, diaphoresis, hypotension, muscle aches, weakness, paresthesias, 
mental  status changes, confusio n, seizures). If any  clinical features are observed, 
recheck potassium, phosphorus, uric acid , calcium  and creat inine within 1 hour 
STAT.
Vital signs sh ould be taken at time of all blood draws or any  Intervent ion.
The m anagement recommendat ions below focus on the minimum initial responses 
requi red. If a di agnosis of TLS i s established, ongoing intensive monitoring and 
multi-disciplinary management will be per inst itutional  protocols
In addit ion to the recommendations in the tablebelow:
For potassium increase ≥0.5 mmo l/L fro m baseline, or any value > 5.0 mmo l/L, 
recheck potassium, phosphorus, uric acid, calcium and creat inine within 1 hour 
STAT and follow first gui deline.
For phosphorus increase of > 0.5 m g/dL AND > 4.5 m g/dL, administer phosphate 
binder and recheck potassium, phosphorus, uric acid, calcium and creatinine wit hin 
1 hour STAT.
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 139Abnormality Management Recommendations1,2
Hyperkalemia (i ncluding rapidly rising potassium)
Potassium ≥0.5 mmol/L increase from 
prior value (even if potassium within 
normal limits [WNL])Recheck potassium, phosphorus, uric acid, calcium and 
creatinine in 1 hour STAT. If further ≥0.2 mmol/L increase in 
potassium, but still < upper limit of normal (ULN), manage as 
per potassium ≥ULN. Otherwise recheck in 1 hour.
Resume per protocol testing if change in potassium is 
<0.2 mmol/L, and potassium < ULN, and no other evidence of 
tumor ly sis.
At discretion of Investigator, may recheck prior to 
hospitalization. If stable or decreased, and still WNL, 
hospitalization is at the discretion of the Investigator. Potassium, 
phosphorus, uric acid, calcium and
Creatinine must be rechecked within 24 hours.
Potassium > u pper limit of normal Perform STAT ECG and commence telemetry.
Nephrology notification with consideration of initiating dialysis.
Administer Kayexalate 60 g (or Resonium A 60 g).
Administer furosemide 20 mg IV × 1.
Administer calcium gluconate 100 –200 mg/ kg IV slowly if 
there is ECG/telemetry evidence of life -threatening arrhythmias.
Recheck potassium, phosphorus, uric acid, calcium and 
creatinine in 1 hour STAT.
oIf potassium < ULN 1 hour later, repeat potassium, 
phosphorus, uric acid, calcium and creatini ne 1, 2 and 
4hours, if no other evidence of tumor lysis.
Potassium ≥6.0 mmol/L (6.0 mEq/L) 
and/o r symptomatic (eg, muscle 
cramps, weakness, paresthesias, nausea, 
vomiting, diarrhea)Perform STAT ECG and commence telemetry.
Nephrology (or other acute dia lysis service) assessment with 
consideration of initiating dialysis.
Administer Kayexalate 60 g (or Resonium A 60 g).
Administer furosemide 20 mg IV × 1.
Administer insulin 0.1 U/kg IV + D25 2 mL/kg IV.
Administer sodium bicarbonate 1 to 2 mEq/kg IV push.
oIf sodium bicarbonate is used, rasburicase should not be 
used as this may exacerbate calcium phosphate precipitation.
Administer calcium gluconate 100 to 200 mg/kg IV slowly if 
there is ECG/telemetry evidence of life -threatening arrhythmias. 
Do not adminis ter in same IV line as sodium bicarbonate.
Recheck potassium, phosphorus, uric acid, calcium and 
creatinine every hour STAT.
Hyperuricemia
Uric acid ≥8.0 mg/dL (476 μmol/L) Consider rasburicase (0.2 mg/kg as an intravenous infusion over 
30minutes).
oIf rasburicase is used, sodium bicarbonate should not be 
used as this may exacerbate calcium phosphate precipitation.
Recheck potassium, phosphorus, uric acid, calcium and 
creatinine in 1 hour STAT.
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 140Abnormality Management Recommendations1,2
Uric acid ≥10 mg/dL (595 μmol/L)
OR
Uric acid ≥8.0 mg/dL (476 μmol/L) 
with 25% increase and creatinine 
increase ≥0.3 mg/dL ( ≥0.027mmol/L) 
from pre -dose levelAdminister rasburicase (0.2 mg/kg as an intravenous infusion 
over 30 minutes).
oWhen rasburicase is used, sodium bicarbonate should not be 
used as this may exacerbate calcium phosphate precipitation.
Consult nephrology (or other acute dialysis service).
Recheck potassium, phosphorus, uric acid, calcium and 
creatinine in 1 hour STAT.
If uric acid < 8.0 mg/dL 1 hour later, repeat potassium, 
phosphorus, uric acid, calcium and creatinine 2 and 4 hours later, 
if no other evidence of tumor lysis.
Hypocalcemia
Calcium ≤ 7.0 mg/dL (1.75 mmol/L)
AND
Patient symptomatic (eg, muscle 
cramps, hypotension, tetany, cardiac 
arrhy thmias)Administer calcium gluconate 50 t o 100 mg/kg IV slowly with 
ECG monitoring.
Telemetry.
Recheck potassium, phosphorus, uric acid, calcium and 
creatinine in 1 hour STAT.
If calcium normalized 1 hour later, repeat potassium, 
phosphorus, uric acid, calcium and creatinine 2 and 4 hours later, 
if no other evidence of tumor lysis. Calculate corrected calcium 
and check ionized calcium if albumin low
Hyperphosphatemia
Phospho rus ≥5.0 mg/dL 
(1.615 mmol/L) with ≥0.5 mg/dL 
(0.16 mmol/L) increaseAdminister a phosphate binder (e.g., aluminum hydroxide, 
calcium carbonate, sevelamer hydroxide, or lanthanum 
carbonate).
Nephrology (or other acute dialysis service) notification (dialysis 
required for phosphorus ≥10 mg/dL). 
Recheck potassium, phosphorus, uric acid, calcium and 
creatinine in 1 hour STAT.
If phospho rus < 5.0 mg/dL 1 hour later, repeat potassium, 
phosphorus, uric acid, calcium and creatinine 2 and 4 hours later, 
if no other evidence of tumor lysis.
Creatinine
Increase ≥ 25% from baseline Start or increase rate of IV fluids.
Recheck potassium, phosphorus, uric acid, calcium and 
creatinine in 1 to 2 hours STAT.
Secti on 2: Ongoing Dosing of Venetoclax
Management of electroly te changes from  last val ue at intervals > 24 hours after either the first 
dose or dose escalation (eg, 48 or 72 hours) are as below.
Note : If the patient is hospitalized, no addit ional venetoclax doses should be administered unt il 
resol ution.
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 141For potassium, admit patient for any  increase ≥1.0 mmo l/L (1.0 m Eq/L), or any  
level > upper limit of normal.
oRefer to the management guidelines for electrolyte changes observed wit hin the 
first 24 hours after either the first dose or dose escalat ion (see Table above).
If a smaller potassium increase is observed that does not meet the criteria for 
admissio n above, recheck pota ssium, phosphorus, uric acid, calcium and creat inine 
in 24 hours and confirm no evidence of tumor lysis prior to further venetoclax 
dosing.
For uric aci d, calcium , phosphorus and creatinine, refer to the management 
guidelines for el ectroly te changes observ ed wi thin the first 24 hours after either the 
first dose or dose escalation (see Table above).
References
1.Coiffier B, Alt man A, Pui CH, et al. Guidelines for the management of pediatric and adult 
tumor lysis syndrome: an evidence- based review. J Clin Onco l.2008;26(16):2767 -78.
2.Cairo MS, Bishop M. Tum our lysis syndrome: new therapeutic strategies and classificat ion. 
Br J Haem atol. 2004;127(1):3 -11.
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 146Appendix J. EQ-5D-5L
 
     
                
IMBRUVICA®(ibrutinib) PCYC -1143-CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 147
              
 
       
       
       
       
      
 
        
        
        
        
        
      
    
        
        
        
        
        
  
      
      
      
      
      
  
      
      
      
      
      
 
                
IMBRUVICA®(ibrutinib) PCYC -1143- CA Amendment 4 16September 2022
FINAL
Pharmacy clics LLC Proprietary  and Confidential Page 148
             
 
        
         
        
              
             
  
     
 
                   
   
 
   
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 